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Abstract: 
 
Glioma therapy relies on induction of cytotoxicity; however, the current combination of 
surgery, irradiation (IR) and temozolomide (TMZ) treatment does not result in a long-
term cure. Our lab previously demonstrated that a small population of glioma cells enters 
a transient cell cycle arrest in response to chemotherapy. Treatment with TMZ 
significantly decreases initial neurosphere formation; however, after a short recovery 
period, a small number of cells resume neurosphere formation and repopulate the culture. 
This recovery of neurosphere growth recapitulates the inevitable glioma recurrence in the 
clinic. The focus of our laboratory is to study direct-target therapies that can be combined 
with TMZ to inhibit neurosphere recovery. The Notch pathway is a promising target 
because it is involved in cell growth and survival. Here, we demonstrate that blocking the 
Notch pathway using gamma-secretase inhibitors (GSIs) enhances TMZ treatment. The 
combination of TMZ and GSI treatments targets the cells capable of recovery. TMZ + 
GSI treated cells do not recover and are no longer capable of self-renewal. Interestingly, 
recovery is inhibited when the GSI is administered 24 hrs after TMZ treatment, 
demonstrating a sequence-dependent mechanism. TMZ + GSI treatment also decreases 
tumorigenicity. When glioma cell lines were treated in vitro and implanted in NU/NU 
nude mice, TMZ + GSI treatment extended latency and greatly increased survival. In 
addition, in vivo TMZ + GSI treatment completely blocked tumor progression and 
resulted in the loss of a palpable tumor in 50% of mice, while none of the TMZ-only 
treated mice survived. TMZ + GSI treated cultures and xenografts display a senescent 
phenotype. Cultures treated with TMZ + GSI have decreased proliferation, but no 
increase in cell death. We observed an increase in the number of cells expressing 
senescence-associated β-galactosidase in vitro and in vivo. This demonstrates that 
inhibition of the Notch pathway shifts TMZ-treated cells from a transient cell cycle arrest 
into a permanent senescent state. Senescent cells can stimulate the innate immune system. 
Here we demonstrate that TMZ + GSI treatment increases phagocytosis in vitro. New 
therapy combinations, such as TMZ + GSI, are arising in the field of therapy-induced 
senescence (TIS). Overall, this data demonstrates the importance of the Notch pathway in 
chemoprotection and maintenance of TMZ-treated gliomas. The addition of GSIs to 
current treatments is a promising target-directed therapy to decrease the rate of brain 
tumor recurrence by inducing senescence and tumor clearance. 
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CHAPTER I: 
Introduction 
 
Gliomas 
Every year, approximately 19,000 new primary brain cancers are diagnosed in the 
United States (www.cancer.gov). Gliomas are the most common type of brain cancers, 
accounting for 32% of all brain and central nervous system tumors and 80% of all 
malignant brain tumors (CBTRUS, 2010). Gliomas are divided into subcategories based 
on their similarity to normal brain tissue. These subcategories include astrocytomas, 
oligodendrogliomas, ependymoma, and mixed gliomas, with astrocytomas being the most 
common. Astrocytomas are further grouped by their malignancy and tumor 
characteristics using the World Health Organization (WHO) classification system. The 
most common gliomas, are the WHO grade III anaplastic astrocytoma (AA) and grade IV 
glioblastoma multiforme (GBM). AAs make up 2% and GBMs make up 17% of all 
primary brain tumors in the United States, with incidences of 0.40 and 3.17 cases per 
100,000 persons per year, respectively (CBTRUS, 2010). AAs and GBMs are infiltrative 
tumors with highly vascular and necrotic regions. GBMs are further delineated by the 
presence of hyperplastic microvascular regions and necrotic regions surrounded by 
anaplastic cells, known as pseudopalisades.  
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Glioma therapy 
Current clinical treatment for gliomas consists of a combination of surgical 
resection, radiotherapy and chemotherapy. In both low- and high-grade gliomas, surgery 
provides the most benefit to the patient. More extensive resections commonly increase 
patient survival times (Sanai and Berger, 2008); however, due to the infiltrative nature of 
AAs and GBMs, even complete macroscopic removal of the tumor is not curative. 
Following surgery, patients receive conventional radiation treatment, with a dosage of up 
to 60 Gy given daily in 2 Gy fractions (Buatti et al., 2008). Patients also receive 
concomitant chemotherapy treatments. The most commonly used chemotherapy drug is 
currently temozolomide (TMZ; Temodar®). TMZ is an alkylating agent that is taken 
orally and readily penetrates the blood-brain barrier (Ostermann et al., 2004). In glioma 
patients, TMZ is administered both concurrently with and adjuvantly to radiotherapy. 
Cellular toxicity from TMZ treatment results from DNA methylation (Sarkaria et al., 
2008). TMZ is an imidazotetrazine derivative that, at physiological pH, spontaneously 
converts to MTIC (5-(3-methyltriazen-1-yl)imidazol-4-carboxamide) (Newlands et al., 
1997). MITC is responsible for methylation of N7-guanine, N3-adenine and O6-guanine. 
In replicating cells, O6-methylguanine mispairs with thymine and is highly toxic (Gerson, 
2002). This leads to futile cycles of the DNA mismatch repair pathway, which induces 
cell cycle arrest and apoptosis (Gunther et al., 2003; Hirose et al., 2001). O6-
methylguanine can be repaired by O-6-methylguanine-DNA methyltransferase (MGMT). 
However, approximately 70% of GBMs have low or negative MGMT expression 
(Friedman et al., 1998). MGMT can be silenced in glioma tissues by methylation of the 
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promoter, which results in increased sensitivity to alkylating agents (Dresemann, 2010). 
MGMT-negative status is a positive prognostic factor. However, TMZ is currently used 
for both MGMT-positive and MGMT-negative GBMs, because TMZ is still more 
efficacious in MGMT-positive patients than irradiation (IR) alone (Dresemann, 2010).  
Phase I and II clinical trials have demonstrated that TMZ treatment decreases tumor 
burden and neurological symptoms with manageable side effects (Bower et al., 1997; 
Brada et al., 1999; Newlands et al., 1992; O'Reilly et al., 1993; Yung et al., 1999). 
Preclinical data demonstrating a synergistic effect by combining TMZ and IR was shown 
in 1997 (Wedge et al., 1997). In 2005, Stupp and colleagues provided a comprehensive 
study demonstrating the synergy of TMZ and IR in the clinic. Their treatment regimen, 
known as the EORTC/NCIC-protocol, has become the standard of care. After surgery, 
TMZ is administered daily at 75 mg/m2 body surface during conventional fractionated IR 
treatment. This is followed by 6 cycles of adjuvant TMZ administered at 150 to 200 
mg/m2 for 5 consecutive days, on a 28-day schedule, referred to as the 5/28-regimen 
(Dresemann, 2010). TMZ has a very short half-life in vitro (1.24 h), in mouse models 
(1.29 h), and in patients (1.81 h) (Newlands et al., 1997). The TMZ concentrations in 
patients can vary from 0.1 to 14.0 µg/ml in the plasma and 0.2 to 1.9 µg/ml in the 
cerebrospinal fluid (CSF) (Baker et al., 1999; Ostermann et al., 2004; Spiro et al., 2001).  
 
Glioma recurrence and survival rates 
Long-term survival for glioma patients remains uncommon, despite advances in 
glioma treatment and increased knowledge of glioma biology over the past decade. Stupp 
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and colleagues have provided the most detailed clinical studies on the benefits of IR with 
concurrent and adjuvant TMZ treatment in GBM patients (Stupp et al., 2009; Stupp et al., 
2005). TMZ treatment increases the two-year overall survival rate to 26.5%, compared to 
a 10.4% survival rate with radiotherapy alone (Stupp et al., 2005). The median five-year 
overall survival rate is 9.8% for the patient group treated with concurrent and adjuvant 
TMZ, while the group treated with IR-alone yields only a 1.9% survival (Stupp et al., 
2009). In the United States, the current five-year and ten-year overall survival rates for 
GBM patients are 4.5% and 2.7%, respectively (CBTRUS, 2010). For AA patients, the 
current five-year and ten-year overall survival rates are 27.4% and 21.3%, respectively 
(CBTRUS, 2010). Despite increased survival rates over the past decade, glioma patients 
quickly succumb to very aggressive recurrent tumors. The median progression free 
survivals in GBM and AA patients are 6.9 months (Stupp et al., 2005) and 15.2 months 
(Chamberlain et al., 2008), respectively. In some instances, recurrent gliomas can be 
treated with additional surgery or radiation. Many patients with recurrent gliomas receive 
adjustments to their TMZ regimens, which can include: dose-dense (7/7-regimen), with 
150 mg/m2 on days 1 through 7, repeated with no break on day 8; prolonged (21/28-
regimen), with 75 to100 mg/m2 for 21 consecutive days on a 28 day schedule; and 
metronomic (28/28-regimen), with continuous treatment of TMZ at 50 mg/m2. Other 
options for recurrent glioma patients include treatment with nitrosourea chemotherapy, 
topoisomerase inhibitors, VEGF (vascular endothelial growth factor) inhibitors, such as 
bevacizumab (Avastin®), and enrollment in various clinical trials (Desjardins et al., 
2008; Dresemann, 2010; Friedman et al., 2009; Kreisl et al., 2009; Zuniga et al., 2009). 
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Despite aggressive treatment after the initial diagnosis and tumor relapse, the current 
median overall survival times are only 14.6 months for GBM patients (Stupp et al., 2005) 
and approximately 3 years for AA patients (Chaichana et al., 2010). Relapse after TMZ 
treatment results in tumors with an increased occurrence of somatic mutations (Chin et 
al., 2008; Hunter et al., 2006). These recurrent tumors commonly have mutations in genes 
from the mismatch repair (MMR) pathway, such as MSH6, MSH2, MLH1, and PSM2 
(Cahill et al., 2007; Hunter et al., 2006; Yip et al., 2009). This suggests a role for the loss 
of the MMR pathway that leads to increased mutations after TMZ treatment, as well as 
TMZ resistance. Another mechanism that may contribute to TMZ resistance of recurrent 
gliomas is a change in the MGMT promoter methylation status. In tumors that had 
unmethylated MGMT at the time of first surgery, 62% of the recurrent cases were 
methylated when analyzed from the second surgery after TMZ and IR treatment (Brandes 
et al., 2010). 
 
Cancer stem cells 
Clonal evolution versus the cancer stem cell hypothesis 
Current glioma therapies fail to cure patients because certain cells evade treatments 
and promote tumor regrowth. There are two competing models describing the cells 
responsible for tumor formation and relapse. First, is the clonal evolution theory, and 
second, is the cancer stem cell (CSC) hypothesis. The clonal evolution theory, also 
referred to as the stochastic model, states that cancer is a multi-step disease that arises 
from clones that have acquired multiple mutations. These clonal populations possess 
  
7 
7 
enhanced tumorigenicity, metastasis and anti-apoptotic properties. Based on this theory, 
tumorigenicity is due strictly to genetic mutations, and does not discriminate based on 
different cell populations. The clonal evolution model states that within the tumor, any 
cell can become resistant to therapy by the acquisition of additional mutations, and it 
does not rely on a hierarchical organization (Shackleton et al., 2009). One example of a 
cancer believed to follow the clonal evolution model is melanoma. A recent study 
demonstrated that the percent of tumor-propagating cells harvested from patient 
melanomas can depend on the model systems used (Quintana et al., 2008). While 
melanoma-propagating cells are relatively rare when grafted into NOD/SCID mice, with 
only 1 cell in 837,000 being tumorigenic, in NOD/SCID that lack the interleukin (IL)-2 
gamma receptor 1 in 9 melanoma cells are capable of tumor formation. Importantly, there 
is no difference in tumorigenicity among any populations based on marker expression. In 
some types of cancer, the majority of the cells within a tumor have similar tumorigenic 
potential, and this potential is due to genetic or epigenetic changes, and not hierarchical 
organization. These data support the key concept that separates this model from the CSC 
model.  
In the second model, the CSC hypothesis, tumors follow a hierarchical model, and 
contain a unique population of CSCs, transit amplifying (progenitor) cells, and 
differentiated cells. The seminal belief behind the CSC theory is that the tumor is 
initiated and maintained by cells with stem cell-like properties. Many pathways that 
regulate normal functions of embryonic and adult stem cells are altered in cancer cells. 
There are three essential properties a CSC should possess (Rich, 2008). First, the cell 
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must be capable of self-renewal. Self-renewal is a property unique to embryonic stem 
cells, adult stem cells, and CSCs (Buick et al., 1979; Kawaguchi et al., 2001). Self-
renewal allows for the continued production of differentiated progeny, without 
exhausting the pool of undifferentiated CSCs. A CSC will also possess high proliferative 
potential. Like normal adult stem cells, the CSC may remain quiescent, but still have the 
ability to re-enter the cell cycle and demonstrate high proliferative potential. The final 
requirement of a CSC is that it must be capable of tumor initiation. There are additional 
characteristics that are commonly associated with CSCs, but are not required. These 
characteristics include: 1) their cell of origin, 2) rarity, 3) potency, 4) the presentation of 
stem cell markers and 5) chemoresistance. These phenotypes are not consistent in all 
CSCs and can vary among different tumor types, grades and individual patients’ tumors. 
1) It is not necessary that a CSC originate from an adult stem cell (Akala et al., 2008; 
Barker et al., 2009; Holland et al., 2000; McCormack et al., 2010). It is unclear whether 
CSCs are derived from adult stem cells, or if mutations in a progenitor or even a 
terminally differentiated cell will lead to a tumor cell with stem cell characteristics. 2) 
CSCs may make up a rare population of the tumor, while the majority of the tumor cells 
are non-tumorigenic (Holyoake et al., 1999). However, recent publications find that the 
percent of CSCs can vary greatly in different cancers, depending on tumor type and 
possibly the tumor microenvironment (Eaves, 2008; Kelly et al., 2007). 3) Although 
multilineage differentiation is a characteristic of normal stem cells, CSCs do not normally 
retain the same pluripotency. CSCs are capable of differentiating into multiple cell types, 
but they commonly follow the lineage of the parent tumor (Canoll and Goldman, 2008; 
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Hill and Perris, 2007). 4) Not all cells that function as CSCs express similar markers 
(Lottaz et al., 2010). Normal embryonic and adult stem cells have been associated with 
specific markers; however, CSCs have proven to be more complicated in their marker 
expression. 5) A very important field of study in CSC research is therapy resistance. 
Since the CSC hypothesis states that only CSCs are capable of tumor formation, the CSC 
hypothesis postulates that these cells are responsible for tumor recurrence after treatment. 
Many laboratories have demonstrated the chemoresistance and radioresistance of the 
CSC population (Bao et al., 2006a; Ghods et al., 2007; Haraguchi et al., 2006; Kang and 
Kang, 2007; Liu et al., 2006; Ma et al., 2008; Salmaggi et al., 2006; Shafee et al., 2008; 
Wang et al., 2010a); however, it has not been demonstrated if all resistant cells are CSCs, 
or if every CSC has a resistant phenotype. It is important to note that the fundamental 
concept of the CSC hypothesis is that there is a functionally distinct group of cells with 
stem cell characteristics that are capable of tumor growth, while the remaining cells in the 
tumor are not tumorigenic (Clarke et al., 2006; Kennedy et al., 2007).  
In the literature, CSC is commonly used interchangeably with the terms tumor-
initiating cell and tumor-propagating cell (Venere et al., 2011). However, the term tumor-
initiating cell can also specifically refer to the initial cell that forms the primary tumor in 
the patient, while tumor-propagating cell can refer to any cell within a patient tumor, 
xenograft, or tissue culture that is capable of forming a tumor. As previously described, 
the quintessential tests for CSCs is to examine self-renewal, proliferative potential and 
tumor formation. The CSC hypothesis postulates that the CSC population are capable of 
tumor initiation, therapy-resistant, and metastatic (Diehn and Majeti, 2010). Since patient 
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cancers are not detected until later stages, the original tumor-initiating cell cannot be 
elucidated, and this is currently only a putative term. It is also not known if the original 
tumor-initiating cell is involved in propagation of the recurrent tumor, or if it can form 
xenografts when isolated from the patient tumor. In contrast, tumor-propagating cells can 
be examined based solely on their ability to form tumors in mouse models. The tumor-
propagating cells do not necessarily include the original tumor-initiating cells, but it is 
likely that these cells include a set of therapy-resistant cells that help drive tumor 
recurrence.  
The existence of CSCs was first demonstrated in acute myeloid leukemia (Bonnet 
and Dick, 1997), and more recently in solid tumors, such as breast (Al-Hajj et al., 2003), 
prostate (Tang et al., 2007), colon (O'Brien et al., 2007), and brain cancers (Singh et al., 
2003; Singh et al., 2004). Accumulating evidence suggests that CSCs play major roles in 
tumor initiation, angiogenesis, maintenance, and metastasis. CSCs are also clinically 
important, because they are more resistant to radiation and chemotherapy treatments than 
the bulk tumor cells, and therefore, are likely the drivers of tumor recurrence (Bao et al., 
2006a; Liu et al., 2006).  
Despite the arguments supporting each model, it is possible that both theories are 
applicable, depending on the tumor type, and there may also be variation within each 
tumor type. In leukemias, it has been strongly documented that only a small percentage of 
cells are capable of recapitulating the disease (Hope et al., 2004), which supports the 
CSC hypothesis, while in melanomas most cells are tumorigenic (Quintana et al., 2008), 
which has been used to argue against the CSC hypothesis. In addition, these two theories 
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do not need to be mutually exclusive (Shackleton et al., 2009). It is very likely that clonal 
evolution occurs in CSCs, resulting in more aggressive CSCs and making it more 
difficult to separate these two models of tumor propagation (Barabe et al., 2007). 
 
Discovery of neural stem cells 
 
The discovery of adult NSCs paved the way for the glioma CSC field (Altman, 
1963; Altman and Das, 1965; Johansson et al., 1999a; Johansson et al., 1999b). Until the 
mid-20th century, the consensus in the neuroscience field was that adult NSCs did not 
exist. The former dogma was that the brain contained mitotic cells only during 
development. It is now known that neurogenesis persists throughout life. In the adult 
brain, NSCs are located primarily in the subventricular zone of the lateral ventricle 
(Altman, 1963) and the dentate gyrus of the hippocampus (Altman and Das, 1965). In the 
subventricular zone, adult NSCs are termed type B cells, and the transit amplifying cells 
are type C cells (Kriegstein and Alvarez-Buylla, 2009) (Fig. 1.1). The type B NSCs are 
mostly quiescent, are derived from embryonic and neonatal radial glial cells, and 
resemble astrocytes (Doetsch et al., 1997). NSCs and transit amplifying cells are closely 
associated with blood vessels in the subventricular zone (Tavazoie et al., 2008). In the 
hippocampus, the NSCs are located in the subgranular zone of the dentate gyrus. These 
cells are referred to as either radial astrocytes or type I progenitors (Fukuda et al., 2003; 
Seri et al., 2004). The subgranular zone is also located next to a vascular network,     
which  may  be  a  niche for adult NSCs  (Palmer et al., 2000). Adult NSCs from both the  
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Figure 1.1 Neural stem cell hierarchy. Embryonic neuroepithelial cells divide 
symmetrically (red arrows) to maintain the stem cell population, and can also produce the 
type B radial glial progeny. These cells are the adult stem cells in the brain. Type B cells 
are also capable of symmetric and asymmetric division. The type C cells are the transit 
amplifying progenitor cells. These cells are multipotent and capable of dividing into the 
three main lineages in the brain, oligodendrocytes, astrocytes, and neurons.  
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subventricular and subgranular zones express the embryonic NSC markers nestin and 
Sox2, in addition to the astrocytic marker, glial fibrillary acidic protein (GFAP) (Doetsch 
et al., 1999; Lendahl et al., 1990; Seri et al., 2004; Suh et al., 2007). In the human fetal 
brain, CD133 is a marker for NSCs (Uchida et al., 2000). CD133 expression has also 
been observed in intermediate radial glial cells in the early postnatal brain, and in 
ependymal cells in the adult brain (Coskun et al., 2008), but not in neurogenic astrocytes 
in the NSC region of the subventricular zone CD133 (Pfenninger et al., 2007). CD15 
(also known as SSEA-1 and Lewis-X Antigen) is also a NSC marker (Barraud et al., 
2007; Pruszak et al., 2007).  
In 1992, it was discovered that NSCs can be expanded as neurospheres in defined, 
serum-free media supplemented with growth factors (Reynolds et al., 1992; Reynolds and 
Weiss, 1992). These cultures maintain their self-renewal properties, have high 
proliferation potential and are capable of differentiation into neurons, astrocytes and 
occasionally oligodendrocytes. The neurospheres are non-adherent, heterogeneous 
aggregates that are derived from single cells. Under serum-free conditions, NSCs and 
transit amplifying cells are the neurosphere-initiating cells. This allows the neurosphere 
formation assay to measure the percentage of these undifferentiated cells in culture. 
NSCs have a greater, long-term proliferation potential than the transit amplifying cells 
and can maintain neurosphere cultures over a large number of serial dissociations, while 
the transit amplifying cells have a limited ability to continuously form neurospheres 
(Reynolds and Weiss, 1996). When neurospheres are dissociated into single-cell 
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suspensions and re-plated, secondary and tertiary neurosphere formation is used to 
measure self-renewal potential. 
 
Glioma stem cells 
While NSCs are necessary for normal neurological development and repair, cells 
with aberrant stem cell characteristics have been detected in brain tumors (Galli et al., 
2004; Singh et al., 2003; Son et al., 2009). Glioma CSCs are capable of self-renewal and 
can divide asymmetrically to maintain the CSC population and produce progeny (Fig. 
1.2). Gliomas display a hierarchical organization, which demonstrates the differentiation 
potential of the glioma CSCs (Piccirillo et al., 2006). NSCs and glioma CSCs share many 
additional characteristics. Both cell types are capable of migrating through normal brain 
tissue. Glioma CSCs have been associated with a vascular stem cell niche, similar to the 
NSC microenvironment niche (Calabrese et al., 2007; Sanai et al., 2005). Brain tumor 
cells expressing nestin and CD133 stem cell markers were consistently located in the 
proximity of the tumor’s vascular system (Calabrese et al., 2007). It has been 
demonstrated that xenografts from CD133+ glioma cells form highly vascular tumors 
compared to xenografts from CD133- cells (Bao et al., 2006b). The vascular niche may 
regulate glioma CSC proliferation and provide a protective shield against treatments. 
Therefore, therapies targeting the fundamental angiogenic factors could indirectly target 
glioma CSCs. Normal NSCs and glioma CSCs also share similar undifferentiated gene 
expression profiles, including nestin, EGFR, and PTEN. However, the nomenclature 
‘stem cell’ in gliomas refers to their function and not their origin.  It is currently unknown  
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Figure 1.2 Glioma stem cell differentiation. Glioma CS are capable of symmetric 
division (red arrows) and maintain the CSC population. The glioma CSCs are also 
capable of asymmetric division (black arrows), which result in the progenitor glioma 
transit amplifying cells. The transit amplifying cells are capable of symmetric division 
and asymmetric division, which yields the differentiated, non-tumorigenic glioma cells. 
Both transit amplifying cells and the differentiated glioma cells can undergo de-
differentiation into glioma CSCs. 
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which cell is the cell of origin for glioma CSCs. Glioma CSCs may originate from normal 
NSCs that have acquired tumorigenic mutations or from more differentiated transit 
amplifying or terminally differentiated neural cells that have acquired multiple mutations 
that allow the cells to be tumorigenic and revert to stemness properties (Fig. 1.2). NSCs 
are probably target cells for malignant transformation. When rodent brains are exposed to 
avian sarcoma virus or carcinogens, tumors form in the subventricular zone, where 
normal NSCs are believed to reside (Sanai et al., 2005). In addition, neural progenitor 
cells can be transformed by expression of oncogenes, such as Akt and K-ras (Holland et 
al., 2000) and EGFRvIII combined with loss of PTEN expression (Li et al., 2009a). 
Conversely, several laboratories have demonstrated that genetic alterations can 
dedifferentiate terminally differentiated astrocytes and induce tumorigenesis (Bachoo et 
al., 2002; Holland et al., 1998). Due to the substantial heterogeneity among gliomas, it is 
likely that tumors from different patients originate from different cells of the adult neural 
hierarchy. The different cell origins for these tumors may cause the inconsistencies of 
glioma CSC marker expression and lead to the presence of distinct molecular subclasses 
observed in gliomas (Phillips et al., 2006).  
 
Glioma stem cell cultures 
Traditionally, glioma cells were grown as adherent cultures in the presence of 
serum (Fig. 1.3). The serum-grown cultures are tumorigenic, but result in circumscribed 
tumors in intracranial xenograft models, unlike the infiltrative, diffuse tumors seen in 
glioma patients (Radaelli et al., 2009).  The gene expression profile of serum cultures can 
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Figure 1.3 Glioma culture methods. Glioma CSCs can be isolated from primary tumors 
and grown in different culture media. Glioma CSCs can be grown in defined, serum-free 
media supplemented with growth factors. Under normal conditions, the glioma CSCs 
form neurospheres in defined medium. The neurospheres are heterogeneous and contain 
CSCs, transit amplifying cells, and differentiated glioma cells; however, if these cells are 
seeded on laminin-coated plates in defined medium, the cells grow as an adherent 
monolayer. The cells in laminin-coated cultures are less differentiated than the 
neurosphere cultures. Finally, the traditional way to grow glioma cultures is in serum-
supplemented media. These cultures are adherent, differentiated cultures, that have 
minimal expression of glioma CSC genes. 
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be drastically different from the original tumor (Lee et al., 2006b). In addition, serum-
supplemented glioma cultures have a very low proportion of CSCs. Similar to normal 
NSC cultures, several laboratories have cultured glioma tissues in defined serum-free 
media supplemented with growth factors. These cultures form non-adherent spheroids 
and have an enhanced population of glioma CSCs (Fig. 1.3) (Galli et al., 2004; Hemmati 
et al., 2003; Singh et al., 2003). The glioma neurospheres are a good in vitro model, 
because the cells maintain genetic profiles similar to the original patients’ tumors and 
form diffuse tumors in intracranial xenografts (Ernst et al., 2009; Lee et al., 2006b; Singh 
et al., 2004). Neurosphere cultures are currently the most common method used to 
propagate glioma CSCs, but a new in vitro technique to grow adherent glioma CSCs is 
emerging, which utilizes laminin-coated plates with serum-free media (Pollard et al., 
2009). 
 
Neurosphere cultures 
Neurosphere cultures were originally developed for propagation of normal NSCs 
(Reynolds and Weiss, 1992). This serum-free culture method is now applied to cancers, 
including breast cancers, colon cancers, and gliomas (Galli et al., 2004; Ponti et al., 2005; 
Ricci-Vitiani et al., 2007; Singh et al., 2003). When plated at a low cell density, each 
neurosphere arises from an individual glioma CSC or transit amplifying cell. Despite 
their clonal origin, neurospheres are heterogeneous aggregates that consist of glioma 
CSCs, transit amplifying cells, and more differentiated glioma cells. Malignant 
transformation can increase neurosphere formation (Li et al., 2009a). The percentage of 
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neurosphere-initiating cells can vary greatly among glioma cultures, from 1-30%. 
Interestingly, the majority of neurosphere-initiating cells are transit amplifying cells 
(Ahmed, 2009). When neurosphere cultures are dissociated to single cells, a percentage 
of the cells can form secondary and tertiary neurospheres for many passages (Chen et al., 
2010b; Reynolds and Weiss, 1996). This demonstrates the presence of cells in the 
neurosphere cultures that possess a high capacity for proliferation and self-renewal.  
When exposed to fetal bovine serum, glioma neurosphere cells differentiate down 
the lineage of the parent tumor (Singh et al., 2003). Therefore, gliomas preferentially 
differentiate to astrocytes (Fig. 1.3), but multilineage differentiation can occasionally be 
observed with neuronal lineages and some abnormal cells with mixed phenotypes 
(Varghese et al., 2008). However, as it is rare for an individual glioma to exhibit the full 
neural hierarchy, it is not expected that each glioma CSC can differentiate into all 
lineages (Sanai et al., 2005). It should be noted that these lineages are based on markers 
but not function. For example, the crucial criterion for a neuron is the action potential, but 
to our knowledge, this has not been tested in differentiated cells from glioma neurosphere 
cultures. A significant difference between NSC and glioma CSC cultures is that serum 
differentiation of normal NSCs is permanent (Lee et al., 2006b), while glioma lines 
established as serum cultures can be converted to neurospheres in serum-free media 
(Qiang et al., 2009). 
Neurosphere cultures derived from primary tumors express known NSC genes, 
such as Musashi1, Sox2, Bmi1, and Nestin (Fan et al., 2010; Hemmati et al., 2003). Many 
laboratories have used the expression of stem cell markers to identify and isolate CSCs; 
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however, there is currently no universally accepted collection of markers for isolation of 
a pure population of CSCs for all gliomas. NSC cell surface markers, such as CD133, 
CD15 and A2B5, are expressed in neurosphere cultures and can be used to isolate 
neurosphere-initiating cells. Expression of CD133 in AA and GBM varies among patients 
and tumor grade, with reports of 0 – 64% in tumors and neurosphere cultures (Ogden et 
al., 2008; Singh et al., 2003; Singh et al., 2004; Son et al., 2009). Singh et al. (2003) were 
the first to demonstrate that CD133+ cells from gliomas are capable of multilineage 
differentiation and have a high capacity for neurosphere formation. The corresponding 
CD133- cells do not proliferate in neurosphere cultures. Tumor formation and serial 
transplantation of xenografts in immunocompromised mice is the gold standard used to 
confirm that a marker identifies the glioma CSC population. CD133+ glioma cells have 
an increased capacity for tumor initiation after intracranial transplantation into mice 
(Singh et al., 2004). Injection of only 100 CD133+ cells results in tumors capable of serial 
transplantation, while 100,000 CD133- injected cells do not form tumors. It is important 
to note that the laboratories that have had the most success studying glioma CSCs based 
on CD133 expression have isolated the cells directly from primary patient tissue and 
fresh xenograft samples (Bao et al., 2006a; Singh et al., 2004; Venere et al., 2011; Wang 
et al., 2010a). A rising concern for CD133 as a glioma CSC marker is that up to 40% of 
freshly isolated glioma tumors do not express CD133 (Son et al., 2009). Tumors negative 
for CD133 expression still contain cells with stem cell-like properties, such as self-
renewal, multilineage differentiation, and xenograft tumor formation (Beier et al., 2007). 
Also, Ogden et al. (2008) reported that even in primary tumors with CD133 expression, 
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CD133 only selects for a fraction of the tumor-initiating cells. In addition, CD133 
expression may be cell cycle-dependent and only identify a subset of glioma CSCs that 
are actively proliferating, and CD133+ populations may include progenitor cells (Grey et 
al., 2009; Jaksch et al., 2008; Snippert et al., 2009). 
In freshly isolated GBM tissues, expression of a second NSC marker, CD15, can 
vary from 2.4 – 70% (Son et al., 2009). CD15+ cells form neurospheres in serum-free, 
defined medium, while CD15- cells have minimal neurosphere formation (Mao et al., 
2009). CD15+ cells isolated from GBMs are highly tumorigenic, while CD15- cells 
display limited tumor formation in mouse intracranial xenografts. Additionally, tumors 
negative for CD133 possess CD15+ cells (Son et al., 2009). Importantly, 23 out of 24 
primary GBMs analyzed contain a subpopulation of CD15+ cells. These results suggest 
that CD15 is an additional glioma CSC marker, and may help to identify new CD133- 
glioma CSCs. A2B5 is a third NSC marker that is expressed in gliomas. A2B5 expression 
varies in AAs and GBMs, from 33 - 90% (Ogden et al., 2008). A2B5+ cells are capable of 
neurosphere formation and intracranial tumor formation, while A2B5- cells do not initiate 
tumors (Ogden et al., 2008; Tchoghandjian et al., 2010). Since glioma cells expressing 
A2B5 form tumors regardless of their CD133 status, A2B5 appears to identify a broader 
population of glioma CSCs. Despite many successes using cell surface markers to 
identify glioma CSCs, it has become increasingly clear that gliomas are very 
heterogeneous and vary greatly from patient to patient (Phillips et al., 2006). 
There are two new promising glioma CSC markers. The first, podoplanin, is a 
mucin-type transmembrane glycoprotein. It is overexpressed in a variety of cancers, 
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including squamous cell carcinomas, colorectal carcinomas and brain tumors (Cortez et 
al., 2010). For glioblastomas, podoplanin is expressed both in tumors and primary 
neurospheres in culture (Christensen et al., 2010). The second new marker, integrin alpha 
6, plays an important role in normal NSCs (Lathia et al., 2010). Integrin alpha 6 binds 
laminin and plays a role in maintaining the stem cells in the subventricular zone. Lathia et 
al. provided strong evidence that integrin alpha 6-positive cells have CSC characteristics. 
These cells are more proliferative and potent for neurosphere and tumor formation.  
Because of the lack of consensus, markers should not be the sole measure of 
stemness. Functional analysis, such as neurosphere and tumor formation, should also be 
used to confirm the CSC phenotype. However, there are caveats with using neurosphere 
cultures to analyze glioma CSC content. As mentioned above, both glioma CSCs and 
transit amplifying cells are capable of forming neurosphere. Therefore, neurosphere 
formation cannot be used to delineate the composition of CSCs and their early progeny. 
After extended periods of growth in serum-free media (> 20 passages), we have observed 
a change in the morphology of neurospheres in many cultures. In some lines, early 
passaged cultures contain densely packed neurospheres with almost indiscernible 
individual cells, which become more loosely packed neurospheres at later passages. The 
rate of neurosphere formation is also increased at higher passages. Other labs have 
observed these changes after 4 months of neurosphere culture, suggesting that although 
serum-free cultures are a better in vitro system than serum cultures, neurosphere tumor 
cells also change with time in culture (Zhang et al., 2006). An additional issue to be 
aware of is that the neurosphere assay is a fastidious assay. The time between 
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dissociation of neurospheres can affect the reproducibility of the results. While splitting 
neurospheres too early can result in an increase in the percentage of neurosphere-
initiating cells, waiting too long to dissociate neurospheres increases the likelihood of cell 
death. In addition, neurospheres aggregate and fuse with one another when the cells are 
plated at higher densities (Singec et al., 2006). Therefore, neurosphere assays measure 
both the number of both glioma CSCs and transit amplifying cells and are accurate only 
when the cells are plated at low densities. In addition, as with any in vitro system, a 
pressing limitation with studying CSC behavior and pathways using neurosphere cultures 
is the absence of the CSC niche. The glioma CSC microenvironment is a hypoxic region 
(Heddleston et al., 2009; Li et al., 2009b) that includes a perivascular niche (Calabrese et 
al., 2007) and infiltrating immune cells (Humphries et al., 2010; Wu et al., 2010a). 
Despite these concerns, neurosphere cultures remain a valuable tool in glioma CSC 
research.  
 
Laminin-coated cultures 
A key aspect of the neurosphere culture system is that the serum-free, defined 
media maintains the CSC phenotype. However, the condensed structure of neurospheres 
hinders the diffusion of the growth factors to the innermost cells, which results in the 
presence of differentiated progeny and regions of cell death (Woolard and Fine, 2009). 
Differentiation and cell death decrease if glioma cultures are grown as a monolayer in the 
presence of serum-free, defined medium. This is achieved by culturing glioma cells in the 
serum-free, defined medium on laminin-coated cell culture plates (Fig. 1.3) (Pollard et 
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al., 2009). When seeded on laminin-coated plates, cells that normally form neurospheres 
under serum-free conditions grow as an adherent culture, which allows the cells equal 
access to growth factors. The adherent glioma CSC lines are less heterogeneous than the 
neurosphere cultures, with almost all of the cells express glioma CSC genes, including 
Sox2, Nestin, CD133 and CD44. There is minimal expression of differentiation markers, 
such as GFAP, Tuj-1 and O4, and the cultures grown on the laminin-coated plates also 
have less cell death compared to neurosphere cultures (Pollard et al., 2009). The 
adherent, laminin cultures are capable of tumor formation when as few as 100 cells are 
intracranially injected into immunocompromised mice, demonstrating the high 
percentage of tumor-propagating glioma CSCs. An additional benefit of the laminin 
glioma CSC culture system is the high success rate of establishing cultures. All patient 
tissues that possessed good cell viability could be established as long-term cell lines. 
Despite the benefit of having an increased purity of CSCs, one large caveat to the laminin 
culture system is its lack of heterogeneity. An important characteristic of CSCs is the 
ability of the cells to form a hierarchy of tumorigenic and non-tumorigenic cells, which is 
restricted in laminin CSC cultures (Venere et al., 2011).  
 
Invincible Glioma Stem Cells? 
Chemoresistance and radioresistance 
Tumor recurrence is due to the presence of glioma cells that can escape 
chemotherapy- and radiotherapy-induced cytotoxicity. In patient tumors, these cells can 
stay dormant for extended periods after treatment. When the resistant cells eventually re-
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enter the cell cycle, they contribute to local tumor recurrence. It has been proposed that 
CSCs are the resistant cells responsible for drug resistance and tumor re-growth in 
multiple cancers (Fig. 1.4). Current glioma treatments are insufficient because they only 
target the bulk of the tumor (Fig. 1.4). Since tumor recurrence is attributed to glioma 
CSCs resistant to therapy, treatments that directly target glioma CSCs could yield long-
term cures. Many have hypothesized that once the glioma CSCs have been eliminated, 
the bulk tumor will not be able to sustain itself and will wither; however, in gliomas, it 
has been hypothesized that some differentiated tumor cells have the ability to revert to 
cells with stem cell-like properties (Fig. 1.2) (Chen et al., 2010b; Gupta et al., 2009). This 
would result in the eventual regrowth of the tumor. Therefore, targeting CSCs in 
combination with current therapies that kill the bulk of the tumor could enhance the 
patients’ chances for long-term survival (Fig. 1.4).  
The stem cell character of glioma CSCs may contribute to resistance of tumor 
cells to therapy through multiple mechanisms. Therapy resistance has been attributed to 
the quiescent phenotype and enhanced DNA repair in CSCs, as well as the expression of 
drug efflux pumps and anti-apoptotic proteins. First, despite their high proliferative 
capacity, normal stem cells can assume a quiescent state that is regulated by the stem cell 
niche. Cells that are not proliferating have less toxicity from chemotherapy- and 
radiation-induced DNA damage. Several groups have proposed that proliferating CSCs 
can readily assume a quiescent state and later, following DNA repair, repopulate the 
tumor (Mellor et al., 2005; Scopelliti et al., 2009). 
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Figure 1.4 Glioma therapy cancer stem cell hypothesis. High-grade gliomas are 
difficult tumors to treat, because current therapies always result in tumor recurrence. This 
is due to a population of therapy-resistant cells that are believed to be glioma CSCs. 
These cells remain dormant after therapy, but quickly re-enter the cell cycle and drive 
tumor recurrence. Therefore, treatments directed against CSCs are promising therapies. 
Killing the CSCs will inhibit tumor growth. This may result in shrinking of the tumor; 
however, non-tumorigenic cells may have the ability to de-differentiate into glioma 
CSCs, which would lead to tumor regrowth. Instead, combination therapy that targets 
both the glioma CSCs and the non-tumorigenic glioma cells has the potential to inhibit 
tumor recurrence. 
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Our laboratory recently demonstrated that two commonly used chemotherapy 
agents, TMZ and BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; carmustine; BiCNU®), 
can induce a transient cell cycle arrest in neurosphere cells followed by a robust recovery 
of the culture (Mihaliak et al., 2010). TMZ has become the staple for chemotherapy 
treatment in glioma patients, while BCNU is an older alkylating agent that has been 
administered both by intravenous infusion and implantation of Gliadel® dissolvable 
wafers into the tumor bed after surgical debulking (Grossman et al., 1992). We 
demonstrated that TMZ and BCNU drastically diminishes initial neurosphere formation 
in many glioma cultures; however, some of these cultures eventually recover and form a 
robust number of secondary neurospheres (Mihaliak et al., 2010). TMZ-treated 
neurospheres also retain their tumorigenicity, and form large tumors in mouse 
subcutaneous xenografts. The ability of the neurosphere cells to repopulate the culture 
and form tumors after chemotherapy suggests that some cells undergo a transient cell 
cycle arrest. Analysis of cell cycle profiles demonstrates that a significant G2 arrest was 
observed 3 days after chemotherapy treatment, but the treated cells re-enter the cell cycle 
by day 7. This suggests that the cell cycle arrest allows a small percent of the 
neurosphere-initiating cells to evade cell death and eventually resume proliferation. 
Although we did not observe any changes in stem cell marker expression after TMZ 
treatment, the cells retain the benchmark CSCs phenotypes of self-renewal and tumor 
formation.  
Several laboratories have published data supporting the chemoresistance of 
glioma CSCs, based on CD133 expression. CD133+ cells are more resistant than CD133- 
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cells to multiple chemotherapeutic agents, including TMZ, carboplatin, VP16, and Taxol 
(Liu et al., 2006). In an additional study, glioma cells that survive BCNU treatment 
express high levels of CD133+ and retain their tumorigenic potential in intracranial 
mouse xenografts (Kang and Kang, 2007). The glioma CSC cultures are more resistant to 
chemotherapy than normal NSC cultures (Gong et al., 2011). After TMZ or cisplatin 
treatment, the number of surviving glioma CSCs is significantly greater than the number 
of surviving NSCs. Cell death is also lower in the chemotherapy-treated glioma CSCs 
compared to the NSCs. Resistance to radiotherapy has also been observed in glioma 
CSCs. IR enriches the CD133+ population of human glioma cultures derived from 
xenografts and GBM patient samples (Bao et al., 2006a). Based on these data, CD133+ 
populations are more resistant to IR in colony formation assays compared to the 
corresponding CD133- populations. In CD133+ cells, IR treatment only moderately 
decrease cell growth (Wang et al., 2010a). In addition, ex vivo IR treatment does not 
inhibit tumor formation in a subcutaneous xenograft model. Glioma patients that undergo 
radiotherapy treatments have increased levels of CD133 expression, demonstrating that 
these cells are also resistant to treatment in the clinical setting (Tamura et al., 2010).  
In contrast, other laboratories have shown that number of CD133+ glioma cells 
can decrease or show no significant change after chemotherapy treatment (Beier et al., 
2008; Mihaliak et al., 2010). There may be several explanations for these inconsistent 
results. First, these differences could indicate that CD133 is not a stem cell marker for all 
gliomas. Second, they could be due to different sources of the glioma CSCs, for example, 
neurosphere cultures versus xenografts or freshly isolated patient tissue (Venere et al., 
  
29 
29 
2011). Finally, the disparate results may be on account of the time points after treatments 
and the drug concentrations for these treatments. Our laboratory previously demonstrated 
that the chemotherapy treatments induce a cell cycle arrest in the neurosphere-initiating 
cells at clinically relevant doses, but require higher concentrations to induce cell death in 
the bulk of the cells (Mihaliak et al., 2010). The drug concentrations needed to achieve 
this cell cycle arrest vary between cell lines. Overall, these data support the theory that 
CSCs are resistant to current glioma therapies; however, due to recent data suggesting 
that CD133 does not identify all CSCs in glioma cultures, experiments using additional 
markers are needed. 
 Glioma CSCs have several hypothesized mechanisms to evade chemotherapy and 
IR treatments. Drug efflux pumps, such as adenosine triphosphate-binding cassette 
(ABC) pumps, ABCG2 and P-glycoprotein, are expressed on glioma CSCs (Lu and 
Shervington, 2008). It has been suggested that these efflux pumps remove the drugs from 
the CSCs, limiting DNA damage; however, in a model system, ABCG2-positive and -
negative cells show no difference in their ability to form tumors mice, suggesting that 
these pumps are not expressed on all CSCs (Patrawala et al., 2005). The ABC 
transporters are often proposed to enhance survival of glioma CSCs by efflux of 
chemotherapy drugs, but TMZ is not a substrate for ABCG2, and expression of ABCG2 
did not provide resistance to TMZ treatment (Bleau et al., 2009). 
 Glioma CSCs express a variety of proteins that promote survival following cancer 
treatment. The major drug resistance protein, MGMT, and anti-apoptotic genes such as 
FLIP, BCL-2, BCL-XL, cIAP1 and Survivin are upregulated in CD133+ glioma cells 
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(Ghods et al., 2007; Liu et al., 2006). IR results in a greater activation of DNA 
checkpoint responses in CD133+ cells by phosphorylation of Rad15, ATM, Chk1 and 
Chk2 than in the autologous CD133- cells (Bao et al., 2006a). This indicates that the 
CD133+ glioma CSCs’ resistance to radiotherapy is partially due to enhanced DNA 
repair. As a result, pathways related to glioma CSC functions and resistance to therapy 
are promising targets for novel therapies. 
A corollary to the CSC model is that signaling pathways associated with stem cells 
could be targeted to enhance therapy. The most effective treatments would consist of IR 
and chemotherapy against the bulk tumor combined with directly targeting the glioma 
CSC population (Fig. 1.4). Signaling pathways associated with either mechanisms of 
resistance or pathways required for the function of glioma CSCs could be targeted to 
enhance therapy.  
 
Notch signaling pathway 
The Notch signaling pathway is a promising target in gliomas. Notch regulates 
proliferation, differentiation, and survival, while deregulation of the pathway has been 
implicated in multiple types of cancer (Allenspach et al., 2002; Koch and Radtke, 2007; 
Roy et al., 2007). In NSCs, Notch activity maintains stemness and regulates fate 
determination during development and in the adult brain (Ables et al., 2010; Breunig et 
al., 2007; Gaiano et al., 2000; Hitoshi et al., 2002; Johnson et al., 2009; Namihira et al., 
2009).  
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Notch was first discovered in flies with a mutated copy of the gene, which 
manifested as visibly ‘notched’ wings (Radtke and Raj, 2003). There are four mammalian 
Notch receptors (Notch1 through 4) and five membrane-associated ligands in the Delta 
and Serrate/Jagged (DSL) family. The Notch receptors and the ligands are single-pass 
transmembrane proteins that contain up to 36 tandem EGF-like repeats in their 
extracellular domains (Fortini, 2009). The Notch receptor begins as single protein 
precursor that is cleaved by a furin-like convertase (proteolytic cleavage S1) into N- and 
C-terminal fragments (Logeat et al., 1998). These fragments are non-covalently linked to 
form a mature, membrane-bound Notch receptor. Activation of the pathway occurs 
through direct cell-cell (trans) interactions with one cell expressing a Notch receptor and 
the other cell expressing a membrane-bound ligand (Fig. 1.5) (Fortini, 2009; Pannuti et 
al., 2010). In contrast, when the ligand and receptor are expressed on the same cell and 
interact in cis, Notch signaling is inhibited (Heitzler and Simpson, 1993; Jacobsen et al., 
1998). When a ligand binds to a Notch receptor through a trans interaction, the 
metalloprotease ADAM protein cleaves the extracellular domain of Notch (proteolytic 
cleavage S2), which initiates endocytosis of the remaining membrane-bound Notch 
fragment. The final intracellular cleavage (proteolytic cleavage S3) of Notch occurs by 
gamma-secretase (Stockhausen et al., 2010). Gamma-secretase is an aspartyl protease 
made up of four membrane proteins, presenilin, nicastrin, PEN2, and APH1 (Wolfe, 
2010). Gamma-secretase cleavage releases the Notch intracellular domain (NICD), 
allowing NICD to be translocated into the nucleus (Fortini, 2009; Miele, 2006).              
In the canonical Notch signaling pathway, the NICD forms a complex on DNA with CSL  
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Figure 1.5 Notch Signaling Pathway. The Notch pathway requires cell-cell interactions. 
Notch signaling is activated when a mature Notch receptor binds to a DSL ligand on a 
neighboring cell. This interaction results in the S2 cleavage of the Notch receptor by the 
ADAM metalloprotease. This is followed by intracellular S3 cleavage by γ-secretase. The 
S3 cleavage results in the translocation of the NICD to the nucleus, where it binds to the 
CSL complex. This leads to transcription of the downstream Notch targets, such as Hes1, 
Hey1 and c-Myc. The Notch pathway can be blocked by treatment with GSIs. The GSI 
blocks the activity of γ-secretase, thereby, preventing the translocation of NICD to the 
nucleus. In the absence of the NICD, the CSL is bound to a co-repressor complex, which 
represses transcription of the downstream Notch targets.  
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(CBF1/Suppressor of Hairless/Lag1, also known as RBP-J) and Mastermind. This 
complex recruits transcription factors p300 and PCAF, facilitating the transcription of 
downstream Notch targets, including members of the Hairy enhancer of split (Hes) and 
Hes-related repressor protein (HERP/Hey) families (Iso et al., 2003), cyclin D (Ronchini 
and Capobianco, 2001), c-myc (Palomero et al., 2006; Sharma et al., 2006), p21 (Guo et 
al., 2009), and NFκB (Oswald et al., 1998). In the absence of NICD, the CSL interacts 
with corepressors blocking target gene transcription. Notch signaling also can occur 
through the non-canonical pathway, which is independent of the CSL complex 
(Sanalkumar et al., 2010). In this pathway, the NICD interacts with other coactivator 
complexes and pathways to activate downstream targets. The non-canonical pathway is a 
less established aspect of Notch signaling. 
Aberrant Notch signaling has been associated with multiple types of cancer. It 
was first identified as an oncogene in T-cell acute lymphoblastic leukemia (T-ALL). In 
many T-ALL patients, Notch1 is constitutively active due to translocations or mutations 
(Ellisen et al., 1991; Weng et al., 2004). Upregulation of the Notch pathway has also been 
demonstrated in models for solid tumors, such as breast cancer (Dievart et al., 1999; 
Robbins et al., 1992), cervical cancer (Zagouras et al., 1995), lung cancer (Dang et al., 
2000), and gliomas (Chen et al., 2010a; Jiang et al., 2011; Kanamori et al., 2007); 
however, upregulation in solid tumors is not due to Notch mutations, and is likely due to 
ligand-mediated hyperactivation of the pathway or upregulation of different upstream 
targets, such as the Id4 protein (Jeon et al., 2008). Directed therapy against Notch 
signaling is promising because this pathway is involved in development and survival and 
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can be blocked at multiple stages of the pathway (Rizzo et al., 2008). The most common 
approach to block the Notch pathway in basic research and in Phase I and Phase II 
clinical trials, is via small molecule inhibitors of gamma-secretase (Miele, 2006). 
Gamma-secretase inhibitors (GSIs) block the S3 cleavage of all four Notch receptors, 
causing the NICD to remain bound to the cell membrane, thereby halting the Notch 
signaling cascade (Fig. 1.5). Treatment with GSIs can induce goblet cell metaplasia of the 
small intestine and lead to gastrointestinal tract cytotoxicity (Barten et al., 2006; Wong et 
al., 2004); however, these side effects can be controlled with intermittent administration 
of low doses of the GSI (Rizzo et al., 2008). 
 
Notch signaling in gliomas 
The Notch receptors, their ligands, and downstream targets are commonly over-
expressed in glioma tissue and cell lines (Chen et al., 2010a; Fischer and Gessler, 2007; 
Jiang et al., 2011; Kanamori et al., 2007; Shih and Holland, 2006). There have been 
several studies demonstrating a correlation between glioma grade and Notch activity. 
Notch1 transcripts and protein levels progressively increase from grade I to grade IV 
gliomas, and high expression is associated with poor prognosis (Jiang et al., 2011; Li et 
al., 2011). GBM tissues possess increased levels of the Notch target, Hes1 (Chen et al., 
2010a; Somasundaram et al., 2005). In addition, Hash-1, a gene negatively regulated by 
Hes1, is upregulated in grade II and III gliomas, but not in primary grade IV GBMs 
(Somasundaram et al., 2005). Inhibition of the Notch pathway with siRNA or a GSI, 
LLNle-CHO, greatly decreases the ability of adherent glioma cultures to form colonies in 
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soft agar and increases differentiation (Kanamori et al., 2007). Loss of Notch in adherent 
glioma lines decreases the number of dividing cells and results in increased apoptosis 
(Purow et al., 2005). Conversely, increased Notch signaling enhances glioma cell 
survival. Adherent glioma lines expressing Notch siRNA also have decreased tumor 
growth and increased survival in an intracranial xenograft mouse model. 
Inhibiting the Notch signaling pathway can specifically target the glioma CSC 
population. In adherent glioma cultures, Notch receptors and the downstream target, Hey, 
are upregulated in the CD133+ population (Ulasov et al., 2011). Components of the Notch 
signaling pathway, have also been associated with neurosphere cultures derived from 
both patient GBMs and adherent glioma lines (Fan et al., 2010; Gunther et al., 2008; 
Zhang et al., 2008). Glioma neurosphere cultures with upregulated Notch signaling have 
higher growth rates than those with low levels of Notch pathway transcripts (Zhang et al., 
2008). In addition, exogenous overexpression of the constitutively active NICD into 
neurosphere cultures further increases cell growth and neurosphere formation (Fan et al., 
2010; Zhang et al., 2008). Notch signaling directly activates transcription of the stem cell 
marker, nestin (Shih and Holland, 2006). Likewise, knockdown of Notch by shRNAs or 
GSIs decreases the expression of the stem cell markers nestin and CD133 in neurosphere 
cultures (Fan et al., 2010; Jeon et al., 2008; Lin et al., 2010b). The GSIs, GSI-18 (2-10 
µM) or MRK-003 (2-10 µM), decreases the downstream Notch target, Hes1, by 80-100% 
and greatly suppressed cell growth in glioma cultures (Fan et al., 2010). Ex vivo treatment 
with GSI-18 also decreases subcutaneous and intracranial xenograft tumor formation, 
while in vivo treatment with GSI-18-soaked beads in intracranial xenografts inhibits 
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tumor formation. This study was confirmed by similar data demonstrating that expression 
of a dominant negative mastermind-like 1 decreases neurosphere formation (Chen et al., 
2010a). GSI treatment with MRK-003 results in a dose-dependent decrease of 
neurosphere formation, with high concentrations (20 µM) inhibiting growth by almost 
100%. These data demonstrate that blocking the Notch pathway can suppress growth and 
survival of glioma CSCs, as measured by neurosphere cell growth, tumor formation, and 
stem cell marker expression.  
Two laboratories have demonstrated that Notch inhibition, through shRNA or 
treatment with GSIs, sensitizes glioma neurosphere cultures to radiotherapy (Lin et al., 
2010b; Wang et al., 2010a). When GSI treatment was combined with IR, neurosphere 
formation is significantly impaired. The decreased neurosphere formation in GSI + IR 
treated glioma cultures is due to enhanced cell death, and the response is unique to the 
CD133+ population. In addition, cells with Notch knockdown by shRNA that are treated 
with IR have decreased tumorigenicity in a subcutaneous xenograft model. In the Wang 
et al. study, treatment with GSIs, DAPT (2 µM) or L685,458 (0.5 µM), alone has 
minimal affect on neurosphere formation. This disparity among data showing a strong 
effect from treatment with GSIs alone (Fan et al., 2010) or lack of an affect (Wang et al., 
2010a) is likely due to both the potency of the inhibitor and the drug concentration. Low 
concentrations of GSIs would be less likely to induce GI toxicity, and are, therefore, 
more clinically relevant. Although these low concentrations of GSIs have a minimal 
affect on glioma cultures when administered as single agents, they may enhance the 
potency of other treatments. Together, these results suggest that an active Notch pathway 
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maintains the glioma CSC population and promotes radioresistance. Therefore, therapies 
targeting Notch receptors, ligands and downstream targets may enhance current glioma 
treatments.  
 
Senescence: An Irreversible Cell Cycle Arrest 
The cell cycle consists of G1 (gap 1), S (synthesis), and G2 (gap 2), and M 
(mitotic) phases (Schafer, 1998). Eventually, normal cells enter a terminally 
differentiated state. Anti-mitotic signals can drive a cell to temporarily exit the cell cycle 
into the G0 phase, known as quiescence. Embryonic stem cells and adult stem cells 
commonly reside in this phase (Jude et al., 2008; Lugert et al., 2010; Shin et al., 2009). In 
culture, quiescence stimuli for normal cells include cell-cell contact inhibition, loss of 
adhesion, and mitogen withdrawal. Quiescence is a transient cell cycle arrest, in which 
cells are viable, metabolically active, and can resume proliferation. Entrance into 
quiescence occurs during the G1 phase (Hartwell et al., 1974; Pardee, 1974), and is 
distinct from G1/S and G2/M cell cycle arrests (Coller et al., 2006). 
Current cancer treatments target the rapidly dividing cells and rely on the 
induction of cell death. However, in many cancers, including gliomas, these treatments 
are not producing long-term cures. Cancer cells that are originally in a quiescent state 
before treatment, or enter into a transient cell cycle arrest after treatment are capable of 
evading the radiation- and chemotherapy-induced cell death (Mellor et al., 2005; 
Scopelliti et al., 2009). Therapy-induced senescence (TIS) is an avant-garde concept for 
cancer treatments that relies on the induction of cytostasis. Cellular senescence is a 
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permanent cell cycle arrest that occurs both in vitro and in vivo, are is distinct from 
terminal differentiation, quiescence, and transient G1/S and G2/M cell cycle arrests. 
Senescence can occur at either cell cycle checkpoint transitions, G1/S or G2/M (Aviv et 
al., 2001; Blagosklonny, 2006, 2011). Despite their inability to re-enter the cell cycle, 
senescent cells remain viable and metabolically active. Senescence was first described in 
normal human diploid cells, where the cells were only capable of a finite number of 
passages in culture (Hayflick and Moorhead, 1961). This characteristic was termed the 
‘Hayflick Limit’, and is now referred to as replicative senescence (Evan and d'Adda di 
Fagagna, 2009). In normal human cells, replicative senescence occurs naturally when 
telomeres reach a critical minimal length. Telomeres are disposable regions of repetitive 
DNA at the end of each chromosome that are shortened after each cell division (Harley et 
al., 1990). The telomere normally forms a loop structure at the ends of chromosomes, 
known as the 5’ DNA cap, which protects them from fusion with other chromosomes. 
Progressive shortening eventually makes the telomerase incapable of forming the 
protective cap structure. This triggers a DNA damage response (DDR) signaling cascade 
that leads to an irreversible cell cycle arrest. Replicative senescence can be deterred by 
expression of telomerase (hTERT), which adds DNA sequence repeats to increase the 
length of telomeres (Counter et al., 1998). Since the discovery of the Hayflick limit, it has 
been shown that senescence can also be induced by reactive oxygen species (ROS), DNA 
damage (Gunther et al., 2003; Mirzayans et al., 2005; te Poele et al., 2002), oncogene 
overexpression (Grandori et al., 2003; Lazzerini Denchi et al., 2005; Michaloglou et al., 
2005; Serrano et al., 1997), and loss of tumor suppressors, (Alimonti et al., 2010; 
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Courtois-Cox et al., 2006; Lin et al., 2010a). Non-replicative senescence, induced by 
signals other than shortening of telomeres, is commonly referred to as premature 
senescence, and cannot be blocked by the expression of telomerase. 
 
Pathways of senescence 
 Regardless of the initial stimuli, p53 and Rb (Retinoblastoma) are the main 
pathways associated with all types of senescence (Fig. 1.6). While p53 and/or Rb are 
critical for senescence, there are many different intermediary genes and signaling forks 
involved. In mice, both the p53 and Rb tumor suppressor pathways are required for 
induction of senescence; however, in humans either pathway is sufficient (Dirac and 
Bernards, 2003; Shay et al., 1991). p14Arf (p19Ink4d in mice; encoded by CDKN2A) can be 
activated by the DNA damage response and other senescence stimuli. p14Arf blocks the 
p53 negative regulator, HDM2 (MDM2 in mice), thereby, activating p53 and its 
downstream target, p21Waf/Cip1 (encoded by CDKN1A). Functional p21Waf/Cip1 binds to and 
inhibits cyclin/CDK complexes, which promotes G1 arrest (Abbas and Dutta, 2009). 
p21Waf/Cip1 has also been associated with G2 arrest in certain cell types, including tumor 
cells (Medema et al., 1998; Niculescu et al., 1998). Senescence signals also upregulate 
cyclin-dependent kinases inhibitors that regulate the Rb pathway, including p16Ink4a 
(encoded by CDKN2A), p27Kip1 (encoded by CDKN1B) and p15Ink4b (encoded by 
CDKN2B). p16Ink4a, p15Ink4b, and p14Arf bind to the cyclin-D dependent CDKs, CDK4 
and CDK6, while p27Kip1 and p21Waf/Cip1 inhibit the cyclin-E and -A -dependent CDK, 
CDK2.  When CDKs are inhibited, and incapable of the forming CDK/cyclin complexes,  
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Figure 1.6 p53 and Rb signaling in senescence. Signals, such as oncogene 
overexpression and DNA damage, can activate the senescence pathway. These signals 
upregulate the expression of cyclin kinase inhibitors (CKIs), such as p14, p27, p16 and 
p15. p14 results in upregulation of the p53/p21 pathway, while the other CKIs upregulate 
the Rb pathway. Both p53 and Rb are the main signaling pathways that instigate 
senescence. The proteins highlighted in yellow are commonly upregulated in senescent 
cells and expression of these genes is often used as a positive marker for senescence. 
Senescent cells are also characterized by permanent cell cycle arrest, aneuploidy, β-
galactosidase, SAHF, SASP, and enlarged, flat morphologies.  Modified from (Campisi 
and d'Adda di Fagagna, 2007).  
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Rb is activated (hypophosphorylation) (Giacinti and Giordano, 2006). Rb binds to the 
transactivation domain of the E2F transcription factor and blocks activity. E2F normally 
stimulates cell proliferation, and blocking E2F transcription induces senescence. Rb can 
also induce senescence through E2F-independent signaling. Rb activity increases the 
formation of promyelocytic leukemia (PML) nuclear bodies, which inhibits proliferation 
and can promote senescence (Fang et al., 2002). Rb can also induce senescence by 
upregulating expression of and stabilizing p27Kip1 through the Rb-Skp2-p27Kip1 pathway 
(Ji et al., 2004). Rb activation is commonly associated with G1 cell cycle arrest, but 
recent studies have demonstrated that DNA damage can induce Rb-dependent G2 arrest 
(Jackson et al., 2005; Naderi et al., 2002; Polager and Ginsberg, 2003). Therefore, 
senescence signals, such as Ras oncogene-induced senescence (OIS), are known to 
activate both p53 and Rb pathways (Fig. 1.6). 
 
The senescent phenotype 
A permanent arrest in cell proliferation is the defining characteristic of 
senescence. In addition to monitoring cell number, cell cycle arrest can be measured by 
multiple assays that focus on protein expression or DNA content. A characteristic 
phenotype of cells that have little or no proliferation is a decrease in the protein levels of 
either Ki67, which is expressed in actively dividing cells during G1, S, G2, and mitosis, 
or proliferating cell nuclear antigen (PCNA), which is upregulated during late G1 and S 
phase (Takahashi and Caviness, 1993). Levels of proliferation can also be measured by 
the incorporation of the synthetic nucleoside, bromodeoxyuridine (BrdU; 5-bromo-2-
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deoxyuridine) into the DNA during the S phase. Senescent and quiescent cells will have 
no BrdU incorporation. More specific analysis of cell cycle arrest can be analyzed by 
measuring the levels of propidium iodide (PI) DNA intercalation in permeabilized cells. 
PI intensity is directly proportional to DNA content and can be used to distinguish cells 
that are in G1 (one set of chromosomes) versus G2 (two sets of chromosomes), as well as 
the presence of aneuploidy. Another method to measure growth arrest is with 
carboxyfluorescein succinimidyl ester (CFSE) label retention. CFSE becomes fluorescent 
in the cytoplasm, and its intensity progressively decreases by half after each cell division. 
Therefore, proliferation can be observed by decreased fluorescence, while label-retaining 
cells make up the non-dividing population. Despite multiple methods to analyze cell 
proliferation, these measurements will not distinguish senescence from transient 
phenotypes, such as quiescence or decreased proliferation.  
The most common measurement for senescence is the expression of senescence 
associated (SA)-β-galactosidase. SA-β-galactosidase expression occurs almost 
exclusively in senescent cells, and can be analyzed both in vitro and in vivo (Debacq-
Chainiaux et al., 2009). Staining for SA-β-galactosidase is pH-dependent. This phenotype 
is poorly understood, but is believed to be due to increased levels of endogenous 
lysosomal β-galactosidase in senescent cells. It has been shown that β-galactosidase 
expression is not required for induction of senescence (Lee et al., 2006a). Knockdown of 
β-galactosidase does not inhibit the induction of a permanent cell cycle arrest. In 
addition, senescent cells often form senescence associated heterochromatin foci (SAHF) 
(Narita et al., 2003). Heterochromatin is made up of condensed regions of chromosomes 
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that are transcriptionally silent. SAHF is a form of facultative heterochromatin that forms 
due to a change in a cell’s phenotype (Zhang and Adams, 2007). Senescent, human cells 
stained with 4’-6-Diamindino-2-phenylindole (DAPI) present with 30 to 50 DNA 
aggregates of SAHF. Each individual SAHF is formed from a single chromosome, and 
possess foci for HP1, HIRA and macroH2A. Another phenotype of senescence is a 
flattened morphology and increased cell size; however, this phenotype has not been 
confirmed in vivo and may only apply to human adherent cultures. Senescent cultures 
also have an increase in aneuploidy (Walen, 2008).  
In addition to the above phenotypes, induction of senescence by replicative 
senescence, OIS, and the DDR upregulates the secretion of many factors involved in 
cellular signaling, such as growth factors, proteases, and cytokines (Coppe et al., 2008; 
Freund et al., 2010). This secretion profile is known as the senescence associated 
secretory phenotype (SASP). Of particular interest are the increased levels of 
inflammatory cytokines. The robustly secreted factors include interleukin (IL)-8, IL-6, 
IL-1, granulocyte/macrophage colony stimulating factor (GM-CSF), and monocyte 
chemotactic proteins (MCPs) (Freund et al., 2010). In combination with other senescent 
phenotypes, such as growth arrest, SA-β-galactosidase expression, and SAHF formation, 
the SASP can be used to determine if cells have entered senescence. 
 
Senescence and cancer 
Senescence has been attributed to four major biological roles, which include 
aging, tissue repair, tumor suppression and tumor promotion (Rodier and Campisi, 2011). 
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There are several features of senescence that might deter cancer growth. First, senescence 
is common in many benign tumors, suggesting that senescence acts as a barrier to prevent 
pre-cancerous lesions from becoming malignant (Braig et al., 2005; Collado et al., 2005; 
Majumder et al., 2008; Michaloglou et al., 2005; Zhuang et al., 2008). Second, 
senescence is associated with blocking initial tumor formation because many tumor-
causing signals lead to senescence in normal cells. These include the overexpression of 
many oncogenes, including Ras, BRAF, E2F1, and c-Myc (Grandori et al., 2003; 
Lazzerini Denchi et al., 2005; Michaloglou et al., 2005; Serrano et al., 1997), the loss of 
tumor suppressors, such as PTEN (Alimonti et al., 2010; Lin et al., 2010a) and NF1 
(Courtois-Cox et al., 2006). This suggests that a cell must evade senescence in order to 
establish a malignant tumor. Indeed, the main pathways in senescence, p53 and Rb, are 
tumor suppressor pathways that are commonly inactivated in cancers (Sherr and 
McCormick, 2002). Also, tumor cells commonly express hTERT, or can combat 
replicative telomere shortening through a mechanism called alternative lengthening of 
telomeres (Muntoni and Reddel, 2005; Shay and Bacchetti, 1997; Silvestre et al., 2011). 
A third link between senescence and tumor suppression is the occurrence of therapy-
induced senescence (TIS). TIS is a new mechanism to target cancer cells. Recent studies 
have found that many current therapies, including chemotherapy (Gunther et al., 2003; 
Mhaidat et al., 2007; Schmitt et al., 2002) and radiation (Mirzayans et al., 2005; Suzuki 
and Boothman, 2008) induce senescence. Specifically, in some gliomas, TMZ treatment 
can induce senescence in a subset of the tumor cells (Gunther et al., 2003; Sato et al., 
2009). There are several new cancer drug treatments that rely on TIS and have proved 
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promising in preclinical studies (Ewald et al., 2010; Huck et al., 2010; Ota et al., 2006). 
Finally, the fourth concept supporting senescence as a tumor-suppressing mechanism is 
that the induction of senescence and the SASP may play a role in activating the immune 
response that is commonly suppressed in tumors. In addition, senescence has been shown 
to stimulate tumor clearance (Xue et al., 2007). Induction of senescence in a liver 
carcinoma model resulted in a SASP. These tumors had increased infiltration of immune 
cells, which resulted in a decrease in tumor volume. 
Senescence can also play a supportive role in tumor growth (Coppe et al., 2010). 
Although contradictory to the role of tumor clearance, the SASP can also contribute to 
tumor promotion. Many of the secreted factors are pro-proliferative, such as CXCL1, IL-
8, and IL-6, and pro-angiogenic, such as vascular endothelial growth factor (VEGF) 
(Bavik et al., 2006; Coppe et al., 2006; Krtolica et al., 2001; Ksiazek et al., 2008). SASP 
can also lead to epithelial-mesenchymal transition (EMT) and invasiveness (Coppe et al., 
2008). The theory that senescence is cancer-promoting has been demonstrated in mouse 
xenograft models, in which the co-injection of senescent cells with malignant cancer cells 
greatly increases tumor formation (Bhatia et al., 2008; Krtolica et al., 2001; Liu and 
Hornsby, 2007). The antagonistic pleiotropy of senescence implies that the benefits of 
therapy-induced senescence may lead to deleterious affects at later stages. Therefore, if 
cells can escape the initial tumor suppressive properties, senescence may support tumor 
growth during later stages. This suggests that TIS from chemotherapy and IR may 
promote aggressive tumor recurrence. Therefore, TIS will be the most efficient when it 
directly targets the population of cells capable of tumor recurrence. 
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Senescence and Notch 
The signals that control the reversibility of quiescence and keep cells from 
entering an irreversible senescent state remain elusive. Insight into the difference between 
these two types of cell cycle arrest became available when Sang et al. (2008) 
demonstrated that quiescent fibroblast cells require an active Notch pathway to maintain 
their transient cell cycle arrest. The Notch target, Hes1, is upregulated in quiescent 
fibroblasts, and loss of either Notch signaling by DAPT treatment or dominant negative 
(dn) Hes1 expression shifts the quiescent cells into a permanent arrested state. These cells 
express increased SA-β-galactosidase and formed SAHF. In addition, re-expression of 
wtHes1 inhibits the cells from entering senescence, while dnHes1 expression keeps cells 
in an arrested state. These data demonstrate that Notch is a key pathway that modulates 
cells between reversible quiescence and irreversible senescence.  
 
 
Research Framework and Objectives 
There is a dire need for new glioma therapies. Combination therapies will likely 
provide the highest success by targeting the bulk of the tumor with cytotoxic-inducing 
treatments, such as chemotherapy and IR, while target-directed treatments can be used 
against the resistant population. This preclinical study described herein focuses on the 
combination of TMZ treatment and inhibition of the Notch pathway with GSIs. The 
theory for this thesis research developed from two studies described above. First, TMZ is 
not curative in glioma patients and only yields short-term results. We were particularly 
interested in our laboratory’s previous results, demonstrating that TMZ induces a 
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temporary cell cycle arrest in the tumor-propagating population (Mihaliak et al., 2010). 
The next study of interest was from Sang et al. (2008), which stated that active Notch 
signaling is essential to maintain the quiescent state of fibroblast cells. When the Notch 
pathway is blocked, the cells were converted from a reversible cell cycle arrest into an 
irreversible cell cycle arrest, known as senescence. This study will analyze the 
assimilation of these two concepts and test our hypothesis that the treatment combination 
of TMZ with a GSI leads to therapy-induced senescence in glioma cells. 
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CHAPTER II: 
 
Gamma-Secretase Inhibitors Enhance Temozolomide Treatment by Inhibiting 
Neurosphere Repopulation and Xenograft Recurrence 
 
The combination of surgery, IR and TMZ is currently the most successful 
treatment for gliomas. The inclusion of TMZ as the standard chemotherapy treatment has 
resulted in a median 2-month increase to patient survival rates (Stupp et al., 2005). 
Gliomas possess a population of cells that are resistant to current therapies and drive 
tumor recurrence. Development of combination therapies that will target both the bulk of 
the tumor cells and the tumor-propagating CSCs is the most promising direction for 
future glioma treatments. Our laboratory previously developed an in vitro neurosphere 
recovery assay to specifically analyze the glioma cells that evade chemotherapy 
treatments and study drug combinations to target these cells.  
Neurosphere cultures are a good model to study gliomas, because the cells 
maintain genetic profiles similar to the patients’ tumors and form invasive intracranial 
xenografts in immunocompromised mice (Ernst et al., 2009; Lee et al., 2006b; Singh et 
al., 2004). Our neurosphere recovery assay measures neurosphere formation at three time 
points to assess the capacity of the culture to repopulate after chemotherapy (Mihaliak et 
al., 2010). First, we assess the ability of the cells to form neurospheres shortly after 
treatment. Second, we count the number of neurospheres that form during a one-week 
recovery period to determine if the surviving cells resume neurosphere formation. Third, 
we dissociate the neurospheres and count the number of secondary neurospheres that 
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form to measure self-renewal (Reynolds and Weiss, 1996). This neurosphere recovery 
assay provides a quantitative assessment of culture repopulation following drug 
treatment, and is highly relevant to tumor recurrence in the clinic. Utilizing the 
neurosphere recovery assay, we previously demonstrated that TMZ drastically 
diminished initial neurosphere formation in many glioma cultures; however, these 
cultures eventually recovered and formed a robust number of secondary neurospheres 
(Mihaliak et al., 2010). The ability of TMZ-treated neurospheres to recover and 
repopulate the culture suggests that some cells undergo a transient cell cycle arrest, 
allowing them to evade cell death and eventually resume proliferation.  
Notch signaling is a promising pathway to target the glioma cells that recover 
after TMZ treatment. Inhibition of the Notch pathway, by either shRNA or GSIs, can 
target neurosphere- and tumor-propagating cells by increasing cell death and sensitizing 
the cells to IR (Fan et al., 2010; Purow et al., 2005; Wang et al., 2010a). In this study, we 
analyze if the combination of TMZ and GSIs enhances glioma therapy by inhibiting 
tumor repopulation and recurrence. In contrast to TMZ-only treatment, the TMZ + GSI 
treatment strongly inhibits neurosphere recovery. This was confirmed by a loss of 
secondary neurosphere formation in cultures treated with TMZ + GSI. We confirm the 
involvement of the Notch pathway in the response to our drug treatments by 
demonstrating that TMZ + GSI treatment does not inhibit recovery and secondary 
neurosphere formation in glioma cells expressing the constitutively active NICD. In 
addition, we show that the response to TMZ + GSI treatment is schedule-dependent. 
Recovery of neurosphere formation is inhibited when TMZ is administered first, followed 
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by GSI treatment 24 hrs later. If a single dose of GSI is administered prior to, or 
concurrently with TMZ, the culture is able to recover and form secondary neurospheres. 
We also observed the effects of TMZ + GSI treatment on tumor formation and 
progression in a mouse xenograft model. Ex vivo and in vivo TMZ + GSI treatment 
decreased tumor formation and progression. These data demonstrate the importance of 
the Notch pathway for chemoprotection in malignant gliomas. The addition of GSIs to 
the current care regimens for GBM patients is a promising new approach to decrease 
brain tumor recurrence.  
 
Results 
Establishment of glioma neurosphere cultures  
As a first step to test the effects of TMZ and GSI treatments on glioma cultures, 
we converted adherent glioma cell lines to serum-free neurosphere cultures and 
established primary neurosphere cultures from patient tissues. Neurosphere morphology 
ranged from very dense neurospheres in the primary lines, such as GS7-2, GS7-25, and 
GS9-6, to less dense neurospheres in the U87NS and U373NS converted lines, as well as 
irregularly shaped, loosely formed aggregates, as seen in the GS1-7 culture (Fig. 2.1 A) 
The percentage of cells that are capable of forming neurospheres when plated at low 
clonal density, termed neurosphere-initiating cells, varies across cultures (Fig. 2.1 B). 
The converted cultures, U87NS and U373NS, had the largest percent of neurosphere-
initiating cells. Although neurosphere formation is commonly used to analyze the 
presence of CSCs and progenitor cells,  it is important to note that survival,  self-renewal  
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Figure 2.1 Neurosphere formation in established primary neurosphere cultures. A) 
Micrographs of select primary neurosphere cultures. Primary lines established from 
patient glioma tissues form neurospheres in defined serum-free medium. The morphology 
of these neurospheres can very greatly among cultures. Bar = 50 µm. B) The percent of 
neurosphere-initiating cells varies among converted and primary neurosphere cultures. 
The percent neurosphere formation is calculated based on the number of neurospheres 
formed divided by the number of single cells plated. 
 
A. 
B. 
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and proliferation are all aspects of the neurosphere formation assays (Lathia et al., 2011). 
In addition, the analysis of neurospheres should not be used to postulate in vivo tumor 
formation or growth, because the in vitro setting is meant to enhance growth and survival, 
and is lacking many factors from the niche that regulate the balance between growth and 
quiescence. The established lines, U87NS and U373NS, are convenient models to study 
gliomas, but one must take into account that long-term culture systems are both prone to 
selection and additional mutations (Venere et al., 2011). All of the neurosphere cultures 
tested had the potential to form subcutaneous tumors in immunocompromised NU/NU 
nude mice when 1 x 106 live cells were injected (Table 2.1), but they have not been 
compared based on in vivo limiting dilutions. When possible, the p53 sequences were 
analyzed in the primary neurosphere cultures to determine if they expressed wild type 
p53. Finally, MGMT expression was analyzed (Table 2.1). The majority of the cell lines 
expressed low to negative levels of MGMT, which is known to promote sensitivity to 
TMZ treatment. The neurosphere cultures demonstrate various sensitivities to TMZ 
treatment (Table 2.1). Cultures classified as resistant lines did not have any decrease in 
initial neurosphere formation with TMZ concentrations up to 200 µM. Highly sensitive 
lines had a significant decrease in initial neurosphere formation with as low as 5 µM 
TMZ, and were not capable of recovery. Sensitive lines were those that showed a 
significant decrease in initial neurosphere formation, but were capable of neurosphere 
recovery. Although MGMT status, in regards to TMZ sensitivity is very important in the 
clinic, since this proposal focuses on the enhancement of TMZ treatment and inhibiting 
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Table 2.1 Neurosphere cultures established from patient gliomas 
CULTURE ORIGIN PASSAGE 
NS 
FORMATION 
CAPABILITY 
XENOGRAFT 
FORMATION MGMT p53 TMZ RESPONSE 
U373NS serum line/GBM >40 high s.c negative mutant Sensitive 
U87NS serum line/GBM >40 high s.c negative wild type Sensitive 
GS7-2 GBM >30 medium s.c negative mutant Sensitive 
AS5-15 AA >20 medium s.c negative wild type Sensitive 
GS8-26 GBM >20 high TBD negative TBD Sensitive 
GS4-8 GBM >15 medium TBD TBD mutant Sensitive 
GS6-22 GBM >30 high TBD negative mutant Highly Sensitive 
GS9-6 GBM >30 high s.c, i.c negative wild type Highly Sensitive 
GS9-19 GBM >15 low TBD TBD wild type Highly Sensitive 
GS11-29 GBM >20 medium s.c TBD TBD Resistant 
GS7-25 GBM >30 high s.c positive wild type Resistant 
GS9-10 GBM >5 medium TBD TBD TBD TBD 
RGS9-10 recurrent GBM >5 medium TBD TBD TBD TBD 
RGS6-20 recurrent GBM >5 medium TBD TBD TBD TBD 
GS12-28 GBM >15 low TBD TBD TBD TBD 
GS1-7 GBM >10 low/abnormal TBD TBD TBD TBD 
GS10-18 GBM <5 - - - - - 
GS1-15 GBM <3 - - - - - 
GS6-25 GBM <3 - - - - - 
GS9-4 GBM <5 - - - - - 
 
Key: 
s.c: subcutaneous 
i.c.: intracranial 
TBD: to be determined 
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regrowth after treatment, we concentrated our studies on a subset of the TMZ-sensitive 
glioma lines, including U87NS, U373NS, GS7-2, GS8-26 and AS5-15. 
 
Glioma neurosphere cell lines express Notch receptors and downstream targets  
Characterized serum glioma cultures (U87MG, U373MG), converted cell lines 
(U87NS, U373NS) and primary neurosphere cultures established from patients’ GBMs 
(GS7-2, GS8-26) and AAs (AS5-15) express the transcripts for Notch1-4 and the 
downstream targets, Hes1 and Hey1 (Fig. 2.2 A). Notch1, Notch2 and Notch4 expression 
is comparable between the serum lines and the corresponding serum-free neurosphere 
cell lines. Interestingly, Notch3 expression is consistently higher in the converted 
neurosphere cultures, compared to their corresponding serum cultures, while expression 
of the targets, Hes1 and Hey1, varies. In both the converted neurosphere cell lines and the 
primary cultures, the highest expression is for Notch2, Notch3 and Hes1 transcripts. 
Although these results demonstrate the presence of an active Notch pathway, more 
detailed experimentation would be required to analyze the differences between the serum 
lines and serum-free neurosphere cultures. Since Notch activation is a cell-cell contact-
dependent, it is expected that the level of cell confluency in the adherent cultures and the 
size of the neurospheres will affect expression levels of the Notch receptors and 
downstream targets. Treatment with DAPT downregulated the mRNA levels of Hes1 and 
Hey1 (Fig. 2.2 B), demonstrating that the GSI blocks the Notch pathway. The DAPT 
concentration  used  was  determined based on a  50%  or greater decrease of Notch target  
  
56 
56 
 
 
 
Figure 2.2 Notch pathway gene expression in glioma cultures. The Notch pathway is 
active in neurosphere cultures and is blocked with DAPT treatment. A) mRNA levels of 
the Notch receptors and downstream targets were measured by RT-PCR. Notch1-4, Hes1, 
and Hey1 were detected in each neurosphere culture. β-Actin was used for the loading 
control. B) Hes1 and Hey1 expression were analyzed by RT-PCR 48 hours after DAPT 
treatment. DAPT treatment decreased Hes1 and Hey1 mRNA levels by 72% and 76% in 
U87NS (1 µM), and by 76% and 51% in U373NS (5 µM). 
 
B. 
A. 
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transcripts. For subsequent experiments, U87NS and GS7-2 cultures were treated with 1 
µM DAPT, while U373NS, GS8-26, and AS5-15 cultures were treated with 5 µM DAPT. 
 
TMZ + DAPT treatment inhibits neurosphere recovery and secondary neurosphere 
formation 
Neurosphere recovery was analyzed after TMZ-only, DAPT-only, and TMZ + 
DAPT treatments (Fig. 2.3). When administered alone, low concentrations of DAPT (1-5 
µM) decreased Notch pathway signaling (Fig. 2.2 B), but had little to no effect on the 
number of neurospheres (Fig. 2.4 A). In addition, low concentrations of DAPT did not 
affect the size of the neurospheres (Fig. 2.5). In U87NS, U373NS, and GS7-2 cultures, 
treatment with 10 µM DAPT decreased neurosphere formation by 41%, 39%, and 49%, 
respectively, compared to DMSO controls (Fig. 2.4 A); however, the DAPT treated cells 
resumed proliferation and formed secondary neurospheres, even at high concentrations 
(Fig. 2.4 B).  
To determine if DAPT enhances TMZ therapy, we examined the effect of 
combined treatment on neurosphere recovery. Cultures treated with TMZ-only and TMZ 
+ DAPT, had similar effects on neurosphere size and initial neurosphere formation (Fig. 
2.5 and 2.6, red bars). TMZ-only and TMZ + DAPT treatments decreased initial 
neurosphere formation by 80-98% and 83-99%, respectively. Cultures were given an 
additional 7 or 10 days to recover in the absence of drugs. During this recovery period, 
the neurospheres that formed after TMZ-only treatment increased in size; however, the 
TMZ + DAPT  treated  neurospheres  remained the same size  (Fig.  2.5).  The number of  
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Figure 2.3 Neurosphere Recovery Assay Schematic. The neurosphere recovery assay 
can be used to assess drug treatments. On day 0, neurosphere cultures are pH dissociated 
and plated as single cells. TMZ (diamond) is administered on day 0. DAPT (inverted 
triangle) is administered on days 0, 2, 4, and 7. Converted neurosphere cultures, U87NS 
and U373NS are counted on day 7, 14, and 21, while the primary neurosphere cultures, 
GS7-2, GS8-26, and AS5-15 are counted on day 10, 20, and 30.   
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Figure 2.4 DAPT does not significantly decrease neurosphere formation. A) The 
DAPT titration curve demonstrated that low concentrations (1-5 µM) of DAPT-only 
treatment had minimal inhibition of neurosphere formation (mean ± SD) in U87NS, 
U373NS, or GS7-2 cultures. DAPT administered at higher concentrations (10 µM) 
significantly decreased neurosphere formation. Neurospheres were counted on day 7 for 
U87NS and U373NS and on day 10 for GS7-2. The t-test was used to calculate statistical 
significance. B) Secondary neurosphere formation for cells treated with varying 
concentrations of DAPT. U87NS, U373NS, and GS7-2 cells were treated with DMSO (0 
µM DAPT) or DAPT-only at concentrations of 1, 5, and 10 µM. Neurospheres were 
dissociated on day 14 for U87NS and U373NS cultures or on day 20 for GS7-2 cultures 
and re-plated for secondary neurosphere formation.  Despite a decrease in secondary 
neurosphere formation a higher concentrations of DAPT, the treated cells are capable of 
repopulating the culture. *,  P < 0.01. **,  P < 0.001. ***,  P < 0.0001 
A. 
B. 
 ***  
 
* 
 
* 
  *  * 
  ** 
  ** 
Primary neurospheres 
Secondary neurospheres 
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Figure 2.5 Neurosphere size is inhibited by TMZ + DAPT treatment.  Representative 
micrographs of U87NS neurospheres with control DMSO, DAPT (1 µM) TMZ (200 µM) 
and TMZ + DAPT (TMZ (200 µM) combined with DAPT (1 µM)) treatment. 
Neurospheres treated with DAPT display a similar size compared to DMSO control 
cultures at treatment (day 7), recovery (day 14) and secondary (day 21) time points. After 
the initial treatment (day 7), TMZ-only and TMZ + DAPT treated neurospheres are 
smaller than the control cultures. TMZ-only treated neurospheres increased in size during 
the recovery period (day 14) and formed secondary neurospheres (day 21), while TMZ + 
DAPT treated neurospheres did not increase in size or form secondary neurospheres. Bar 
= 50 µm. 
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Figure 2.6 TMZ + DAPT treatment blocks recovery and secondary neurosphere 
formation. The neurosphere recovery assay demonstrates that TMZ + DAPT treatment 
inhibits recovery and secondary neurosphere formation. Initial treated neurospheres 
(mean ± SD) were counted on day 7 for A) U87NS; and B) U373NS cultures; or on day 
10 for C) GS7-2, D) GS8-26, and E) AS5-15 cultures. Recovery neurospheres were 
counted on day 14 or 20, and secondary neurospheres were counted on day 21 or 30. *, P 
< 0.001. **, P < 0.0001. 
 
      * 
   ** 
  ** 
  ** 
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neurospheres also increased after recovery in the TMZ-only treated cultures, but this 
recovery was not observed in the TMZ + DAPT treated cultures. After recovery from the 
TMZ-only treatment, U87NS showed a 2-fold increase and U373NS showed a 1.5-fold 
increase in the number of neurospheres (Fig. 2.6 A and B, blue bars). The primary 
neurosphere cultures also showed a recovery from the TMZ-only treatment: the number 
of GS7-2 neurospheres increased by 1.8-fold, GS8-26, by 1.6-fold and AS5-15, by 3.4-
fold (Fig. 2.6 C-E, blue bars). In contrast, TMZ + DAPT effectively inhibited recovery 
for U87NS, U373NS, GS7-2 and GS8-26 (Fig. 2.6 A-D, blue bars). The number of 
neurospheres in these cultures was essentially the same after recovery on day 14 or 20 
relative to the number of initial neurospheres counted on day 7 or 10. Only AS5-15 
displayed a small recovery (1.7-fold) when treated with TMZ + DAPT, but this recovery 
was not statistically significantly (Figure 2.6 E, blue bar).  
To assess if the cultures retained cells capable of self-renewal, the initial 
neurospheres were dissociated to single cells and re-plated to measure secondary 
neurosphere formation. TMZ-only treated cultures readily formed secondary 
neurospheres, but secondary neurosphere formation for TMZ + DAPT treated cultures 
was significantly diminished. U87NS secondary neurosphere formation in the TMZ-only 
treated culture was 36-fold greater (P < 0.0001) than secondary neurosphere formation in 
the TMZ + DAPT treated culture (Fig. 2.6 A, green bar), and U373NS secondary 
neurosphere formation in the TMZ-only treated culture was 23-fold greater (P < 0.001) 
than in the TMZ + DAPT treated culture (Fig. 2.6 B, green bar). The primary cultures 
also had profuse secondary neurosphere formation after TMZ-only treatments, but 
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minimal secondary neurosphere formation after TMZ + DAPT treatments. Secondary 
neurosphere formation was 45-fold greater (P < 0.001) in the GS7-2 TMZ-only treated 
culture (Fig. 2.6 C, green bar), 25-fold greater (P < 0.001) in the GS8-26 TMZ-only 
treated culture (Fig. 2.6 D, green bar), and 7-fold greater in the AS5-15 treated culture 
(Fig. 2.6 E, green bar), when compared to the TMZ + DAPT treated cultures.  
The number of cells in each neurosphere capable of self-renewal can be calculated 
by dividing the number of secondary neurospheres by the number of neurospheres 
formed during the recovery period. After recovery from TMZ-only treatment, there were 
an average of 8 and 3 cells per neurosphere that maintained self-renewal properties in the 
U87NS and U373NS cultures, respectively; however, in the TMZ + DAPT treated 
cultures there were only approximately 0.5 cells per neurosphere that were capable of 
self-renewal after the recovery period. In the primary lines treated with TMZ-only, each 
neurosphere from the GS7-2, GS8-26 and AS5-15 cultures contained a large number of 
cells capable of self-renewal, an average of 38, 31, and 9 cells, respectively. In contrast, 
the average number of cells capable of self-renewal after TMZ + DAPT treatment 
decreased to only 2 cells per neurosphere in the GS7-2, GS8-26, and AS5-15 cultures.  
To demonstrate that the lack of recovery and secondary neurosphere formation 
after TMZ + DAPT treatment was a specific response to the inhibition of gamma-
secretase activity, we repeated the neurosphere recovery assay with LY411,575 (LY) 
(Fauq et al., 2007). When LY was administered to U87NS and U373NS cultures at 
various concentrations, there was a dose-dependent decrease in neurosphere formation 
(Fig. 2.7 A);  however,  the  LY-only  treated cultures retained the ability to form a robust  
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Figure 2.7 LY411,575 alone does not significantly decrease neurosphere formation. 
LY targets the Notch pathway and synergizes with TMZ treatment to inhibit neurosphere 
recovery. A) U87NS and U373NS cells were treated with varying concentrations of LY, 
and neurospheres were counted after 7 days. B) U373NS LY treated cultures have 
decreased secondary neurosphere formation, when compared to DMSO treated samples; 
however, secondary neurosphere formation was still robust. *, P < 0.01. **, P < 0.001. 
 
    ** 
 * 
     * 
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number of secondary neurospheres (Fig. 2.7 B). In contrast, the combination of TMZ + 
LY significantly repressed neurosphere recovery secondary neurosphere formation (Fig. 
2.8 A and B, red and green bars). 
It was previously shown that cells expressing MGMT have an increased 
resistance to TMZ, because they are can repair the O6-methyl-guanine lesion (Fukushima 
et al., 2009). Therefore, we analyzed MGMT expression by real time PCR. Each of our 
neurosphere lines studied had low to negative MGMT expression, expect for the primary 
line, GS7-25 (Fig. 2.9). Compared to the other lines, GS7-25 had minimal response to 
TMZ treatment. There was only a 24% decrease in neurosphere formation with TMZ-
only treatment (Fig. 2.10 A). Therefore, it appeared that no cells were entering the 
quiescent state due to TMZ treatment. There was no increase in neurosphere formation 
during the recovery period for either the TMZ-only or the TMZ + DAPT treated cultures 
(Fig. 2.10 B). This demonstrates that MGMT-positive lines are unresponsive to the 
double treatment. 
  
Serum cultures are more sensitive to TMZ and do not recovery  
To determine if this recovery was specific to the neurosphere cultures, we tested 
the combined drug treatment in the original serum cultures, U87MG and U373MG. After 
treatments, proliferation was analyzed based on the number of live cells present on days 
7, 14, and 21. The low concentrations of DAPT (1 µM for U87MG and 5 µM U373MG) 
used in the previously described neurosphere assays had minimal affect on cell number 
when administered alone  (Fig.  2.11  A  and  B).  We found that the adherent glioma cell  
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Figure 2.8 TMZ + LY blocks neurosphere recovery and secondary neurosphere 
formation. The recovery assay for A) U87NS and B) U373NS cells demonstrated that 
combined treatment with TMZ + LY inhibited neurosphere recovery and secondary 
neurosphere formation. The t-test was used to calculate statistical significance. Initial 
treated neurospheres (mean ± SD) were counted on day 7. Recovery neurospheres were 
counted on day 14, and secondary neurospheres were counted on day 21.  *, P < 0.01. 
     * 
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Figure 2.9 MGMT expression levels by real time PCR in neurosphere converted 
cultures and primary lines. PC-3 is a human prostate cancer cell line is used here as a 
positive control because of it’s high expression of MGMT. Of the tested lines, U87NS, 
U373NS and GS7-2 had no detectable levels of MGMT transcript. AS5-15 displayed 
minimal levels of MGMT transcript, and GS7-25 was positive for MGMT expression. 
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Figure 2.10 MGMT+ lines are not responsive to TMZ treatment. A) Neurosphere 
assay to test TMZ sensitivity among cultures. Converted lines, U87NS and U373NS, 
were counted on day 7, and the primary lines, GS7-2, GS8-26, AS5-15, and GS7-25 were 
counted on day 10. All the lines with negative or low MGMT expression were sensitive 
to TMZ treatment at 200 µM, while the MGMT-positive line, GS7-25 was resistant. B) 
The addition of DAPT to did not enhance TMZ treatment in the GS7-25 MGMT-positive 
culture. There was no increase in neurosphere formation between the treated day 7 
cultures and the recovery on day 14 for either TMZ-only or TMZ + DAPT treatments. 
 
A. 
B. GS7-25 
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Figure 2.11 Adherent glioma cultures do not recover after TMZ or TMZ + DAPT 
treatments. Cell survival was analyzed in the serum cultures A) U87MG and B) 
U373MG. DAPT treatment did not significantly affect cell growth in either culture. 
However, TMZ treatment was highly affective in the adherent lines. TMZ treatment 
resulted in a decrease in cell number, and no recovery occurred in either the U87MG or 
U373MG cultures. TMZ + DAPT treatment showed the same effect as TMZ-only 
treatment. 
 
A. 
B. 
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lines are more sensitive to 200 µM TMZ than the neurosphere cultures. Both adherent 
cultures demonstrate a loss of cell number by day 14, and there is no recovery observed. 
Due to the high efficiency of TMZ treatment alone in the serum-grown, adherent lines, 
there was no detectable enhancement of treatment when TMZ was combined with Notch 
inhibition. It is possible that lower concentrations of TMZ may uncover a subpopulation 
of cells in the adherent culture that are capable of recovery. However, these data 
demonstrate that the neurosphere cultures have a more heterogeneous response to TMZ 
than the adherent cultures, demonstrating the benefit of using neurosphere cultures as the 
in vitro model to study the resistant subpopulations within gliomas. 
 
Constitutive expression of NICD protects neurosphere cultures from TMZ + DAPT 
treatment 
In addition to the Notch receptors, gamma-secretase can cleave other substrates 
(Beel and Sanders, 2008). To establish that DAPT enhances TMZ treatment by targeting 
the Notch pathway, we infected U87NS and GS7-2 cells with a retrovirus to express the 
constitutively active NICD1 (Pui et al., 1999). Expression of the GFP reporter gene was 
used to sort the cells infected with NICD or the empty control vector pMIG. Expression 
of functional NICD was confirmed by measuring increased mRNA levels of the 
downstream targets, Hes1 and Hey1 (Fig. 2.12 A). When NICD is constitutively 
expressed, the Notch pathway is not inhibited by DAPT treatment (Fig 2.12 B). NICD-
expressing U87NS and GS7-2 cells treated with TMZ-only were capable of recovery and 
robust secondary neurosphere formation, similar to the control cells expressing the empty  
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Figure 2.12 Expression of constitutively active NICD blocks GSI knockdown of 
Notch targets. A) RT-PCR analysis of Hes1 and Hey1 expression was used to confirm 
NICD activity. Hes1 and Hey1 expression increased in U87NS-NICD and GS7-2-NICD 
cultures compared to cultures expressing the empty vector (pMIG). B) DAPT does not 
inhibit the Notch pathway in neurospheres constitutively expressing NICD. U87NS-
pMIG and U87NS-NICD cells were treated with 1 µM DAPT and collected 48 hours 
after treatment. qRT-PCR analysis demonstrated that Hes1 and Hey1 expression 
decreased in the representative DAPT treated samples. However, U87NS-NICD culture 
had a minimal decrease of Hes1 and Hey1 expression in the DMSO and DAPT treated 
samples. 
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vector (pMIG) (Fig. 2.13 A and B). Importantly, NICD expression attenuated the effects 
of TMZ + DAPT treatment, and the culture demonstrated neurosphere recovery and 
robust secondary neurosphere formation. The control U87NS-pMIG TMZ-only treated 
cells had a 1.9-fold recovery, but no increase was seen in the TMZ + DAPT treated 
culture (Fig. 2.13 A, blue bars). U87NS-NICD cells showed a 2.3–fold recovery in TMZ-
only treated cultures and a 1.8-fold recovery in TMZ + DAPT treated cultures. GS7-2-
pMIG TMZ-only treated cells showed a 2.1-fold increase in neurospheres during 
recovery, while TMZ + DAPT treated cells showed no recovery (Fig. 2.13 C, blue bars). 
GS7-2-NICD cells showed a 2.6–fold recovery after TMZ-only and a 2.8–fold recovery 
after TMZ + DAPT treatment. 
Similar to the parental lines, U87NS-pMIG and GS7-2-pMIG cultures treated 
with TMZ-only had robust secondary neurosphere formation, but cultures treated with 
TMZ + DAPT had minimal secondary neurosphere formation (Fig. 2.13 A and B). In 
contrast, U87NS-NICD and GS7-2-NICD cultures had robust secondary neurosphere 
formation for both TMZ-only and TMZ + DAPT treatments. When treated with TMZ + 
DAPT, U87NS-NICD secondary neurosphere formation was 61.2-fold greater (P < 
0.0001) than U87NS-pMIG secondary neurosphere formation (Fig. 2.13 A, green bars). 
In the GS7-2-NICD TMZ + DAPT treated cultures, secondary neurosphere formation 
was 47.8-fold greater (P < 0.0001) than secondary neurosphere formation in the GS7-2-
pMIG TMZ + DAPT treated cultures (Fig. 2.13 B, green bars). Hence, constitutive NICD 
expression eliminates GSI enhancement of TMZ therapy, identifying the Notch pathway 
as the relevant GSI target. 
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Figure 2.13 Expression of constitutively active NICD attenuates the TMZ + DAPT 
treatment synergy. NICD-expressing cultures resume neurosphere formation following 
TMZ + DAPT treatment. A) Treating U87NS-pMIG with TMZ + DAPT inhibited 
recovery, but U87NS-NICD cultures recovered after both TMZ-only and TMZ + DAPT 
treatment. B) In GS7-2-pMIG and GS7-2-NICD cultures treated with TMZ-only or TMZ 
+ DAPT, cultures constitutively expressing NICD, but not the empty vector, were able to 
recover after TMZ + DAPT treatment. *, P < 0.0001. 
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TMZ + DAPT treatment response is schedule-dependent 
We tested if single DAPT doses administered before, during, or after TMZ 
treatment would have distinct effects. TMZ and DAPT were administered to U87NS, 
U373NS and GS7-2 neurosphere cultures with three treatment schedules (Fig. 2.14). 
Interestingly, pre-treatment with DAPT decreased the efficacy of TMZ. Initial 
neurosphere formation was 7.2-fold, 1.7-fold and 2.7-fold greater than neurosphere 
formation in TMZ-only treated U87NS, U373NS and GS7-2 cultures, respectively (Fig. 
2.15 A-C, red bars). When dissociated, the pre-treated and co-treated samples formed a 
large number of secondary neurospheres; however, post-treated samples had minimal 
secondary neurosphere formation (Fig. 2.15 A-C, green bars). Secondary neurosphere 
formation was significantly greater in TMZ-only, pre-treated and co-treated cultures 
compared to post-treated cultures. Secondary neurosphere formation in U87NS cultures 
was 5.7-fold greater (P < 0.001) with TMZ-only treatment, 8.1-fold greater (P < 0.001) 
with DAPT pre-treatment, and 4.8-fold greater (P < 0.01) with co-treatment, relative to 
secondary neurosphere formation after DAPT post-treatment (Fig. 2.15 A, green bars). 
For U373NS secondary neurosphere formation, TMZ-only treatment was 5.7-fold greater 
(P < 0.01), DAPT pre-treatment was 8.1-fold greater (P < 0.01), and co-treatment was 
4.8-fold greater (P < 0.01) than to secondary neurosphere formation in DAPT post-treated 
samples (Fig. 2.15 B, green bars). The inhibition of GS7-2 secondary neurosphere 
formation was also greatest with post-treatment. Secondary neurosphere formation in the 
GS7-2 cultures was 85.7-fold greater (P < 0.0001) with TMZ-only treatment, 98.5-fold 
greater  (P < 0.0001)  with DAPT pre-treatment, and 72.8-fold greater  (P < 0.0001)  with  
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Figure 2.14 Neurosphere recovery assay drug schedule treatment schematic. The 
neurosphere recovery assay was used to analyze single dose GSI treatments and the effect 
of schedule treatment with TMZ + DAPT on neurosphere secondary neurosphere 
formation. TMZ (diamond) and DAPT (inverted triangle) treatments were either 
administered with DAPT 24 hours prior to TMZ (pre-treat), simultaneously with TMZ 
(co-treat), or 24 hours after TMZ (post-treat). 
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      * 
Figure 2.15 Schedule treatment affects recovery 
and secondary neurosphere formation. A) 
U87NS, B) U373NS, and C) GS7-2 cultures were 
treated with different DAPT treatment schedules 
and recovery was analyzed. Initial neurospheres 
were counted on day 7 or 10 (mean ± SD), 
recovery neurospheres were counted on day 14 or 
20, and secondary neurospheres were counted on 
day 21 or 30. Secondary neurosphere formation 
was inhibited only in cultures treated with the 
post-treat schedule. The t-test was used to calculate 
statistical significance. *, P < 0.001. 
 
      * 
      * 
       
  * 
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co-treatment, when compared to the DAPT post-treatment (Fig. 2.15 C, green bars). The 
differences of neurosphere growth and secondary neurosphere formation among the 
various TMZ and DAPT treatment schedules could also be observed by neurosphere size 
(Fig. 2.16). In general, the neurospheres present on day 7 were of similar size in all three 
treatment schedules; however, at day 14, there were more neurospheres that had 
increased in size in the DAPT pre-treated and co-treated samples. In addition, at day 21, 
secondary neurospheres for DAPT pre-treatment and co-treatment were normal sized, 
while most of the DAPT post-treatment sample consisted of single cells. 
The number of cells per neurosphere that were capable of secondary neurosphere 
formation where similar for TMZ-only, pre-treatment, and co-treatment, while the self-
renewal capacity was greatly reduced in the DAPT post-treated samples. After recovery 
from TMZ-only treatment, there were an average of 8, 3, and 29 cells per neurosphere 
that maintained self-renewal properties in the U87NS, U373NS and GS7-2 cultures, 
respectively. The number of cells capable of self-renewal in the pre-treated U87NS, 
U373NS and GS7-2 cultures were 4, 1, and 22 cells per neurosphere, respectively. 
Similarly, co-treated samples had 10, 3, and 36 cells per neurosphere, for U87NS, 
U373NS, and GS7-2, respectively. However, for the post-treated samples, only 2, 0.8, 
and 2 cells per neurosphere formed secondary neurospheres, demonstrating a decrease in 
self-renewal. Overall, these results led to two observations. First, TMZ + DAPT 
treatment acts through a specific, sequence-dependent mechanism. Second, these results 
provide insight for in vivo treatment schedule. 
  
78 
78 
 
 
 
Figure 2.16 Neurosphere size after schedule treatment assay. Representative 
micrographs of U87NS neurospheres with schedule treatments administered either with 
DAPT 24 hours prior to TMZ (pre-treat), simultaneously with TMZ (co-treat), or 24 
hours after TMZ (post-treat). Pre-treated and co-treated neurospheres displayed an 
increase in neurosphere size treatment (day 7) to recovery (day 14). These treated spheres 
also demonstrated normal secondary neurosphere formation (day 21). In contrast, post-
treated U87NS cells did not have an increase in neurosphere size from the treatment 
period (day 7) to the recovery period (day 14). After dissociation, the post-treated 
samples contained mostly single cells and did not form secondary neurospheres (day 21), 
Bar = 50 µm. 
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TMZ + DAPT ex vivo treatment greatly reduces tumor formation  
We tested if neurosphere recovery correlated with the ability of cells to initiate 
tumors in a subcutaneous xenograft model. The converted neurosphere cultures, U87NS 
and U373NS, were used for xenograft experiments, because they have a high incidence 
of tumor formation and short tumor latency. Primary lines will be ideal for future 
experiments, but were not used for these mouse studies, due to their significantly longer 
time required for tumor formation and limitations with cell number availability. U87NS 
cultures were treated with DMSO, DAPT-only, TMZ-only or TMZ + DAPT. Since TMZ-
only and TMZ + DAPT treatments lead to an increase in the percentage of dead cells, it is 
important to use the same number of live cells for the subcutaneous injections from each 
treatment cohort. This is assessed using trypan blue staining. Immunocompromised 
NU/NU nude mice were subcutaneously injected in the right flank with 2.5 x 105 live 
cells, and tumor initiation was scored when a palpable tumor formed. DMSO and DAPT-
only ex vivo treated cells showed similar tumor incidence (6/7 and 7/7, respectively) and 
average latencies of 15 and 14 days, respectively. TMZ-only treated cells had an 
increased tumor latency of 32 days, but the tumor incidence (6/7 mice) was similar to 
control xenografts (Fig. 2.17 A; Table 2.2). Impressively, none of the mice injected with 
TMZ + DAPT treated cells (0/7 mice) formed tumors, even after 90 days. When a higher 
number of live U87NS cells (3 x 106) were injected, we saw a similar trend (Table 2.2). 
Mice with 3 x 106 cells for U87NS DMSO (2/2 mice) and DAPT-only (2/2 mice) 
xenografts developed palpable tumors at 3 and 4 days, respectively, and 3/4 mice formed 
tumors in  TMZ-only  treated cells with an average latency of  25  days.  With this higher  
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Figure 2.17 Ex vivo TMZ + DAPT treatment decreases tumorigenicity. TMZ + DAPT 
treatment decreases tumorigenicity. A) U87NS cells were treated ex vivo with DMSO, 
DAPT 1 µM, TMZ 200 µM or TMZ 200 µM + DAPT 1 µM, and 7 days post-treatment, 
mice were subcutaneously injected with 2.5 x 105 live cells. TMZ treatment increased 
latency, but xenografts still formed. TMZ + DAPT inhibited xenograft formation. B) 
U373NS cells were treated ex vivo, and mice were subcutaneously injected with 3 x 106 
live cells. TMZ 200 µM treatment increased latency, but tumors still formed. TMZ 200 
µM + DAPT 5 µM treatment decreased xenograft formation. 
A. 
B. 
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Table 2.2 Tumor formation in subcutaneous xenografts after ex vivo drug treatment 
Ex vivo Treated Xenografts  
Tumor Incidence and Average Latency (days) 
 
 U87NS U373NS 
 
 2.5 x 10
5 3 x 106 3 x 106 
DMSO 6/7 (15) 2/2 ( 3 ) 7/7 (15) 
DAPT 7/7 (14) 2/2 ( 4 ) 7/7 (16) 
TMZ 6/7  (32) 3/4 (25) 6/7 (45) 
TMZ + DAPT 0/7  ( - ) 1/4 (43) 1/7 (96) 
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number of cells injected, U87NS TMZ + DAPT xenografts formed tumors in only 1/4 
mice with a longer latency of 43 days.  
U373NS cultures were treated with DMSO, DAPT-only, TMZ-only or TMZ + 
DAPT, and 3 x 106 live cells were injected subcutaneously into NU/NU nude mice (Fig. 
2.17 B; Table 2.2). The control DMSO cells formed palpable tumors in an average of 15 
days for 7/7 xenografts, and DAPT-only treated cells formed tumors in an average of 16 
days for 7/7 xenografts. Ex vivo treatment with TMZ-only increased the latency of tumor 
formation; however, the tumor incidence was similar to the DMSO control xenografts. 
Palpable tumors formed for 6/7 TMZ-treated U373NS xenografts in an average of 43 
days. Ex vivo treatment with TMZ + DAPT greatly reduced tumor formation in mice. 
Only 1/7 mice formed a tumor in the TMZ + DAPT U373NS xenografts with an 
extended latency of 96 days. The tumor-free mice were observed for up to 120 days 
before sacrifice. These ex vivo experiments demonstrate the potency of TMZ + DAPT 
combined treatment in reducing tumor formation. 
 
TMZ + LY in vivo treatment inhibits tumor regrowth  
Although DAPT greatly enhances TMZ treatment in vitro, it has a poor potency in 
vivo, and requires high doses to target to observe an effect (Dovey et al., 2001; Lanz et 
al., 2004). In contrast, LY411,575 (LY) is a potent GSI both in vitro and in vivo. We 
tested the effect of in vivo TMZ + GSI treatments on pre-existing subcutaneous glioma 
xenografts with two i.p. injections of TMZ (20 mg/kg/day) alone, or combined with a 
ten-day diet of LY411,575 chow (Samon et al., 2008). During drug administration, 
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toxicity was determined by weight loss. TMZ-only and TMZ + LY chow cohorts initially 
showed a slight weight loss after TMZ injections (Fig. 2.18 A). However, the TMZ-only 
and TMZ + LY chow mice returned to their starting body weight, and no significant 
weight difference was observed throughout the remainder of the treatment. This 
demonstrates that the mice tolerated the LY chow alone and the combination of the TMZ 
+ LY chow. The lack of overall weight loss also suggests that the mice on LY chow diets 
did not significantly reduce their food consumption compared to control mice and 
received the estimated average dose of 5 mg/kg/day of LY (Samon et al., 2008). The ten-
day diet of LY chow significantly decreased the mRNA levels of the Notch targets Hes1 
and Hey1 (Fig. 2.18 B). Mice were subcutaneously injected with 1 x 106 U87NS cells and 
treated when the tumors reached a volume of approximately 150 mm3. When the tumor 
reached a volume that was double the original volume measured at the start of the drug 
treatments, we judged the xenograft as progressing. The DMSO control and LY chow-
only cohorts did not have any delay in tumor progression (Fig. 2.19 A). TMZ treatment 
initially decreased tumor volumes (Fig. 2.19 B and 2.20 A). However, the TMZ-only 
treated tumors eventually progressed in 8/8 xenografts, and tumor volume doubled in an 
average of 23 ± 7 days after treatment (Fig. 2.19 A, C and 2.20 A). These tumors had a 
normal growth rate and were sacrificed between 23 to 39 days post-treatment. 
Impressively, 4/8 the mice treated with TMZ + LY chow displayed no tumor progression 
(Fig. 2.19 A). In the other 4/8 mice treated with TMZ + LY chow, tumor progression 
occurred in an average of 26 ± 3 days (Fig. 2.20 B), and mice were euthanized between 
24  to  33  days  post-treatment.  The  TMZ  +  LY  chow  mice  that  did not  have tumor  
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Figure 2.18 In vivo TMZ and LY chow treatment effects on toxicity and gene 
expression. A) Tolerance of the drug treatments was determined by measuring the 
weight of the mice during the period of drug administration. Initially, TMZ-only and 
TMZ + LY chow cohorts demonstrate a slight decrease in body weight, but the mice 
quickly recover. There was no significant change in the final weight of the mice for any 
of the drug treatments. For DMSO, n = 4; LY chow, n = 5; TMZ-only, n = 6; and TMZ + 
LY chow, n = 6. B) LY chow significantly decreased the mRNA levels of the Notch 
targets Hes1 and Hey1 in glioblastoma tumors. Immunocompromised NU/NU nude mice 
with pre-existing U87NS xenografts were given a diet of normal chow (n = 4) or LY 
chow (n = 4) for ten consecutive days. After LY treatment, mRNA was isolated from the 
xenografts and Notch activity was analyzed by qRT-PCR. Hes1 and Hey1 expression 
significantly decreased in the LY chow cohorts. ***, P < 0.0001. 
 
A. 
B. 
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Figure 2.19 In vivo TMZ + LY treatment blocks tumor progression. A) In vivo TMZ 
treatment increased the tumor latency in U87NS xenografts, but 100% of the mice 
succumbed to progression. TMZ + LY chow treatment completely blocked progression in 
50% of the mice. B) Tumor volumes at the midpoint, measured between drug treatment 
and mouse sacrifice. No significant difference in tumor volume is observed between 
DMSO and LY chow cohort at the midpoint measurement.  TMZ-only treated mice 
possess smaller tumors at the midpoint measurement, while TMZ + LY chow treated 
mice present with the lowest tumor volume. C) Tumor volumes at the time sacrifice. In 
the TMZ + LY chow treated mice, two separate groups were observed at the endpoint 
measurement. 50% of the mice showed full progression, while the remaining 50% had no 
progression. The U87NS TMZ + LY chow treated xenografts that lacked progression had 
no palpable tumor at 150 days post-treatment. 
A. 
B. C. 
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Figure 2.20 Individual tumor volumes from in vivo TMZ + LY treatment. A) Mice 
with pre-existing tumors were treated in vivo with TMZ-only when tumors reached 
approximately 150 mm3 and observed for tumor progression, which was classified as the 
point when the tumor doubled in volume, approximately 300 mm3. Tumors initially 
began to decrease in volume 5 days after the beginning of treatment. Although all TMZ-
only tumors demonstrated regrowth, the time until tumor progression varied greatly 
between 14 to 32 days after treatment. B) Mice with pre-existing tumors were treated 
with TMZ + LY chow when the tumors reached approximately 150 mm3. Tumors 
initially decreased in volume 5 days after the beginning of treatments. 4/8 mice 
demonstrated tumor progression between 23 to 30 days.  The other 4/8 mice 
demonstrated a complete loss of tumor mass and remained at 0 mm3 for 150 days after 
treatment until the mice were sacrificed. 
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progression displayed a complete loss of a palpable tumor and remained tumor-free until 
euthanized at 150 days (Fig. 2.19 A, C and 2.20 B). In these mice, no tumor masses were 
evident by gross dissection and examination of H&E stained sections (Fig. 2.21). Hence, 
the TMZ + LY chow treatment had a dramatic effect on pre-existing tumors by curing 
50% of the mice. It is important to note that the in vivo drug administration recapitulated 
the GSI post-treatment used for studying the affect of treatment schedules on neurosphere 
recovery in vitro.  
 
Discussion 
With current AA and GBM treatment, tumor recurrence is highly probable. Our 
laboratory’s neurosphere recovery assay demonstrates that glioma cells that survive 
chemotherapy can repopulate neurosphere cultures and form tumors (Mihaliak et al., 
2010). Neurosphere cultures are useful to study glioma responses to drug treatments, 
since the neurospheres have similar phenotypes and genotypes to patient tumors (Ernst et 
al., 2009; Lee et al., 2006b). When neurospheres established from patient gliomas are 
treated with clinically relevant concentrations of TMZ, a small number of cells survive, 
recover from the chemotherapy and repopulate the cultures. In converted cell lines, this 
recovery was also observed with high TMZ drug concentrations. These results resemble 
tumor recurrence in the clinic after glioma patients are treated with TMZ. The quick 
tumor recurrence observed in the clinic, and the repopulation of neurosphere cultures 
after TMZ treatment, demonstrate the dire need for combination therapies to target the 
cells that recover from chemotherapy.  
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Figure 2.21 In vivo TMZ + LY treatment leads to tumor regression in 50% of treated 
mice. H&E staining of mouse skin paraffin sections shows xenograft loss in TMZ + LY 
treated mice (4x objective). After gross dissection, strips of skin at the location where the 
tumor originally formed were fixed and placed in paraffin. When sections were stained 
with H&E, a small region of scar tissue (arrow) with low cell density remained from the 
original U87NS xenograft. 
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The Notch pathway is active in gliomas, and can be inhibited with GSI treatment. 
In culture, we demonstrated that low concentrations of GSIs alone (1 µM and 5 µM) did 
not have a significant effect on neurosphere formation. These results are consistent with 
Wang et al. (2010a), who demonstrated that low concentrations of DAPT or L685,458 
only moderately reduced cell growth. However, a recent publication demonstrated that 
the potent GSI-18 inhibited neurosphere formation and xenograft growth (Fan et al., 
2010). GSI-18 is more effective at blocking the Notch pathway and less toxic than DAPT 
(Yu et al., 2008), which may be the cause of the decreased neurosphere growth with GSI-
18 treatment alone. In the presence of higher concentrations of DAPT or LY411,575, a 
dose-dependent response was observed. At 10 µM, the GSIs had a moderate effect on 
initial neurosphere formation; however, following drug removal, these cells retained their 
ability to form secondary neurospheres. It appears that high concentrations of GSIs 
impede the proliferation of neurosphere cells, but these cells retain the ability to 
repopulate the culture. On the other hand, we demonstrated that low concentrations of 
two GSIs, DAPT and LY411,575, enhanced TMZ treatment. Neurosphere recovery was 
inhibited, and tumor formation was greatly reduced with TMZ + GSI treatment. This 
response was most drastic when analyzing the secondary neurosphere formation after 
treatment. TMZ-only treated cultures were capable of robust secondary neurosphere 
formation, while TMZ + GSI treated cultures were no longer capable of self-renewal, 
based on their inability to form secondary neurospheres. This supports the hypothesis that 
TMZ treatment induces a transient cell cycle arrest in neurosphere-initiating cells that 
block them from forming initial neurospheres, but they can recover and repopulate the 
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culture. One interesting question is whether the cells that form the original neurospheres 
after initial TMZ treatment and after recovery are part of the neurosphere-initiating cell 
population during secondary neurosphere formation. This question could be studied using 
single-cell, clonal neurosphere assays and lineage tracking experiments. A caveat to the 
secondary neurosphere formation in the recovery assay is that the cells are not re-counted 
after dissociation and same number of cells are not plated for each treatment cohort. 
Therefore, the cells, specifically in DMSO and GSI-only treatments, are not plated at a 
clonal density. Plating the cells for secondary neurosphere formation at clonal density 
would also allow the comparison of the percent of neurosphere-initiating cells before and 
after treatments.  
The specific population of cells that is targeted by TMZ + GSI treatment is 
unknown. Research in the CSC field shows that glioma CSCs exhibit chemo- and radio-
resistance (Bao et al., 2006a; Kang and Kang, 2007; Liu et al., 2006). Since Notch 
activity is associated with glioma CSC function and survival (Jeon et al., 2008; Shih and 
Holland, 2006), and the cells that survive TMZ-only treatment are capable of self-
renewal and tumor initiation, it is probable that the cells targeted by TMZ + GSI 
treatment possess a CSC phenotype. There is controversy about the current glioma CSC 
markers, such as CD133 (Gilbert and Ross, 2009), and further progress in the field will 
be necessary to determine if the TMZ + GSI responsive cells and the CSCs are the same 
population.  
Combined drug treatment with TMZ and GSIs targets tumor-propagating cells 
and inhibits tumor progression, consistent with the targeting of a CSC population. Our 
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mouse experiments demonstrate that the addition of GSIs to TMZ treatment can 
significantly enhance the survival of mice with glioma xenografts. Ex vivo treatment of 
U87NS and U373NS cultures with TMZ + DAPT greatly decreased tumorigenicity. The 
in vivo treatments demonstrated that TMZ-only treatment of pre-existing only 
temporarily blocked tumor progression. In contrast, 50% of the TMZ + LY chow treated 
mice had a complete lack of tumor progression, which culminated with the loss of a 
palpable tumor. In the other 50% of treated mice, there was substantial tumor volume at 
the time of sacrifice. This variability may result from several sources. In the mice that 
have a shorter latency the TMZ concentration may not be high enough to induce a cell 
cycle arrest in all of the cells capable of recovery, which would hinder GSI enhancement. 
Also, a slight variability in the food consumption between mice in the TMZ + LY chow 
cohort could explain the heterogeneous response. To circumvent this variability, future 
experiments will utilize drug administration by gavage to control the LY dosing in each 
mouse. These observations emphasize the need for personalized treatment and drug 
dosing. The response to the in vivo treatment schedule was analogous to the DAPT post-
treatment schedule in the neurosphere recovery assay, which demonstrated that TMZ + 
GSI treatments permanently blocked culture repopulation and tumor regrowth. These 
studies suggest a role for TMZ + GSI therapy to reduce recurrences in patients with low 
tumor burden after surgical resection of the bulk tumor. 
The advantage of the subcutaneous xenograft model is it is easy to establish the 
tumor and quantify tumor volume. It is also more cost effective to quantify tumor burden 
of subcutaneous xenografts by measure the diameter than the methods to measure 
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intracranial xenograft tumor burden, such as xenogen cameras and MRI. Due to the 
constant observation of the tumor burden over a large time period (up to 150 days), it was 
most practical to begin TMZ + GSI in vitro and in vivo studies using the subcutaneous 
xenograft model. The subcutaneous assays were acceptable for this study, because it 
allows a visible analysis of tumor regrowth after TMZ treatment; however, the 
weaknesses of testing drug response in the subcutaneous xenograft model include the 
lack of the tumor microenvironment and the lack of the blood brain barrier. Drug 
treatments on pre-existing intracranial xenografts would help to overcome these 
limitations.  
Inhibiting the repopulation of the neurosphere cultures is dependent on the 
sequence of TMZ and GSI treatments. With single doses of DAPT, secondary 
neurosphere formation was inhibited only when TMZ was administered prior to DAPT 
(post-treated). Simultaneous treatment of TMZ and DAPT did not significantly inhibit 
self-renewal. When DAPT was administered before TMZ (pre-treated), secondary 
neurosphere formation was similar to the TMZ-only treated cells. Pre-treatment also 
resulted in a higher number of initial neurospheres forming. Although the explanation for 
this was not examined in further detail, dividing cells are the population normally 
sensitive to TMZ-induced cytotoxicity, and it is possible that pre-treatment with DAPT 
slows down the cell cycle enough to decrease the efficiency of TMZ treatment (Jing et 
al., 2010; Suwanjunee et al., 2008). These results were important in determining in vivo 
treatment schedules for mice, and will be valuable to translate this research into the 
clinic. Since current treatments also include radiotherapy, we ultimately need to add IR to 
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our TMZ + GSI treatment schedule. Recently, it was found that TMZ and IR are additive 
when TMZ is administered prior to IR (Chalmers et al., 2009).  
An additional benefit of the combined treatment with TMZ + GSI is that lower 
concentrations of the GSI can be used, and in culture, a single dose of GSI is sufficient to 
enhance TMZ therapy. These may be important clinical factors, because GSIs can cause 
cytotoxicity in the gastrointestinal tract (Barten et al., 2006); however, the combination of 
TMZ with low GSI doses and intermittent treatment schedules will diminish the chances 
of these side effects (Rizzo et al., 2008). Previous clinical studies in Alzheimer patients 
demonstrated that achievable GSI (LY450139) levels in the CSF ranged between 0.8 to 
2.3 µM, and the half life of the studied GSI was approximately 2.5 hours (Siemers et al., 
2005; Siemers et al., 2006). It is also possible that more specific inhibitors, such as anti-
Notch receptor antibodies (Wu et al., 2010b), could be utilized in conjunction with TMZ. 
 
Materials and Methods 
Cell culture 
U373MG (Dr. Larry Recht, Stanford University) and U87MG (ATCC) were 
cultured in high glucose DMEM (GIBCO, Carlsbad, CA) with supplemented with 1X 
sodium pyruvate (GIBCO, Carlsbad, CA), 10% fetal bovine serum (Sigma-Aldrich, St. 
Louis, MO) and 1% penicillin-streptomycin (GIBCO, Carlsbad, CA). To convert the 
U87MG adherent serum culture into the U87NS neurosphere culture, cells were 
trypsinized and immediately plated in serum-free, defined medium consisting of 
DMEM/F12 1:1 (GIBCO, Carlsbad, CA), B27 (GIBCO, Carlsbad, CA), 15 mM HEPES 
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(GIBCO, Carlsbad, CA), 20 ng/ml EGF (Invitrogen, Carlsbad, CA), and 20 ng/ml bFGF 
(Invitrogen, Carlsbad, CA) and 1% penicillin-streptomycin (GIBCO, Carlsbad, CA). To 
convert the U373MG adherent serum culture into the U373NS neurosphere culture, cells 
were propagated in DMEM/F12 1:1 (GIBCO, Carlsbad, CA) containing 20% FBS until 
confluent and adherent neurospheres formed. The media was then switched to serum-
free, defined media and the cells grew as suspension neurospheres.  
The University of Massachusetts Medical School Tissue Bank Core supplied 
resected brain tumor tissues after surgery. All procedures had Institutional Review Board 
approval. Tumor tissue was cut into small sections and incubated at 37oC in a 1:1 mixture 
of defined medium and crude trypsin. The tissue was triturated every 10 minutes to 
obtain single cell suspensions. After one hour, the cells were washed with PBS and plated 
in defined medium. The first neurospheres formed within two to three weeks. We classify 
primary cultures from grade III AAs or IV GBMs and named them AS or GS, 
respectively (Tom Smith, University of Massachusetts Medical School). The primary 
neurosphere cultures, GS7-2 and GS7-25, were received from Brent Cochran (Tufts 
School of Medicine) (Sherry et al., 2009). All primary neurosphere experiments were 
carried out with cultures between passages 10 and 20.  
Glioma cell lines converted to neurosphere cultures and primary GBM lines were 
grown in serum-free defined medium consisting of DMEM/F12 1:1 (GIBCO, Carlsbad, 
CA), B27 (GIBCO, Carlsbad, CA), 15 mM HEPES (GIBCO, Carlsbad, CA), 20 ng/ml 
EGF (Invitrogen, Carlsbad, CA), and 20 ng/ml bFGF (Invitrogen, Carlsbad, CA) and 1% 
penicillin-streptomycin (GIBCO, Carlsbad, CA). Cultures were passaged using a pH 
  
95 
95 
dissociation method (Sen et al., 2004). There are several methods of neurosphere 
dissociation. The most common means of obtaining single cell suspensions from 
neurospheres are mechanical and enzymatic dissociations. Our lab has had greater 
success in maintaining primary cultures through multiple passages when neurospheres are 
dissociated by brief exposure to a strong alkaline solution and gentle trituration (Sen et 
al., 2004). The alkaline solution, pH 11.6, is prepared by adding 1 ml of 1.0 N NaOH to 
20 ml of defined neurosphere media. The neurospheres are pelleted and resuspended in 
200 µl of unaltered defined media, followed by the addition of 200 µl of the alkaline 
solution. The neurospheres are then gently pipetted, and incubated at room temperature 
for 2 min. The neurospheres are then triturated a second time, incubated at room 
temperature for 3 min, triturated a third time, and incubated an additional 2 min. The 
neurospheres are triturated for a final time, and then 200 µl of an acidic solution (pH 1.7; 
1 ml of 1.0 N HCl in 20 ml of defined media) is added to return the solution to a neutral 
pH. This pH dissociation method is less harsh on the cells than traditional mechanical 
dissociation and does not affect the stem cell properties of the culture. Using the pH 
dissociation method, we have successfully established 14 primary neurosphere cultures 
from 18 received glioma tissues (Table 1.1). 
 
Drug treatment  
TMZ and N-[N-(3,5-difluorophenacetyl)-L-alanyl]-5-phenylglycine t-butyl ester 
(DAPT) were purchased from Sigma-Aldrich (St. Louis, MO). N-2((2S)-2-(3,5-
difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo 
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[b,d]azepin-7-yl)-L-alaninamide (LY411,575) (Fauq et al., 2007) was a gift from Lisa 
Minter and Barbara Osborne (University of Massachusetts, Amherst).  
 TMZ concentrations for each culture were selected based on two factors: 1) at 
least an 80% decrease of initial neurosphere formation; and 2) the ability of the culture to 
recover after treatment and form secondary neurospheres. DAPT and LY concentrations 
were chosen for each culture based on the decrease in Hes1 and Hey1 expression. RNA 
was isolated from the cultures 48 hours after DAPT treatment, and Hes1 and Hey1 cDNA 
expression levels were analyzed by PCR or qPCR.  
 
RT-PCR and RT-qPCR 
Neurosphere cultures were pelleted and tumor tissues from subcutaneous 
xenografts were broken into a powder using a BioPulverizer (Biospec Products, Inc., 
Bartlesville, OK). RNA was isolated from neurosphere cultures and frozen tumor 
samples using TRIzol Reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s 
protocol. RNA was treated with DNase I, Amplification Grade (Invitrogen, Carlsbad, 
CA). cDNA was made using the SuperScript II Reverse Transcription (RT) Kit with 
Oligo(dT)12-18 primers (Invitrogen, Carlsbad, CA), followed by a 20 minute incubation at 
37 oC with RNaseH. PCR was carried out using Platinum Taq DNA Polymerase, 
following the manufacturer’s protocol (Invitrogen, Carlsbad, CA). Real time qPCR was 
carried out using QuantiTect SYBR Green (QIAGEN, Valencia, CA). Hes1 and β-Actin 
primers were developed using Primer3 (Rozen and Skaletsky, 2000), while previously 
published primer sequences include primers for Hey1 (Osipo et al., 2008), Notch1 (Lefort 
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et al., 2007), Notch2 (O'Neill et al., 2007), Notch3 (Buchler et al., 2005) and Notch4 
(Buchler et al., 2005) (Table 2.3). The RT-PCR products were analyzed on 2% agarose 
gels. Quantification of band intensity for DAPT treated lines was determined using 
ImageJ (Rasband, 1997-2004). cDNA levels for qRT-PCR products were calculated 
using the PFAFFL method (Pfaffl, 2001). p53 transcripts were amplified to analyze the 
sequences for mutation as previously described (Mihaliak et al., 2010). Briefly, mRNA 
was extracted using a QuickPrep micro mRNA purification kit (GE Healthcare, 
Piscataway, NJ) and was incubated for 2 h at 37 °C with 1 µl of Oligo(dT)12−18 (500 
µg/ml), 4 µl of 5x First strand cDNA buffer, 2 µl of 0.1 mM DTT and 1 µl of 10 mM 
dNTP mix. SuperScriptII Reverse Transcriptase (1 µl) was added and incubated for 50 
min at 42 °C, followed by heat inactivation for 15 min at 70 °C. The cDNA was 
amplified using Platinum Taq DNA Polymerase (Invitrogen Carlsbad, CA). The two 
primer sets were used for amplification and sequencing of the human p53 cDNA (Table 
2.3). The PCR products were analyzed in both directions using automated DNA 
sequencing (GENEWIZ, South Plainfield, NJ). 
 
Neurosphere recovery and secondary neurosphere assays  
 Neurosphere cultures were dissociated to single cell suspensions by pH 
dissociation followed by filtration through 40 µm filters. For the neurosphere assay, 
3,000 cells/ml of defined medium were seeded in 6-well plates. Immediately after 
plating, cells were treated with DMSO (Research Organics, Cleveland, OH) carrier 
control, TMZ-only, DAPT-only, or TMZ + DAPT. Additional DAPT was added on days 
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Table 2.3 List of PCR primer sequences 
Gene Forward primer (5’ - 3’) Reverse primer (5’ - 3’) 
Hes1 CTAAACTCCCCAACCCACCT AAGGCGCAATCCAATATGAACATAT 
Hey1 AGCTCCTCGGACAGCGAGCTG TACCAGCCTTCTCAGCTCAGACA 
Notch1 GAACCAATACAACCCTCTGC AGCTCATCATCTGGGACAGG 
Notch2 CACAGAGGCTGGGAAAGGATGATA GGCCACCTGAAGGGAAGCACATA 
Notch3 AGATTCTCATCCGAAACCGCTCTA GGGGTCTCCTCCTTGCTATCCTG 
Notch4 GCGGAGGCAGGGTCTCAACGGATG AGGAGGCGGGATCGGAATGT 
p53 
ATGGAGGAGCCGCAGTCAGAT 
 
AAGGAAATTTGCGTGTGGAGT 
TGCGCCGGTCTCTCCCAGGAC 
 
CAGTCGGAGTCAGGCCCTTCT 
β-Actin (RT-
PCR) GCTCGTCGACAACGGCT CAAACATGATCTGGGTCATCTTCTC 
β-Actin (qRT-
PCR) TTGCCGACAGGATGCAGAAGGA AGGTGGACAGCGAGGCCAGGAT 
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2 and 4. Neurospheres consisting of 10 or more cells were counted under a light 
microscope on day 7 for the converted cell lines. Primary lines have a slightly longer 
doubling time and were counted on day 10. After counting the neurospheres from the 
initial treatment, 2 ml of fresh defined medium was added to each well. DAPT was also 
added once more to the DAPT-only and TMZ + DAPT samples, and the cells were 
incubated for an additional 7 or 10 days. Neurospheres from the recovery period were 
counted on day 14 or day 20. To analyze secondary neurosphere formation, cells were 
collected, pelleted and dissociated to a single cell suspension by the pH method (Sen et 
al., 2004). DMSO and DAPT-only samples were split at 1:30 and reseeded into 6-well 
plates with 2 ml of defined medium, while TMZ-only and TMZ + DAPT were split at 
1:1, and all cells were reseeded into 6-well plates with 2 ml of defined medium. The 
number of secondary neurospheres formed by converted cell lines and primary cultures 
were counted on day 21 or day 30, respectively. All recovery assays were repeated with a 
minimum of 6 data sets. For the LY experiments, LY411,575 was administered in place 
of DAPT using the same regimen. 
For the samples labeled ‘pre-treat’, a single dose of DAPT was administered 
when the cells were plated, and then TMZ was added to the medium 24 hours later. For 
the ‘co-treat’ samples, single doses of TMZ and DAPT were added simultaneously when 
the cells were plated. Finally, samples labeled ‘post-treat’ were treated with TMZ, and 
then DAPT was added 24 hours later.  
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Cell proliferation assay 
 To analyze the effect of drug treatment on the adherent lines, U87MG and 
U373MG were plated in 6-well plates at 3,000 cells/ml in 2 ml DMEM, supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin. Cultures were treated with 
DMSO-only, DAPT-only (1 µM for U87MG and 5 µM for U373MG), TMZ-only (200 
µM) or TMZ + DAPT. As described for the neurosphere recovery assay, TMZ was 
administered on day 0, and DAPT was administered on days 0, 2, 4, and 7. Cultures were 
trypsinized on day 7, 14 and 21 to count the total number of live cells using trypan blue. 
On days 7 and 14, cells were reseeded in fresh 6-well plates. DMSO and DAPT-only 
treated cultures were split 1:10 due to high levels of proliferation, while TMZ-only and 
TMZ + DAPT treated cultures were split 1:1 and all cells were re-plated.  
 
Virus infections  
NICD-pMIG (Pui et al., 1999) or pMIG vectors were co-transfected with 
retrovirus envelope and gag-pol vectors into HEK293T cells, with FuGENE 6 (Roche 
Applied Science, Indianapolis, IN). Retrovirus was collected after 48 hours. Neurosphere 
cultures were infected in non-coated bacterial dishes to avoid the cells becoming adherent 
in the presence of serum. Cells were incubated with virus and 8 µg/ml polybrene (Sigma-
Aldrich, St. Louis, MO) at 37oC for 6 hours. GFP-positive cells were sorted on a FACS 
Aria (BD Biosciences, Franklin Lakes, NJ).  
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Subcutaneous xenografts: ex vivo drug treatment  
U87NS and U373NS neurospheres were dissociated and 2.5 x 104 cells/ml were 
plated in defined media and treated with DMSO, TMZ-only (200 µM), DAPT-only (1 
µM or 5 µM), or TMZ + DAPT as described for recovery assays. After 7 days, 2.5 x 105 
or 3 x 106 live cells were counted using trypan blue and re-suspended in 100 µl PBS. 
Cells were subcutaneously injected into the flanks of nude mice. Mice were monitored 
for tumor formation for up to 120 days post-injection and euthanized when tumors 
reached volumes of 1.5 to 2 cm3. 
 
Subcutaneous xenografts: in vivo drug treatment  
For the in vivo experiments, we used LY411,575 incorporated into 7012 Teklad 
LM-485 rodent chow (LY chow) at a concentration of 0.0275 g/kg (Harlan Laboratories 
Inc, Madison, WI) (Samon et al., 2008). U87NS cells (1 x 106) re-suspended in 100 µl 
PBS were subcutaneously injected into the flanks of male nude mice. When the tumor 
reached approximately 150 mm3 (volume = (¾) x (π) x (length/2) x (width/2)2), we began 
the following treatments: 1) DMSO control: two days of 100 µl DMSO/PBS (1:1) 
intraperitoneal (i.p.) injections; 2) TMZ-only: i.p. injections of TMZ (20 mg/kg) in 100 µl 
DMSO/PBS on days one and two; 3) LY chow-only: two days of 100 µl DMSO/PBS i.p. 
injections. The mice were fed LY chow from day 3 to 12; 4) TMZ + LY chow: i.p. 
injections of TMZ (20 mg/kg) in 100 µl DMSO/PBS on days one and two. The mice 
were fed LY chow from day 3 to 12. Mice were observed for up to 150 days and 
euthanized when the tumor reached 1.5 to 2 cm. 
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CHAPTER III: 
 
Combined Treatment with Temozolomide and Gamma-Secretase Inhibitors Targets 
Glioma-Propagating Cells by Inducing Senescence 
 
 
 
Parts of this chapter represent work submitted as: 
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A. Kurt-Jones, and Alonzo H. Ross. Enhancing Temozolomide Treatment by 
Inhibition of Notch Signaling Induces Senescence in Gliomas. Manuscript in 
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CHAPTER III: 
 
Combined Treatment with Temozolomide and Gamma-Secretase Inhibitors Targets 
Glioma-Propagating Cells by Inducing Senescence 
 
Glioma cultures contain a population of cells that escape TMZ-induced 
cytotoxicity. This population includes neurosphere-initiating and tumor-propagating 
cells. We have demonstrated that blocking the Notch pathway with low concentrations of 
GSIs has a minimal affect on neurosphere formation and tumor formation, but when 
combined with TMZ, they greatly enhance TMZ efficacy. The combined TMZ + GSI 
treatment targets the TMZ-resistant cells and inhibits both neurosphere recovery and 
tumor growth. After demonstrating the success of TMZ + GSI treatments, our laboratory 
was interested in studying the biological mechanism of combined treatment with TMZ + 
GSIs. 
The Notch pathway was previously implicated in regulating the switch between a 
reversible quiescent state and an irreversible senescent state (Sang et al., 2008). We have 
demonstrated that TMZ induces a temporary cell cycle arrest in neurosphere-initiating 
and tumor-propagating cells (Mihaliak et al., 2010) and that TMZ + GSI treatment 
enhances the TMZ efficiency when administered after TMZ treatment, in a schedule-
dependent manner (Gilbert et al., 2010). Together, these data demonstrate that the 
induction of a transient cell cycle arrest by TMZ treatment must precede GSI 
administration to enhance the therapy’s efficiency. This suggests that TMZ and GSI 
treatment inhibits neurosphere recovery and tumor progression of glioma cultures 
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through therapy-induced senescence (TIS). In addition to arresting tumor cell growth, 
TIS has been shown to stimulate tumor clearance. This occurs due to the secretion of 
secrete pro-inflammatory proteins by senescent cells, which are part of the SASP (Coppe 
et al., 2008; Freund et al., 2010). This can activate an innate immune response and result 
in tumor clearance (Xue et al., 2007). 
In this study, we analyze the biological mechanism of TMZ + GSI treatment in 
vitro and in vivo. We found that TMZ + GSI treatment does not increase cell death in 
neurosphere cultures. Instead, when glioma cells are treated with TMZ + GSI the 
majority of the cultures enters into a permanent senescent state. The cells show 
characteristics of senescence, including a temporary growth arrest and SA-β-
galactosidase expression. These data demonstrate that TMZ + GSI treatment induces a 
permanent growth arrest that blocks regrowth of glioma cultures and xenografts. In 
addition, we demonstrate that in vitro TMZ + GSI treatment stimulates macrophage 
phagocytosis of the neurosphere cells. This treatment has the potential to greatly reduce 
glioma recurrence in the clinic by TIS.  
 
Results 
TMZ + DAPT treatment does not increase cell death in neurosphere cultures 
 PI staining was used to analyze cell death in U87NS cultures after drug treatment. 
Control neurosphere samples treated with DMSO had a baseline PI+ population of 14.2 ± 
4.0% on day 3 of the neurosphere recovery assay. There was no significant difference 
observed on day 3 between the DMSO control and the other treatments  (Fig.  3.1 A  and  
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Figure 3.1 TMZ + DAPT treatment does not increase cell death.  A) Representative 
dot plots for PI-uptake 3 days and 7 days after treatment of the U87NS neurosphere 
culture. Events are gated for PI+ expression against the unstained FL1 channel to select 
for the dead cell population capable of PI-uptake. B) Quantification of the PI+ population 
in the U87NS treated cultures on day 3 and day 7. (mean ± SD; n = 6). There is no 
difference between the different treatments on day 3. On day 7, TMZ-only and TMZ + 
DAPT treated cultures have higher cell death than the controls, but there is a significant 
decrease in the PI+ population from the TMZ-only to the TMZ + DAPT treated 
populations. *, P < 0.01  
A. 
B. 
* 
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B). The average percentage of PI+ cells in DAPT-only, TMZ-only, and TMZ + DAPT 
treated cultures was 16.7 ± 2.3%, 17.5 ± 1.6%, and 19.0 ± 0.3% (Fig. 3.1 A). On day 7, 
the DMSO and DAPT-only treatments were similar with 8.9 ± 2.5% and 9.3 ± 3.1%, 
respectively. A 2.7-fold increase (P < 0.01) in cell death was observed in the TMZ-only 
treated cultures on day 7, compared to the DMSO controls. The PI+ population in the 
TMZ-only treated U87NS culture was 24.0 ± 7.9%. Interestingly, the PI+ population for 
the TMZ + DAPT treated neurospheres was only 17.9 ± 6.8%, which was significantly 
less than the cell death observed in the TMZ-only treated culture (P < 0.01). 
 
SA-ß-galactosidase expression is increased in TMZ + DAPT treated cultures 
To determine if the inhibition of neurosphere recovery in TMZ + DAPT treated 
cultures is due to an induction of senescence, SA-β-galactosidase expression was 
analyzed in U87NS and U373NS treated cultures on day 7 and day 21 (Fig. 3.2 A and B). 
On day 7, DMSO and DAPT-only treated U87NS samples had a minimal number of cells 
with SA-β-galactosidase expression, 2.2 ± 0.9% and 2.4 ± 1.0%, respectively (Fig. 3.3 
A). TMZ-only treated U87NS cells stained 36.3 ± 11.1% SA-β-galactosidase positive on 
day 7 (Fig 3.3 A). TMZ + DAPT treated neurospheres showed a 1.8-fold increase (P < 
0.00001) of SA-β-galactosidase expression on day 7, with 64.0 ± 9.5%. This trend was 
also observed in the U373NS treated culture on day 7 (Fig. 3.2 B). U373NS DMSO and 
DAPT-only treated cultures had 1.9 ± 1.8% and 1.9 ± 1.7%, respectively (Fig. 3.3 B). 
TMZ-only treatment increased SA-β-galactosidase expression, but SA-β-galactosidase 
expression in TMZ + DAPT treated cultures was 1.7 fold greater (P  <  0.0001). U373NS  
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Figure 3.2 TMZ + DAPT induces SA-β-galactosidase in neurosphere cultures. 
Senescence was analyzed using SA-β-galactosidase expression in A) U87NS and B) 
U373NS cultures with DMSO, DAPT-only, TMZ-only, and TMZ + DAPT treatments. 
SA-β-galactosidase positive cells stain blue. DMSO and DAPT treated cultures have 
minimal SA-β-galactosidase positive on both day 7 and day 21. TMZ-only and TMZ + 
DAPT treated cultures have an initial induction of SA-β-galactosidase positive on day 7. 
However, after secondary neurosphere formation, TMZ-only samples on day 21 have a 
reduced number of SA-β-galactosidase positive, and there are SA-β-galactosidase 
negative neurospheres present. In contrast, the TMZ + DAPT samples on day 21 consist 
largely of single cell that are SA-β-galactosidase positive. 
A. 
B. 
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Figure 3.3 TMZ + DAPT induces SA-β-galactosidase in U87NS and U373NS 
cultures. SA-β-galactosidase expression was quantified for A) U87NS and B) U373NS 
cultures with DMSO, DAPT-only, TMZ-only, and TMZ + DAPT treatments. DMSO and 
DAPT treated cultures have minimal levels of SA-β-galactosidase on both day 7 and day 
21. TMZ-only and TMZ + DAPT treated cultures have an initial induction of SA-β-
galactosidase positive on day 7. However, after secondary neurosphere formation, TMZ-
only samples on day 21 have a reduced percentage of SA-β-galactosidase positive cells, 
while the TMZ + DAPT samples remain mostly SA-β-galactosidase positive. In both 
U87NS and U373NS cultures, the TMZ + DAPT treatments induce a significantly greater 
percentage of SA-β-galactosidase positive cells compared to the TMZ-only treatments on 
day 7 and 21. (mean ± SD) *, P < 0.0001; **, P < 0.00001 
 
A. 
B. 
  
   ** 
 
 ** 
 
 **  
 * 
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TMZ-only treated cultures showed 33.8 ± 22.2% SA-β-galactosidase expression was and 
TMZ + DAPT treated cultures showed 56.3 ± 24.4%. 
To analyze the long-term effects of the drug treatments, neurosphere cultures 
were dissociated on day 14, and SA-β-galactosidase expression was analyzed in 
secondary neurospheres on day 21. The percent of SA-β-galactosidase-positive cells in 
DMSO and DAPT-only treated U87NS cultures remained low with only 2.3 ± 0.5% and 
2.6 ± 0.3%, respectively (Fig. 3.3 A). Neurospheres from day 21 TMZ-only treated 
cultures demonstrated a decrease in the overall SA-β-galactosidase expression compared 
to day 7 samples (Fig. 3.2 and 3.3). In U87NS cultures, the percentage of SA-β-
galactosidase positive cells dropped to 11.6 ± 3.4%, demonstrating that the cells negative 
for SA-β-galactosidase on day 7 were capable of repopulating the culture (Fig. 3.3 A). In 
contrast, SA-β-galactosidase expression in the TMZ + DAPT treated neurospheres 
remained high and was 6.8-fold greater (P < 0.00001) than expression in the TMZ-only 
treated culture. TMZ + DAPT treated samples on day 21 were 79.2 ± 7.6% SA-β-
galactosidase positive. Similarly, U373NS showed minimal SA-β-galactosidase at day 21 
for DMSO and DAPT-only samples, 2.3 ± 0.3% and 2.4 ± 0.3%, respectively (Fig. 3.3 
B). SA-β-galactosidase expression decreased in the TMZ-only treated U373NS samples 
on day 21, with only 18.5 ± 6.6% positive, but high expression persisted in the TMZ + 
DAPT U373NS samples, with 82.1 ± 8.8%. At day 21, SA-β-galactosidase expression in 
TMZ + DAPT treated U373NS cultures was 4.4-fold greater (P < 0.00001) than the 
expression in TMZ-only treated cultures. This demonstrates that TMZ + DAPT treatment 
induces a persistent SA-β-galactosidase expression. 
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 We previously demonstrated that endogenous expression of the constitutively 
active NICD attenuates the affects of TMZ + DAPT treatment in neurosphere cultures 
(Gilbert et al., 2010). To determine if NICD expression will also block an increase in SA-
β-galactosidase expression, the U87NS-pMIG and U87NS-NICD cultures were 
administered DMSO, DAPT-only, TMZ-only and TMZ + DAPT treatments. In the 
DMSO treated controls, the baseline expression of SA-β-galactosidase on day 7 increased 
by 4.0-fold (P < 0.01), from 3.3 ± 1.3% in the U87NS-pMIG cultures to 13.2 ± 5.2% in 
the U87NS-NICD cultures (Fig. 3.4). A 3.8-fold increase (P < 0.01) was also observed in 
the DAPT-treated cultures, from 3.3 ± 1.3% in the U87NS-pMIG cultures to 12.5 ± 6.7% 
in the U87NS-NICD cultures. This data corresponds with a recent publication 
demonstrating that Notch overexpression can induce senescence (Venkatesh et al., 2011). 
Expression of SA-β-galactosidase in the U87NS-pMIG culture was 47.9 ± 2.5% positive 
in the TMZ-only treated cultures and 77.1 ± 5.8% positive in the TMZ + DAPT treated 
cultures (Fig. 3.4). While the U87NS-pMIG culture displayed a 1.6-fold (P < 0.00001) 
increase in SA-β-galactosidase when treated with TMZ + DAPT compared to TMZ-only, 
no significant fold increase of SA-β-galactosidase expression was observed between the 
U87NS-NICD TMZ-only and TMZ + DAPT treated cultures, with 62.1 ± 6.9% and 69.3 
± 8.1% positive, respectively. Although NICD expression increases the baseline levels of 
SA-β-galactosidase expression, the U87NS-NICD cells did not show an increase of SA-
β-galactosidase between TMZ-only and TMZ + DAPT treatments. Since NICD-
expression cultures are capable of robust secondary neurosphere formation after TMZ + 
DAPT treatment, this suggests that Notch signaling protects the neurosphere-initiating  
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Figure 3.4 SA-β-galactosidase in the U87NS NICD-expressing culture SA-β-
galactosidase expression was analyzed on day 7 after DMSO, DAPT-only, TMZ-only. 
and TMZ + DAPT treatments NICD-expressing U87NS culture displays an increased 
SA-β-galactosidase expression (P < 0.01) in the control treatments compared to the 
U87NS-pMIG cell line. SA-β-galactosidase expression in the U87-pMIG is induced in 
TMZ-only and further enhanced in TMZ + DAPT treatments; however, there is no 
difference between TMZ-only and TMZ + DAPT treated samples in the U87NS-NICD 
culture. (mean ± SD). *, P < 0.01; **, P < 0.0001 
 
    ** 
       *   * 
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cells that enter the TMZ-induced transient cell cycle arrest from switching to the 
permanent senescent state after GSI treatment. 
 
TMZ + DAPT-induced senescence is schedule-dependent in vitro 
The response of neurospheres to TMZ + DAPT is dependent on the drug 
treatment schedule (Gilbert et al., 2010) (Fig. 2.14). We previously demonstrated that 
pre-treatment with DAPT, followed 24 hours later by TMZ treatment, or co-treatment 
with single doses of TMZ and DAPT, do not inhibit secondary neurosphere formation. In 
contrast, the post-treatment schedule, which consists of initial TMZ treatment, followed 
by DAPT treatment 24 hours afterwards, has a large affect and inhibits secondary 
neurosphere formation (Gilbert et al., 2010). Consistent with the neurosphere formation 
on day 7, TMZ-only, pre-treatment with DAPT, and TMZ + DAPT co-treatment has 
similar SA-β-galactosidase expression levels, while post-treatment with DAPT shows an 
increase in SA-β-galactosidase (Fig. 3.5 and 3.6). For SA-β-galactosidase expression in 
U87NS cultures, TMZ-only treatment resulted in 36.3 ± 8.2% positive, pre-treatment 
resulted in 50.5 ± 7.5% positive, co-treatment resulted in 59.5 ± 3.8% positive and post-
treatment resulted in 79.1 ± 2.4% positive (Fig. 3.7 A). The pre-treatment SA-β-
galactosidase expression was not significantly greater than expression levels observed 
after TMZ-only treatment. SA-β-galactosidase expression in U87NS co-treated samples 
was 1.6-fold greater (P < 0.01), while expression in the post-treated samples was 2.2-fold 
greater (P < 0.01). In U373NS treated cultures, levels of SA-β-galactosidase positive 
cells on day 7 was 55.4 ± 3.5% for TMZ-only, 58.3 ± 3.5% for pre-treatment, 61.2 ±  
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Figure 3.5 Therapy-induced senescence in the neurosphere assay schedule treatment 
is unique to DAPT post-treatment in U87NS. Senescence was analyzed using SA-β-
galactosidase expression in U87NS cultures treated with TMZ + DAPT treatment 
schedules. SA-β-galactosidase positive cells stain blue. DMSO and DAPT treated 
cultures have minimal SA-β-galactosidase positive cells on both day 7 and day 21. TMZ-
only and pre-treated, co-treated and post-treated cultures have an initial induction of SA-
β-galactosidase on day 7. However, after secondary neurosphere formation, day 21 
samples for TMZ-only, pre-treatment, and co-treatment have a reduced number of SA-β-
galactosidase positive cells, and neurospheres are present that are the majority SA-β-
galactosidase negative. In contrast, the DAPT post-treated samples on day 21 consist 
largely of single cell that are SA-β-galactosidase positive. 
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Figure 3.6 Therapy-induced senescence in the neurosphere assay schedule treatment 
is unique to DAPT post-treatment in U373NS. Senescence was analyzed using SA-β-
galactosidase expression in U373NS cultures treated with TMZ + DAPT treatment 
schedules. SA-β-galactosidase positive cells stain blue. DMSO and DAPT treated 
cultures have minimal SA-β-galactosidase positive cells on both day 7 and day 21. TMZ-
only and pre-treated, co-treated and post-treated cultures have an initial induction of SA-
β-galactosidase on day 7. However, after secondary neurosphere formation, day 21 
samples for TMZ-only, pre-treatment, and co-treatment have a reduced number of SA-β-
galactosidase positive cells, and neurospheres are present that are the majority SA-β-
galactosidase negative. In contrast, the DAPT post-treated samples on day 21 consist 
largely of single cell that are SA-β-galactosidase positive. 
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Figure 3.7 Therapy-induced senescence in the neurosphere assay schedule treatment 
is unique to DAPT post-treatment. SA-β-galactosidase expression was quantified in A) 
U87NS and B) U373NS cultures treated with TMZ + DAPT treatment schedules. TMZ-
only and pre-treated, co-treated and post-treated cultures have an initial induction of SA-
β-galactosidase on day 7. However, after secondary neurosphere formation, day 21 
samples for TMZ-only, pre-treatment, and co-treatment have a reduced number of SA-β-
galactosidase positive. In contrast, the DAPT post-treated samples on day 21 maintain the 
higher percentage of SA-β-galactosidase positive cells. Compared to TMZ-only samples, 
DAPT post-treated samples consistently showed significantly greater levels of SA-β-
galactosidase expression. *, P < 0.01. **, P < 0.001.  
B. 
A. 
 * 
  * 
  * 
 ** 
  
 ** 
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3.5% for co-treatment, and 82.2 ± 4.5% for post-treatment (Fig. 3.7 B). In the day 7 
U373NS schedule treatment samples, only the post-treated samples demonstrated 
increased SA-β-galactosidase expression compared to TMZ-only treatment, with a 1.4-
fold increase (P < 0.01). By day 21, SA-β-galactosidase expression decreased in TMZ-
only, pre-treatment, and co-treatment. U87NS TMZ-only showed 23.6 ± 8.7% positive, 
pre-treatment showed 24.4 ± 7.1% positive, and co-treatment showed 41.5 ± 9.0% 
positive (Fig. 3.7 A). The percent SA-β-galactosidase positive in U373NS demonstrated 
the same trend, TMZ-only, 8.8 ± 1.9%, pre-treatment, 15.6 ± 3.6%, and co-treatment, 
23.3 ± 2.5% (Fig. 3.7 B). However, the samples administered the post-treatment schedule 
maintained high levels of SA-β-galactosidase expression at day 21. Post-treatment 
resulted in 78.8 ± 5.0% positive in U87NS secondary neurospheres (Fig. 3.7 A) and 64.5 
± 5.4% in U373NS secondary neurospheres on day 21 (Fig. 3.7 B). SA-β-galactosidase 
expression in post-treated samples was 3.3-fold (P < 0.001) and 7.3-fold (P < 0.001) 
greater than SA-β-galactosidase in the TMZ-only treated samples for U87NS and 
U373NS cultures, respectively. 
 
TMZ + LY treated xenografts have decreased proliferation  
Ki67 staining was used to determine the number of proliferating cells in the 
subcutaneous U87NS xenografts after in vivo treatment. Decreased proliferation is 
expected based on the increase in the percent of senescent cells. In tumors harvested on 
13 days after the beginning of treatment, there was no significant difference of Ki67 
expression between the control DMSO and LY chow-only groups  (Fig.  3.8  and  3.9).  
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Figure 3.8 Ki67 expression decreases in TMZ + LY treated U87NS xenografts. Ki67 
expression was analyzed to determine the levels of proliferation in U87NS in vivo treated 
xenografts. Quantification of percent Ki67+ demonstrates a range of Ki67 levels for each 
treatment cohort. Each point represents the average Ki67 expression from five fields for 
an individual tumor. DMSO and LY chow-only mice have the highest percent of Ki67+ 
cells. TMZ-treatment decreased Ki67 staining in the majority of the treated mice, while 
TMZ + LY chow cohorts had the greatest decrease in Ki67+ cells. 
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Figure 3.9 Ki67 expression in DMSO and LY chow treated U87NS xenografts. Ki67 
expression was analyzed to determine the levels of proliferation in U87NS in vivo treated 
xenografts. Representative micrographs for Ki67 staining 13 days after the start of 
treatment. A) DMSO and B) LY chow-only treated xenografts have the highest number 
cells staining positive for Ki67.  
A. 
B. 
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DMSO treated samples were 32.3 ± 13.6% (Fig. 3.8 and Fig. 3.9 A) positive and LY 
chow-only samples were 28.5 ± 15.4% (Fig. 3.9 B). Xenografts treated with TMZ-only 
showed a significant (P < 0.00001) decrease in proliferation compared to DMSO, with 
only 18.2 ± 10.4% positive for Ki67 (Fig. 3.8 and Fig. 3.10 A). TMZ + LY chow samples 
had the greatest decrease of Ki67 expression (P < 0.00001). Only 6.9 ± 4.3% of the cells 
were positive for Ki67 in the TMZ + LY chow tissue, a 2.6-fold decrease (P < 0.00001) 
in expression compared to the TMZ-only tissue (Fig. 3.8 and 3.10 B).  
 
SA-ß-galactosidase is induced in xenografts by in vivo TMZ + LY treatment  
Next we tested if SA-β-galactosidase expression is induced after in vivo treatment 
in mice with pre-existing subcutaneous U87NS xenografts. Previously, we demonstrated 
that 50% of mice had complete tumor regression when treated in vivo with TMZ + 
LY411,575 (LY) chow (Gilbert et al., 2010). All mice treated in vivo with DMSO, LY 
chow-only and TMZ-only showed 100% tumor progression. SA-β-galactosidase 
expression was grouped into four categories depending on the number of positive, blue 
cells in each microscope field. The ‘negative’ category has less than 10 SA-β-
galactosidase-positive cells per field, ‘low’ has between 11 to 50 positive cells, ‘medium’ 
has between 51 to 100 positive cells, and ‘high’ has greater than 101 positive cells. When 
tumor sections were excised and analyzed 13 days after in vivo treatment began, DMSO, 
LY chow-only and TMZ-only samples had minimal SA-β-galactosidase staining (Fig. 
3.11, 3.12, and 3.13). In DMSO tumor sections, 85% of the fields of view were negative 
and 15% low (Fig. 3.11). LY chow-only treated mice showed similar levels of SA-β- 
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Figure 3.10 Ki67 expression in TMZ-only and TMZ + LY treated U87NS xenografts. 
Ki67 expression was analyzed to determine the levels of proliferation in U87NS in vivo 
treated xenografts. Representative micrographs for Ki67 staining 13 days after the start of 
treatment. The number of Ki67+ cells is greatly reduced in A) TMZ-only and B) TMZ + 
LY chow xenografts.  
A. 
B. 
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Figure 3.11 DMSO in vivo control treatment and SA-β-galactosidase staining. Tumor 
sections collected from U87NS xenografts, 13 days after the start of treatment, were 
analyzed by microscopy for H&E and SA-β-galactosidase staining (40x). DMSO treated 
mice possess xenografts with minimal SA-β-galactosidase-positive staining.  
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Figure 3.12 LY chow-only in vivo treatment and SA-β-galactosidase. Tumor sections 
collected from U87NS xenografts, 13 days after the start of treatment, were analyzed by 
microscopy for H&E and SA-β-galactosidase staining (40x). There is a small increase in 
the number of SA-β-galactosidase-positive cells after LY chow-only treatment. 
 
  
123 
 
 
Figure 3.13 TMZ in vivo treatment induces SA-β-galactosidase. Tumor sections 
collected from U87NS xenografts, 13 days after the start of treatment, were analyzed by 
microscopy for SA-β-galactosidase staining (40x). H&E staining shows a slight decrease 
in cellular density in the TMZ-only treated xenografts. SA-β-galactosidase staining is 
increased in the TMZ-only samples.  
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galactosidase as TMZ-only samples. LY chow-only sections were 37% negative, 55% 
low and 8% medium (Fig. 3.15). Tumor sections from TMZ + LY chow treated mice 
have a large number of SA-β-galactosidase positive cells (Fig. 3.14). In contrast to other 
treated groups, only 4% of the view fields were classified as negative (Fig. 3.15). 26% of 
the view fields were SA-β-galactosidase low and 35% were SA-β-galactosidase medium. 
Only the mice treated with TMZ + LY chow yielded tumor sections with high levels of 
SA-β-galactosidase (greater than 101 cells). 35% of the fields classified as high SA-β-
galactosidase (Fig. 3.15). These data demonstrate that TMZ + LY chow induces SA-β-
galactosidase in vitro and in vivo. 
 
TMZ + DAPT treatment enhances macrophage phagocytosis of the neurosphere cells  
Based on the reports that macrophages can clear senescent cells, we investigated 
the interactions of macrophages with our glioma neurosphere cultures. Drug treated 
neurosphere cultures from 7 and 14 days after treatment were labeled with Alexa 647 and 
co-cultured with mouse macrophages labeled with Alexa 488. Cultures were analyzed for 
co-expression of Alexa 647 and Alexa 488 by flow cytometry to observe phagocytosis. 
On day 7 and 14 days after treatment, U87NS DMSO and DAPT treated cultures showed 
similar baseline levels of phagocytosis (Fig. 3.16 A). TMZ-only treatment increased the 
phagocytosis of U87NS cells 2.4-fold in the day 7 samples and 1.9-fold in the day 14 
samples. U87NS cultures treated with TMZ + DAPT had the highest phagocytosis. The 
population  of  cells  from  the TMZ  +  DAPT  treated  culture  phagocytosed  by  mouse  
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Figure 3.14 TMZ + LY in vivo treatment induces SA-β-galactosidase. Tumor sections 
collected from U87NS xenografts, 13 days after the start of treatment, were analyzed by 
microscopy for SA-β-galactosidase staining (40x). H&E staining shows a slight decrease 
in cellular density in the TMZ + LY chow treated xenografts. SA-β-galactosidase-
positive staining is greatly increased in the TMZ + LY chow samples.  
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Figure 3.15 SA-β-galactosidase in vivo quantification. Quantification of the number of 
positive SA-β-galactosidase cells per view. The majority of DMSO treated xenografts 
have negative levels (≤ 10 positive cells) of SA-β-galactosidase expression. Interestingly, 
the LY chow-only xenografts have similar levels of SA-β-galactosidase expression, with 
over half of the views having low expression (11 – 50 positive cells), and a small percent 
of the views had medium expression (51 – 100 positive cells). The xenografts treated 
with TMZ + LY chow showed a significant upregulation of SA-β-galactosidase 
expression.  Thirty-five percent of the views displayed medium expression. In addition, 
TMZ + LY chow xenografts were the only cohort to have any views that had high 
expression (≥ 101 positive cells), thirty-five percent of the views displaying high 
expression of SA-β-galactosidase levels.  
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Figure 3.16 TMZ + DAPT treated cells are more susceptible to macrophage 
phagocytosis. Representative histograms displaying macrophage phagocytosis of A) 
U87NS and B) U373NS cultures. Neurosphere were treated, collected on either day 7 or 
14, and labeled with Alexa 647. After co-culture with Alexa 488-labeled macrophages, 
cells were analyzed for phagocytosis by flow cytometry. Neurosphere cells were gated 
for Alexa 647+ staining, and analyzed for co-expression with Alexa 488. Co-expression is 
represented the occurrence of phagocytosis. TMZ-only treatment induces some levels of 
phagocytosis; however, TMZ + DAPT treated neurospheres induce the highest 
percentage of phagocytosis. 
A. 
B. 
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macrophages was 3.9-fold and 3.8-fold higher than the DMSO samples. In the U373NS 
cultures, DMSO and DAPT treated cells showed similar levels of phagocytosis when co- 
cultured with macrophages 7 and 14 days after treatments. Phagocytosis of the TMZ-only 
treated U373NS cells is increased by 1.7-fold and 2.6-fold in day 7 and day 14 cultures, 
when compared to DMSO controls (Fig. 3.16 B). TMZ + DAPT treated samples co-
cultured with macrophages induced the highest phagocytosis, with a 2.5-fold increase on 
day 7 and a 6.1-fold increase on day 14, compared to DMSO controls (Fig. 3.16 B). Next, 
day 21 U87NS Alexa 647 neurospheres were co-cultured with the Alexa 488-labeled 
macrophages and analyzed by confocal microscopy, many neurospheres that remained 
single positive were present in the DMSO and DAPT-only treated samples, while TMZ-
only and TMZ + DAPT treated samples showed a high number of macrophages that 
contained double-positive foci, representative of phagocytosis (Fig. 3.17).  
 
Discussion 
While TMZ treatment induces cell death and senescence (Gunther et al., 2003), 
some cancer cells survive by entering a transient cell cycle arrest (Mihaliak et al., 2010). 
We have demonstrated that the combined treatment of TMZ + GSI greatly enhances 
glioma therapy by blocking neurosphere recovery and tumor progression. We believe that 
the loss of Notch signaling triggers the arrested cells to enter a permanent senescent state. 
We have demonstrated that TMZ + GSI treatment increases senescence in neurosphere 
cultures and glioma xenografts. These cultures display decreased levels of proliferation, 
as measured by cell growth and Ki67 expression. TMZ + DAPT treatment increases SA-
  
 
 
Figure 3.17 TMZ + DAPT treated cells are more susceptible to macrophage phagocytosis. U87NS labeled with Alexa 647 
(red) and Hoechst 33342 (blue, in 1 hour samples) were co-cultured with Alexa 488 labeled macrophages (green) and analyzed 
by confocal microscopy. After 1 hour, macrophages were in contact with the neurospheres from each treated sample. However, 
after 18 hours of co-culture, the majority DMSO and DAPT-only treated neurospheres remained single-positive for Alexa 647. 
In contrast, the TMZ-treated neurospheres were both double-positive and single-positive. In the TMZ + DAPT treated samples, 
the majority of the cells were double-positive. These cells appeared as Alexa 488 labeled macrophages, with compartments co-
labeled with Alexa 647, reminiscent of phagosomes in phagocytic macrophages. 
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β-galactosidase expression in neurosphere cultures. When these treated neurospheres are 
dissociated and re-plated, the cells neither proliferate nor form neurospheres, but remain 
as single viable cells expressing SA-β-galactosidase. Senescence cells in adherent 
cultures are classically characterized by a flattened morphology, an increase in vacuoles 
and increased cell size. Due to the non-adherent nature of the neurosphere cultures, we do 
not observe the flattened morphology in the SA-β-galactosidase-positive cells. It is 
interesting to note, however, that a percentage of the SA-β-galactosidase-positive appear 
to have an increased size and an increase in vacuoles. This feature was not used to further 
characterize the cells, but it would be interesting to sort the cells by flow cytometry after 
TMZ + GSI treatment based on size and granularity to see if there are differences in 
expression levels of senescence-associated genes, such as p21 and p27. 
Our data supports the hypothesis that TMZ + DAPT treatment targets both the, as 
the bulk tumor cells and the cell cycle arrested tumor-propagating population through 
TIS. First, we demonstrate that that TMZ + DAPT treatment does not increase cell death. 
In contrast, TMZ + DAPT treated neurospheres show decreased levels of cell death, 
suggesting some cells that undergo cell death with TMZ-only treatment enter into 
senescence with TMZ + DAPT treatment. TMZ treatment alone induces senescence in a 
subpopulation of glioma cells. These cells are likely the non-tumorigenic cells, because 
the cancer progresses after TMZ treatment. Since we demonstrated that the upregulation 
of SA-β-galactosidase expression occurs specifically when GSI is administered after 
TMZ treatment, this implies that the GSI can only induce senescence if the cells have 
first entered a transient cell cycle arrest.  
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Our TMZ + DAPT schedule treatment assay suggests that treatments must be 
administered in a schedule-specific manner. We hypothesis that GSIs will be beneficial 
when administered after initial concurrent and adjuvant TMZ treatments to enhance TIS. 
However, GSIs can also enhance IR-induced cell death when administered within 24 
hours before or after radiotherapy (Wang et al., 2010a). Further experiments are 
necessary to determine how IR will contribute to combination therapy with TMZ and 
GSIs and the sequence of treatments that will provide the most efficient therapy. GSI 
treatment concurrent with IR may further enhance the proposed efficacy of TMZ + GSI 
adjuvant treatments, however, it may hinder the TMZ efficacy as we observed in our 
DAPT pre-treatment experiments. 
 TIS has the potential to increase patient progression-free survival and overall 
survival rates. Our TMZ + GSI treatment regimen is promising because it stimulated TIS 
to directly target the population of cells capable of tumor progression, while also 
inducing cell death and senescence in the bulk tumor cells. Under normal conditions, 
senescence is a permanent cell cycle arrest; however, genetic mutations can interfere with 
the senescence pathways (Beausejour et al., 2003; Dirac and Bernards, 2003). Therefore, 
it is possible that over time a senescent cancer cell could exit the senescent state, become 
resistant to TMZ + GSI treatment, and drive tumor recurrence. In this scenario, a 
promising feature of senescence is that it produces a SASP that activates tumor clearance 
by the innate immune system (Coppe et al., 2008; Freund et al., 2010; Xue et al., 2007). 
Indeed, we found that TMZ + DAPT treated neurosphere cells are more likely to be 
phagocytosed by macrophages in vitro than TMZ-only, DAPT-only and DMSO treated 
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cells. Interestingly, we previously observed that TMZ + GSI in vivo treatment of 
subcutaneous xenografts resulted in complete tumor loss in 50% of the treated mice 
(Gilbert et al., 2010). Since TMZ + GSI treatment induces a cytostatic senescent state in 
the xenograft cells, and there is no increase in cell death compared to the TMZ-only 
treated cultures, it was expected that the tumor progression would halt, but the pre-
existing xenograft would remain after treatment. These data, combined with the in vitro 
phagocytosis assay, suggest that the senescent cells are cleared by the innate immune 
system in vivo, which further enhances the efficacy of the TMZ + GSI treatment. 
 
Materials and Methods 
Cell Culture  
U87MG (ATCC) and U373MG (Dr. Larry Recht, Stanford University) serum 
cultures were converted to neurosphere cultures, U87NS, U87NS-luc and U373NS, as 
described in the previous chapter. All neurosphere cultures are maintained in defined 
media consisting of DMEM/F12 1:1 (GIBCO, Carlsbad, CA), supplemented with 1X 
B27, without vitamin A (GIBCO, Carlsbad, CA), 15 mM HEPES (GIBCO, Carlsbad, 
CA), 20 ng/ml EGF (Invitrogen, Carlsbad, CA), and 20 ng/ml bFGF (Invitrogen, 
Carlsbad, CA) and 1% penicillin-streptomycin (GIBCO, Carlsbad, CA). All cultures were 
passaged using a pH dissociation method with brief exposure to a strong alkaline solution 
and gentle trituration (Sen et al., 2004). Cells were incubated at 37oC with 5% CO2. 
Mouse immortalized macrophages were provided by Evelyn Kurt-Jones (University of 
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Massachusetts Medical School, Department of Medicine). Mouse macrophages are 
maintained in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. 
 
Drug Concentrations  
TMZ (Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO (Research 
Organics, Cleveland, OH) to a stock concentration of 10 mM and stored at -20oC. TMZ 
concentrations for each culture were selected based on previous experiments (Mihaliak et 
al., unpublished), i.e., high enough to produce an 80% or greater decrease in neurosphere 
formation, but low enough to allow recovery of neurosphere formation after treatment. 
U87NS and U373NS cultures were treated with 200 µM TMZ. DAPT (Sigma-Aldrich, 
St. Louis, MO) concentrations were chosen for each culture by the decrease in Hes1 and 
Hey1 expression as previously described (Gilbert et al., 2010). U87NS was treated with 1 
µM DAPT and U373NS was treated with 5 µM DAPT. 
 
Neurosphere Recovery and Secondary Neurosphere Assays  
Neurosphere cultures were dissociated to single cell suspensions by pH 
dissociation followed by filtration through 40 µm screens. Neurospheres were seeded at 
either 3,000 cells/ml or 6,000 cells/ml in defined neurosphere medium. Immediately after 
plating, cells were treated with DMSO carrier control, TMZ-only, DAPT-only, or TMZ + 
DAPT. Additional DAPT was added on days 2 and 4. On day 7, fresh defined 
neurosphere medium was added to each sample, DAPT was administered to the DAPT-
only and TMZ + DAPT samples, and the cells were incubated for an additional 7 days. 
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For secondary neurosphere formation, cells were collected on day 14, dissociated to a 
single cell suspension by the pH method, and re-seeded in defined neurosphere medium. 
Secondary neurospheres were cultured for an additional 7 days. 
For the TMZ + DAPT schedule treatment, neurosphere assays were plated as 
described above. Pre-treated samples were administered a single dose of DAPT 
immediately after plating, and TMZ was added 24 hours later. For co-treated samples, 
single doses of TMZ and DAPT were administered together, immediately after plating. 
For post-treated samples, TMZ was added to the culture immediately after plating, and 
DAPT was added 24 hours later.  
 
Subcutaneous Xenografts: in vivo Drug Treatment  
As previously described (Gilbert et al., 2010), 1 x 106 U87NS cells were pH 
dissociated and re-suspended in 100 µl PBS. Cells were subcutaneously injected into the 
right flank of male nude mice. Tumor volume was calculated as (¾) x (π) x (length/2) x 
(width/2)2. When the tumor reached approximately 200 mm3 we began the following in 
vivo treatments: 1) DMSO control mice received 2 days of 100 µl DMSO/PBS (1:1) i.p. 
injections; 2) TMZ-only mice received i.p. injections of 20 mg/kg of TMZ in 100 µl 1:1 
DMSO/PBS on days one and two; 3) LY chow-only mice received i.p. injections of 100 
µl of DMSO carrier on days one and two. Beginning on day three, the mice were fed 
7012 Teklad LM-485 rodent chow infused with LY411,575 at a concentration of 0.0275 
g/kg (Harlan Laboratories Inc, Madison, WI) (Samon et al., 2008). At this concentration, 
the estimated dosage of LY411,575 ingested by the mice is 5 mg/kg/day (Samon et al., 
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2008); 4) TMZ + LY chow mice received i.p. injections of 20 mg/kg of TMZ in 100 µl 
1:1 DMSO/PBS on days one and two. Beginning on day three, the mice were fed LY 
chow for 10 consecutive days. Mice were euthanized 13 days after the beginning of 
treatment and tumor tissue was extracted. Tumors were embedded in O.C.T Compound 
(Sakura, Torrance, CA) and stored at -80 oC. 
 
PI staining for cell death 
 U87NS cells were plated at 3,000 cells/ml in 15 ml of defined neurosphere 
medium and treated with DMSO, DAPT-only, TMZ-only, and TMZ + DAPT, as 
described above. Cells were harvested on either day 3 or day 7, pH dissociated, and 
resuspended at 1 x 106 cells/ml PBS. Cells were incubated at room temperature for 15 
minutes with PI (BD Biosciences, Franklin Lakes, NJ) at a final concentration of 0.5 
µg/ml. PI uptake was detected by flow cytometry analysis on a BD™ LSRII (BD 
Bioscience, Franklin Lakes, NJ). 
 
β-galactosidase staining 
SA-β-galactosidase expression was measured using the Senescence Detection Kit 
(Calbiochem, San Diego, CA). For in vitro staining, 6,000 cells were plated in 12-well 
plates in 1 ml of defined neurosphere medium. DMSO, TMZ-only, DAPT-only and TMZ 
+ DAPT treatments were repeated as described for the neurosphere assays. On days 7 and 
21, the 12-well plates were centrifuged at 2,000 rpm for 10 minutes to attach the 
neurospheres to the plates. Wells were then washed with PBS and centrifuged to save any 
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dislodged cells. The cells were fixed with 0.5 ml of the fixative solution and incubated at 
room temperature for 15 min. The plates were centrifuged briefly, the fixative solution 
was removed, and cells were washed twice. A staining mixture, containing staining 
solution, staining supplement and X-gal (20 mg/ml) were added to each well and 
incubated at 37oC, as described in the manufacturer’s protocol. After 12 hours, the 
staining solution was removed and cells were washed with PBS. β-galactosidase positive 
and negative cells were counted by light microscopy, and the percentage of positive cells 
was calculated based on the total number of cells.  
To analyze SA-β-galactosidase expression in tumors treated in vivo, O.C.T. 
frozen samples were sectioned at 8 µm by the Tissue Bank Core at the University of 
Massachusetts Medical School. The Senescence Detection Kit (Calbiochem, San Diego, 
CA) staining mixture, containing staining solution, staining supplement and X-gal (20 
mg/ml) was added to each slide (200 µl), incubated at 37oC for 12 hours, and then 
washed with PBS. Under blind conditions, β-galactosidase positive cells (blue) were 
counted using a light microscope, and the number of senescent cells per field was 
quantified from a total of . The percentage of fields with either 0 - 10 (negative), 11 - 50 
(low), 51 - 100 (intermediate) and greater than 100 (high) β-galactosidase positive cells 
were quantified for each set of tumors from mice treated with DMSO (n = 5), LY chow-
only (n = 4), TMZ-only (n = 5) and TMZ + LY chow (n = 5). For each mouse, 6 tumor 
sections were stained and 5 views were counted at 40X for SA-β-galactosidase positive. 
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Immunohistochemistry staining 
Subcutaneous tumors were extracted 13 days after the start of treatment and 
embedded in O.C.T. reagent. All sections were cut at a 6 µm thickness. Frozen sections 
were fixed with ice-cold 100% methanol at room temperature for 5 min. Antigen retrieval 
was carried out in Tris-EDTA pH 9.0. Antibodies were used as follows: Ki67 (1:1000; 
Nova-Castra, Newcastle, UK) and biotinylated anti-rabbit IgG (1:200; Vector 
Laboratories, Burlingame, CA). Sections were stained with Ki67 antibody overnight at 
4oC, followed by secondary antibody for one hour at room temperature. To visualize the 
Ki67 expression, Vectastain Elite ABC reagent and diaminobenzidine tetrachloride 
(DAB) kits were used, following manufacturer protocols, to produce a brown stain 
(Vector Laboratories, Burlingame, CA). Five random fields at 20X were analyzed and 
quantified for positive expression of Ki67 in day 13 tumors from DMSO (n = 6), LY 
chow-only (n = 5), TMZ-only (n = 6), and TMZ + LY chow (n = 5). Ki67 stained 
sections were counted blind by two laboratory members. 
 
In vitro phagocytosis assay 
 U87NS and U373NS cultures were plated at 25,000 cells/ml in 20 ml of defined 
neurosphere medium in flasks and treated with DMSO, DAPT-only, TMZ-only, and 
TMZ + DAPT as described above. Neurosphere cells were harvested and pH dissociated 
on days 7, 14, and 21. Mouse immortalized macrophages were harvested and labeled with 
cholera toxin subunit B (CT-B) conjugated to Alexa Fluor® 488 (Invitrogen Molecular 
Probes, Eugene, OR), which attaches to the cell surface through the pentasaccharide 
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chain of ganglioside GM1. Mouse macrophages were stained with 5 µg/ml CT-B-Alexa 
488 in PBS/B27/HEPES staining buffer at room temperature for 30 minutes. 
Macrophages were washed three times with PBS to remove free CT-B. 6,000 cells were 
seeded onto 35 mm glass bottom dishes (MatTek, Ashland, MA) in DMEM 
supplemented with 10% FBS and incubated at 37oC for 1 hour. Simultaneously, the pH 
dissociated neurosphere cells were labeled with 5 µg/ml CT-B-Alexa Fluor® 647 
(Invitrogen Molecular Probes, Eugene, OR) and 5 µg/ml Hoechst 33342 (Invitrogen 
Molecular Probes, Eugene, OR) at room temperature for 30 minutes. The neurosphere 
cells were then washed three times with PBS to remove free CT-B and Hoechst 33347 
dye. The serum media was removed from the macrophages and 300,000 Alexa 647-
labeled neurosphere cells were co-cultured with the Alexa 488-labeled macrophages in 
defined medium for 1, 10 or 18 hours. For flow cytometry analysis, cells were harvested 
after 10 hours of co-culture, resuspended in PBS/B27/HEPES staining buffer and run on 
a BD™ LSRII (BD Biosciences, Franklin Lakes, NJ). Flow cytometry data was analyzed 
using FlowJo (TreeStar, Inc, Ashland, OR). Debris and doublets were not included in 
data analysis. Alexa 488 events were gated to select for the labeled neurosphere 
population, and co-expression of Alexa 488 and Alexa 647 were analyzed to quantify 
phagocytosis. Co-cultures were also analyzed by confocal microscopy at 1 hour and 18 
hours time points on a DM-IRE2 inverted microscope (Leica, Mannhein, Germany). 
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Final Conclusions and Future Directions 
 
Previous studies in T-ALL and multiple myeloma, have demonstrated synergistic 
effects between chemotherapy and GSI treatment (De Keersmaecker et al., 2008; Liu et 
al., 2009; Nefedova et al., 2008). GSIs have been shown to sensitize glioma cells, 
specifically the tumor-propagating CSC population, to IR treatment (Lin et al., 2010b; 
Wang et al., 2010a). Our laboratory was the first to combine TMZ chemotherapy with 
GSI treatment in gliomas (Gilbert et al., 2010; Gilbert et al., unpublished). While the 
effects of GSI-only and TMZ-only treatments are only temporary and do not inhibit 
tumor regrowth, we have demonstrated that TMZ + GSI treatment blocks neurosphere 
and tumor formation, and inhibits tumor progression through TIS. This response has the 
potential to enhance TMZ therapy in the clinic by inhibiting glioma recurrence. We 
propose that the cells that evade TMZ cytotoxicity do so by entering a temporary 
reversible cell cycle arrest. Notch activity appears to prevent these cells from entering a 
permanent senescent state, while GSI treatment, when administered after TMZ treatment, 
induces senescence (Fig. 4.1).  
 
What population is targeted by TMZ + GSI treatment? 
Glioma cancer stem cells 
One of the largest caveats to this study is that we have not characterized the 
specific population that is targeted by the TMZ + GSI treatment. Since the TMZ + GSI  
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Figure 4.1 TMZ + GSI Treatment Mechanism. TMZ treatment targets proliferating 
cells, which leads to either apoptosis, senescence or a transient cell cycle arrest. 
Unfortunately, the cells that enter the transient cell cycle arrest include tumor-
propagating cells. These cells eventually re-enter the cell cycle, and are responsible for 
tumor recurrence. We have demonstrated that these cells can be targeted by combination 
treatment with TMZ and GSI, in a sequence-dependent manner. When the cell enters the 
transient cell cycle state, Notch signaling protects the cell from the permanent cell cycle 
arrested, senescent state. Therefore, after TMZ treatment, we can target the chemo-
evasive cells by blocking Notch pathway with GSI treatment. 
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treatment induces senescence and blocks neurosphere recovery and tumor growth, we 
believe that CSCs are the targeted cells. However, to confirm that TMZ + GSI treatment 
induces senescence in the CSC population requires the isolation of the CSC population. 
Cell surface markers are commonly used to identify and isolate different cells types by 
fluorescence-activated cell sorting or magnetic bead isolation. Leukemias currently are 
the most accepted models of CSCs due to an excellent set of markers for the lineages of 
both normal hematopoietic and leukemia cells (Ratajczak, 2008). Unfortunately, a 
definitive set of markers to delineate all glioma CSCs has not been described. The most 
commonly used cell surface marker for glioma CSCs has traditionally been CD133 (Bao 
et al., 2006a; Hemmati et al., 2003; Singh et al., 2003; Wang et al., 2010a), but despite 
many successes using this cell surface marker, it has become increasingly clear that 
individual gliomas are very heterogeneous and vary greatly from patient to patient 
(Phillips et al., 2006). Although this heterogeneity may be an example of the stochastic 
model and acquired mutations, differences in expression of stem cell markers among 
gliomas may also be explained by variability in the hierarchy of the original tumor-
initiating cells for different tumors, such as CSCs, progenitors, or further differentiated 
cells (Lottaz et al., 2010). Cells isolated from CD133+ tumors are more likely to express a 
“proneural” gene signature and resemble fetal neural stem cells, while cells from CD133- 
tumors have “mesenchymal” genes and resemble adult neural stem cells (Phillips et al., 
2006). Collectively, these data demonstrate that CD133 is not a universal stem cell 
marker for GBMs and highlight the limits of selecting for glioma CSCs using CD133. 
Researchers in the field have recognized the caveats of using a single CSC marker, such 
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as CD133, and new work has been published on markers CD15, A2B5, podoplanin, and 
integrin alpha 6.  
An additional way to determine whether the cells targeted by TMZ + GSI 
treatment in vivo are part of a CSC population, is to analyze if the senescent cells are 
associated with a CSC niche. If the SA-β-galactosidase-positive in the TMZ + GSI 
treated mice were CSCs, it is expected that they would localize to regions of hypoxia and 
the perivascular niche (Calabrese et al., 2007; Heddleston et al., 2009).  
Since there is not a single marker consistent for all patients that can be used to 
successfully isolate a pure and inclusive population of CSCs, it is likely that isolation of 
glioma CSCs will require the use of a set of markers to identify and purify CSCs in all 
gliomas. Until we are able to definitively isolate the glioma CSCs using stem cell 
markers, we will use the following criteria to support the hypothesis that the TMZ + GSI 
treatment targets CSCs: the targeted population includes 1) neurosphere-initiating cells; 
2) tumor-propagating cells; 3) chemoresistant cells; and 4) cells capable of self-renewal. 
 
Notch-expressing subpopulation 
We have demonstrated that Notch is an active target in TMZ + GSI treatment, 
since expression of constitutively active NICD attenuates the inhibition of neurosphere 
recovery. Therefore, the cells that escape TMZ treatment, but respond to TMZ + DAPT 
treatment, should express one or multiple Notch receptors. To determine if the cells 
expressing Notch receptors make up the entire population that escapes TMZ toxicity, 
glioma cells can be sorted for Notch1-4 expression. If only cells with active Notch 
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signaling escape TMZ treatment, then a Notch-negative population will not be capable of 
recovery or secondary neurosphere formation after TMZ-only treatment. In addition, a 
Notch-positive population will recover and form secondary neurospheres with TMZ-only 
treatment, but not with TMZ + DAPT treatment. Since the TMZ + DAPT treatment is so 
effective, I would hypothesize that the cells that evade TMZ treatment will only be present 
in the Notch-positive population. The correlation between Notch status and TMZ response 
could be further analyzed based on the expression of individual Notch receptors to 
determine if there any of the four receptors play a specific role in TMZ + GSI treatment. 
We know Notch1 is involved in the biologic response of TMZ + GSI treatment, because 
our NICD1 reconstitution experiments attenuate the effects of the combined treatment. In 
gliomas, Notch1 and Notch2 have been shown to play the largest role in growth and 
survival. Knockdown of Notch1 by RNAi resulted in decreased cell growth through cell 
cycle arrest and apoptosis, and decreased tumorigenicity (Chen et al., 2010a; Purow et al., 
2005; Xu et al., 2010; Zhao et al., 2010). Knockdown of Notch2 also decreases cell 
growth (Chen et al., 2010a). RNAi techniques or specific inhibitory antibodies could also 
be used to examine the importance of each individual Notch receptor when combined with 
TMZ treatment. However, according to the TMZ + GSI treatment schedule data, TMZ 
treatment must precede Notch knockdown to induce senescence. Therefore, inducible 
vectors will be necessary to analyze the effects of knocking down individual Notch 
receptors.  
Despite the high level of secondary neurosphere formation in NICD-expressing 
cells treated with TMZ + GSI, it is possible that a unique population responds to TMZ + 
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GSI treatment through a pathway other than Notch. If any Notch-negative cells can evade 
TMZ toxicity, but respond to TMZ + GSI treatment, this would suggest that additional 
gamma-secretase substrates play a role in TMZ + GSI treatment. To test this, Notch-
sparing GSIs can be utilized (Augelli-Szafran et al., 2010). If Notch is the only important 
target in TMZ + GSI treatment, administration of Notch-sparing GSIs will not enhance 
TMZ treatment and there will be no inhibition of neurosphere recovery or tumor 
progression.  
 
Multifaceted effects of TMZ + GSI treatment 
 TMZ + GSI treatment is a promising glioma therapy in MGMT-negative because 
it permanently blocks cell proliferation by inducing senescence in the neurosphere-
initiating and tumor-propagating cells. In addition to growth arrest, the combination 
treatment has the potential to target the tumor by other mechanisms. First, senescence is 
known to stimulate an immune response, resulting in tumor clearance (Xue et al., 2007). 
Since we demonstrated that TMZ + GSI treatment increases phagocytosis in vitro, and in 
vivo treatment results in dissipation of the tumor, TMZ + GSI treatment may activate the 
innate immune system for tumor clearance (Fig. 4.2). The second mechanism is that the 
inhibition of Notch in the TMZ + GSI treatment also targets the tumor vasculature. Other 
laboratories have demonstrated that Notch signaling is important for angiogenesis, and 
Notch inhibition can decrease glioma growth by targeting the endothelial cells (Bae et al., 
2011; Hovinga et al., 2010; Noguera-Troise et al., 2006; Ridgway et al., 2006; Wang et 
al., 2010b).  
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Figure 4.2 TMZ + GSI treatment model. TMZ treatment has a heterogeneous affect, 
resulting in apoptosis, senescence and reversible cell cycle arrest. With TMZ treatment 
alone, a population of the cells enters the transient cell cycle arrest and evades 
chemotoxicity. These cells eventually re-enter the cell cycle and drive tumor progression. 
When the tumor is treated with TMZ first, followed by a GSI, the transiently arrested 
cells enter a senescent state. The TIS stimulates an innate immune response, and the 
remaining tumor cells are cleared by the microglia. 
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Senescence and the immune system in gliomas 
Although the TMZ + DAPT treatment induces cytostasis in the tumor cells, the 
ultimate result is a loss of tumor volume. We believe this is due to tumor clearance 
through by the immune system. Our TMZ + GSI treatment has the potential to influence 
the immune system and enhance therapy through two methods. First, the TMZ + GSI 
treatment may target the CSC population, which is responsible for immunosuppression in 
gliomas, and second, the treatment increases senescence, resulting in a SASP, which can 
prompt an immune response. 
Although the brain is commonly considered immune privileged, there are active 
immune responses in normal brain and brain tumors (Carson et al., 2006). The most 
prevalent immune cells infiltrating gliomas are microglia. In GBMs, up to 30% of the 
tumor can be microglia (Hanisch and Kettenmann, 2007). Microglia are the macrophage 
counterpart in the brain and are part of the innate immune system. Like macrophages, 
microglia are polarized and exist in M1 and M2 states. M1 is the classically-activated 
state, in which the microglia are capable of phagocytosis and secrete cytotoxic and pro-
inflammatory factors. However, tumor-associated microglia (TAMs) are in an 
alternatively-activated M2 state (Rodrigues et al., 2010). TAMs are also capable of 
phagocytosis, but are known to promote cancer growth, angiogenesis and invasion in 
gliomas and other cancers (Pollard, 2004; Sliwa et al., 2007). There is also a high 
incidence of neutrophils in gliomas (Fossati et al., 1999). Neutrophils are white blood 
cells that function in the innate immune system by phagocytosis. Natural killer (NK) cells 
are present in brain and glioma tissue; however, they are relatively rare and likely play a 
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minimal role in gliomas (Stevens et al., 1988; Yamasaki, 2004). Peripheral blood 
mononuclear cells (PBMCs), including T-cells, are also relatively rare in gliomas 
(McVicar et al., 1992). In addition, since our in vivo TMZ + GSI treatments were 
performed in athymic nude mice, which lack functional T cells, we know that T cell 
activity is not necessary for tumor clearance in our system. In recent studies, the host 
model has been demonstrating to play an important role on tumor formation and 
maintenance (Quintana et al., 2008). Therefore, further studies focusing on the role the 
immune system plays in tumor clearance after TMZ + GSI treatment must be diligently 
carried out. To avoid the limitations of host models, it would be best to test the role of the 
immune system in endogenous glioma mouse models or in humanized mouse models. 
The capacity to evade tumor surveillance by the immune system is a key step in 
the development of cancer (Jaiswal et al., 2010). In gliomas, CSCs appear to play a large 
role in immunosuppression. Glioma CSCs secrete immunosuppressive factors, including 
IL-10, TGF-β2, VEGF, and CCL-2 (Qiu et al., 2010; Wei et al., 2010a; Wei et al., 
2010b). Glioma CSC cultures inhibited T-cell proliferation and induces T regulatory cells 
(Tregs) (Di Tomaso et al., 2010; Wei et al., 2010a). Tregs can suppress the functions of 
T-cells, B-cells, dendritic cells, monocytes, macrophages and natural killer (NK) cells. 
Glioma CSCs also directly induce an immunosuppressive phenotype in microglia (Wu et 
al., 2010a). Factors secreted by glioma CSCs that induce immunosuppressive microglia 
include sCSF-1, TGF-β1, and MIC-1. These microglia secrete IL-10, possess a M2 
polarization, and are not capable of phagocytosis.  Since CSCs strongly influence 
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immunosuppresion in gliomas, targeting the CSCs with TMZ + GSI treatment may 
dampen immunosuppression, and allow the immune system to target the malignant cells.  
While the immune system defends against microorganism infections and tumor 
cells and can promote the clearance of debris and dead cells, an immune response can 
also be triggered in damaged and malignant tissues in response to senescent cells 
(Krizhanovsky et al., 2008; Xue et al., 2007). Senescent cells in fibrotic livers are 
targeted by NK cells (Krizhanovsky et al., 2008). In addition to NK cells, there is a high 
incidence of other infiltrating immune cells near the senescent tissue, including 
macrophages and neutrophils. This senescence-induced immune response has also been 
detected in a murine liver carcinoma model (Xue et al., 2007). p53 restoration induces 
senescence in these tumor cells, and leads to an upregulation of the SASP and infiltration 
of immune cells. Xue and colleagues found that inhibiting macrophage, neutrophil or 
natural killer cell functions significantly delayed tumor regression, demonstrating that the 
innate immune system plays an active role in senescence-driven tumor clearance.  
In gliomas, the high prevalence of microglia makes them a strong candidate as a 
driver of tumor clearance after TMZ + GSI treatment. Microglia are capable of both 
phagocytosis and cytotoxic activity against foreign bodies (Gehrmann et al., 1995; 
Graeber and Streit, 2010; Hanisch and Kettenmann, 2007; Yang et al., 2010). We have 
demonstrated that macrophages have an enhanced phagocytosis in vitro when co-cultured 
with TMZ + DAPT treated glioma neurosphere cells. Senescent cells are known to have a 
SASP, which includes production of pro-inflammatory cytokines. We have preliminary 
data demonstrating that the TMZ + DAPT treated glioma cultures have an significant 
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increase in secretion of IL-6 and IL-8 (See Appendix, Fig. A.2). These data help 
demonstrate that the induction of senescence supports an pro-immune response in the 
TMZ + GSI treated gliomas and that the decreased tumor volume observed in the in vivo 
treated mice is due to tumor clearance, at least in part, through macrophage phagocytosis 
of senescent cells (Fig. 4.2). To further study this, it will be necessary to analyze immune 
cell infiltration in glioma xenografts with and without treatments. TMZ + GSI treatment 
may enhance the percentage of infiltrating innate immune cells, such as microglia; 
however, it is also possible that there is no increase in the number microglia after TMZ + 
GSI treatment, but the cells shift from TAMs in the M2 state, to classically-activated 
microglia in the M1 state. We propose to study this in an intracranial xenograft system 
(see Appendix, Fig. A.3), in which we can analyze infiltration of microglia, and the levels 
of secreted cytokines specific to classically-activated microglia, such as IL-12, versus 
cytokines specific to alternatively-activated TAMs, such as IL-10 (Wang et al., 2010c). 
Compounds that induce microglial toxicity or inhibit microglial maturation, such as 
clodronate or gadolinium chloride (Xue et al., 2007; Zeisberger et al., 2006), could also 
be administered in conjunction with TMZ + GSI treatments. If macrophages and 
microglia are responsible for tumor clearance after the induction of senescence, these 
compounds would delay tumor regression. It is important to be aware when studying this 
system in vivo, that there are differences between species reactivity, and not all human 
cytokines will activate mouse cells, nor will all mouse cytokines activate human cells 
(Cayphas et al., 1987; Schoenhaut et al., 1992).  
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Interestingly, Notch signaling is known to affect the activity of macrophages and 
microglial cells. Active Notch signaling in microglia stimulates phagocytosis 
(Grandbarbe et al., 2007). In macrophages, Notch signaling regulates their M1 versus M2 
status (Wang et al., 2010c). Notch signaling promotes the classically-activated M1 
macrophages, while blocking Notch leads to alternatively-activated M2 macrophages. 
Therefore, macrophages that have Notch signaling have enhanced tumor clearance 
activity. At first glance, these data are counterintuitive for TMZ + GSI treatment inducing 
tumor clearance. However, the most robust tumor regression in the TMZ + GSI treated 
mice that have complete tumor clearance occurs after the GSI treatment ceased. This 
would imply that an added benefit to short-term GSI treatment in a clinical setting would 
be the enhancement of tumor clearance.  
 
Notch signaling and the glioma vasculature 
 Notch signaling is necessary for normal angiogenesis (Bae et al., 2011; Krebs et 
al., 2000). In addition, Notch plays a significant role in tumor angiogenesis. Blocking the 
Notch pathway can inhibit growth of different types of cancers by disrupting the tumor’s 
vasculature system (Noguera-Troise et al., 2006; Ridgway et al., 2006). In gliomas, 
DAPT treatment greatly decreased the presence of endothelial cells in special ‘tumor 
slice’ cultures (Hovinga et al., 2010). Interestingly, this disturbed the CSC vascular niche, 
which resulted in a decreased number of CD133+ cells and neurosphere-initiating cells in 
the ‘tumor slice’ cultures. These data demonstrate that blocking the Notch pathway can 
inhibit glioma growth by disruption of angiogenesis, which in turn affects the CSC 
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vascular niche. Therefore, we propose that in addition to TIS and enhanced tumor 
clearance, the TMZ + GSI treatment has the potential to inhibit glioma growth by 
disrupting the tumors vasculature system.  
 Furthermore, it was recently demonstrated that tumor vascularization can occur 
through the differentiation of glioma CSCs into endothelial cells (Ricci-Vitiani et al., 
2010; Wang et al., 2010b). Theoretically, endothelial cells derived from CSCs may be a 
mechanism for tumor cells to ‘hide’ from treatment. If these CSC-derived endothelial 
cells survive chemotherapy and IR, they might have the ability to de-differentiate and 
initiate tumor recurrence. Wang and colleagues (2010b) found that the differentiation of 
the CSCs into endothelial cells required Notch signaling. Therefore, in addition to 
potentially depleting the tumor-associated endothelial cells, the TMZ + GSI treatment 
may target the CSC-derived endothelial cells. 
 
Future Directions  
Our studies demonstrate that the combination of TMZ + GSI is a promising new 
treatment to induce senescence in glioma cells that evade TMZ-only treatment. However 
the mechanism by which this occurs has not been elucidated. We demonstrate that there 
is a sequence-dependent mechanism that requires the induction of a temporary cell cycle 
arrest. Previous studies in fibroblasts have demonstrated that blocking the Notch pathway 
will target quiescent cells and induce senescence (Sang et al., 2008). Our laboratory 
previously demonstrated that TMZ treatment leads to a G2/M arrest in neurosphere 
cultures (Mihaliak et al., 2010); however, we have not determined if all of the cells 
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capable of recovery and secondary neurosphere formation after TMZ-only treatment fall 
into this G2/M arrest, or if they are in a G0, or G1 transient arrest. As a future direction, 
cell cycle profiles of TMZ-only and TMZ + GSI treated samples will be compared at 
early time points and after secondary neurosphere formation. Then, live cell sorting of 
TMZ-only treatment samples will be employed using DNA content to isolate cells in the 
G1/G0, S, and G2/M phases. Analysis of the recovery and secondary neurosphere 
formation in each sorted population will help determine which phase the chemoresistant 
cells arrest in. Additional future experiments will focus on inducing specific cell cycle 
arrests, such as G1/G0 arrest by overexpression of exogenous p27Kip1 (Li et al., 2000), to 
determine if the combination of p27Kip1 overexpression and Notch inhibition can induce 
senescence. This will be an important study, because it will test whether Notch inhibition 
can cause neurosphere cells to transition from a transient cell cycle arrest to a permanent 
senescent in the absence of DNA damage. Conversely, future studies can also analyze if 
other DNA damaging agents, such as IR, ultra-violet light exposure and other alkylating 
agents, such as BCNU, can be combined with GSIs to induce senescence. This will help 
to elucidate if the TIS from TMZ + GSI treatment is specific to TMZ, if it is unique to 
alkylating agents, or if any form of DNA damage is sufficient. 
 
Final Thoughts 
The CSC model has had a positive effect on cancer research, leading to a renewed 
examination of tumor heterogeneity and therapy resistance. An important question for the 
clinic is whether the glioma CSCs are the cells resistant to therapy and hence, drive tumor 
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recurrence? We believe that the population of glioma cells that escapes chemotherapy-
induced cell death and senescence do include CSCs (Mihaliak et al., 2010). Advocates for 
the CSC model suggested that therapy be should be specifically directed against glioma 
CSCs, and the remainder of the tumor cells will eventually wither away (Cheng et al., 
2010). However, since it is possible for differentiated tumor cells to dedifferentiate into 
stem cell-like cells (Chen et al., 2010b; Gupta et al., 2009), targeting just the glioma 
CSCs may only delay tumor recurrence. Therefore, long-term survival of glioma patients 
will require combination therapies that target both the bulk of the tumor and the glioma 
CSCs (Cheng et al., 2010). Our TMZ + GSI treatments offer a promising glioma therapy 
because both populations are targeted.  
The TMZ + GSI treatment may be further enhanced by directly targeting other 
proteins in the Notch pathway. The most relevant downstream Notch target is Hes1, 
which was shown to be necessary for maintenance of the quiescent status (Sang et al., 
2008). Currently, we hypothesize that the TMZ + GSI treatment will only be effective in 
gliomas with MGMT-negative or low expression levels. Although TMZ treatment 
provides some benefit to MGMT-positive cases in the clinic, we did not observe the 
induction of a transient cell cycle arrest in our MGMT-positive neurosphere cultures. 
Since MGMT can repair the O6-methyl-guanine product after TMZ treatment, new 
imidazotetrazine derivatives synthesized by a collaborator result in DNA damage that 
cannot be repaired by MGMT (Wheelhouse, RT, personal communication). A future 
direction is to test if treatment with these imidazotetrazine derivatives induces the 
transient cell cycle arrest in both MGMT-positive and -negative gliomas cultures, and 
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then determine if they can be combined with GSI treatment to induce senescence. Using a 
chemotherapy drug that does not rely on the MGMT status would broaden the pool of 
patients that could benefit from the TMZ + GSI regimen.  
In conclusion, the TMZ + GSI treatment was highly successful at eliciting TIS. 
Specifically, we were able to target the cells that evade current treatment by shifting the 
cells that enter the TMZ-induced transient arrested state into a permanent senescent state. 
In addition, the TIS may cooperate with the innate immune system to induce tumor 
clearance. Therefore, TMZ + GSI treatment has the potential to decrease glioma 
recurrence when combined with surgical debulking. We believe that these studies will be 
successful for clinical translation, because TMZ is already the chemotherapy drug of 
choice for GBMs (Stupp et al., 2005), and GSIs are currently in being tested in clinical 
trials (Fleisher et al., 2008; Kreft et al., 2009; Olson and Albright, 2008; Rizzo et al., 
2008).  
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APPENDIX: 
Preliminary Data 
 
p21 is persistently upregulated in TMZ + DAPT treated neurosphere cultures  
One of the most commonly upregulated members of the senescence pathway is 
p21. Therefore, we were interested in analyzing p21 transcript levels in the neurosphere 
treated cultures. U87NS cells were treated with DMSO, DAPT-only, TMZ-only and 
TMZ + DAPT are previously described. Fresh media was added to the cultures on day 7, 
and the neurospheres were pH dissociated and re-plated for secondary neurosphere 
formation on day 14. Cells were harvested on days 2, 6, 10, 16, and 18. cDNA was made 
using the SuperScript II Reverse Transcription (RT) Kit (Invitrogen, Carlsbad, CA). Real 
time qPCR was carried out using QuantiTect SYBR Green (QIAGEN, Valencia, CA) 
following the manufacturer protocol. p21 forward primer: 5’ CACCTCACC 
TGCTCTGCTG 3’ and reverse primer: 5’ GGCGTTTGGAGTGGTAGAAA 3’. β-Actin 
forward primer: 5’ TTGCCGACAGGATGCAGAAGGA 3’ and reverse primer: 5’ 
AGGTGGACAGCGAGGCCAGGAT 3’. These preliminary experiments were drug 
treated in duplicate. 
p21 levels were normalized to the DMSO control samples for each individual 
time point. The p21 transcript levels in DMSO and DAPT-only treated cultures remained 
low for all time points (Fig. A.1). Day 2 demonstrated a slight increase of p21 levels in 
both the TMZ-only and TMZ + DAPT treated cells. Transcript levels peaked on day 6 
and remained upregulated in both TMZ-only and TMZ + DAPT treated samples on day  
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Figure A.1 TMZ + DAPT treatment induces a persistent upregulation of p21 
transcript levels. U87NS neurosphere cultures were treated with DMSO, DAPT 1 µM, 
TMZ 200 µM and TMZ 200 µM + DAPT 1 µM. p21 expression levels were analyzed by 
real time RT-qPCR. TMZ-only and TMZ + DAPT treatments induced p21 expression; 
however, p21 upregulation was transient in the TMZ-only cultures and persistent in the 
TMZ + DAPT cultures. This correlates with the difference between the TMZ-only 
induction of a transient cell cycle arrest and the TMZ + DAPT induction of senescence. 
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10. However, while the p21 expression remained high through day 18 for the TMZ + 
DAPT samples, the TMZ-only samples had decreased p21 levels on day 16, and 
expression returned to control levels by day 18. This data demonstrates that p21 is 
temporarily increased in TMZ-only treatments, but is persistently upregulated in the TMZ 
+ DAPT treatments (Fig. A.1). p21 expression is also associated with reversible cell cycle 
arrests. The decreased levels of p21 in the TMZ-only samples corresponds the cell cycle 
re-entry of cells during secondary neurosphere formation. In contrast, the persistent p21 
expression in the TMZ + DAPT treated culture is consistent with the maintenance of 
senescence. 
 
Cytokine secretion is upregulated in TMZ + GSI treated cultures  
Senescent cells secrete cytokines as part of the SASP (Coppe et al., 2010; Freund 
et al., 2010). Two important factors in the SASP are IL-6 and IL-8, which are major 
mediators of the immune system and associated with inflammation. We analyzed the 
secretion of IL-6 and IL-8 to determine if there was an upregulation in the TMZ + DAPT 
treated cultures that correlated with the increase in senescent cells. U87NS cells were 
plated at 50,000 cells/ml in 3 ml of defined media. Cultures were treated as previously 
described, with TMZ and multiple doses of DAPT. On day 14, cultures were dissociated. 
DMSO and DAPT-only cultures were reseeded at a 1:30 ratio, while TMZ-only and TMZ 
+ DAPT cultures were seeded at a 1:1 ratio. Supernatants were collected on days 15, 16, 
17, 18, 19, 20 and 21. Supernatants were assayed for human IL-6 or IL-8 with ELISA kits 
(BD Biosciences, Franklin Lakes, NJ) according to manufacturer’s instructions. These 
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experiments represent data from only one biological experiment analyzed in duplicate by 
ELISA.  
In the neurosphere cultures treated with DMSO or DAPT-only, secretion of IL-6 
and IL-8 remained low with no difference between the two treatments, consistent with 
low levels of senescence (Fig. A.2). TMZ-only and TMZ + DAPT samples showed a 
large increase in secretion of IL-6 and IL-8, compared to DMSO controls. The greatest 
difference between TMZ-only and TMZ + DAPT treatments was observed in day 21 
supernatants. Compared to the supernatant from U87NS TMZ-only treated cultures, the 
TMZ + DAPT supernatants expressed IL-6 levels that were 1.7-fold greater (Fig. A.2 A), 
The IL-8 levels were 3.1-fold greater in the TMZ + DAPT treated cultures compared the 
TMZ-only treated cultures (Fig. A.2 B). These levels of secreted IL-6 and IL-8 are not 
normalized to cell number. Since the TMZ-only population greatly recovers during the 
secondary neurosphere formation, while the cell number remains low in the TMZ + 
DAPT treated cultures, the difference between the stimulation of IL-6 and IL-8 is even 
greater in the TMZ + DAPT samples than observed. This preliminary data suggests that 
the TMZ + DAPT treatment upregulates secretion of cytokines, as seen with SASP. 
 
TMZ-only treated gliomas progress after in vivo treatment in an intracranial xenograft 
model 
 The most accurate model to test the TMZ + GSI treatments is in an intracranial 
xenograft model. To do this, we first analyzed the proof-of-concept with our DMSO and 
TMZ-only  treatments.  U87MG-luciferase  cells  (provided  by  Dario  Altieri,  Wistar 
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Figure A.2 Secretion of IL-6 and IL-8 are highest in TMZ + DAPT treated cultures. 
In U87NS treated cultures, DMSO and DAPT-only treatment do not stimulate A) IL-6 or 
B) IL-8 production. TMZ-only and TMZ + DAPT treatment induce IL-6 and IL-8 
production during secondary neurosphere formation, with a significantly greater 
production from the TMZ + DAPT treated samples. ***, P < 0.0001 
B. 
A. 
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Institute) were converted to neurosphere cultures in defined serum-free medium under 
G418 selection. 1 x 106 U87NS-luciferase cells were pH dissociated and resuspended in 5 
µl of medium. The mice were anesthetized by i.p. injection with Ketamine-xylazine.  
Using sterile techniques, the cells were injected into the striatum of immunocompromised 
NU/NU nude mice by stereotaxic surgery. The coordinates from bregma are lateral +2.3, 
anterior 0.7, and distal 3.0. Tumors were allowed to form for 7 days. Then mice were 
treated with luciferin to image the U87NS-luciferase cells on an IVIS xenogen camera 
(Caliper Life Sciences, Hopkinton, MA). Mice were then treated randomly with either 
DMSO carrier  (n = 3) or TMZ 20 mg/kg (n = 2) by i.p. injection, on day 0. Mice were 
given a second DMSO or TMZ 20 mg/kg i.p. injection on day 1. Mice were analyzed 5 
days after the start of treatment. DMSO control mice (n = 3) presented with robust 
luciferase signals on day 5 (Fig. A.3 A). These mice also possessed neurological 
symptoms (decreased motility) and loss of weight. All DMSO mice demonstrated 
significant tumor progression and were sacrificed. In contrast, the TMZ-only treated mice 
showed a decrease of the luciferase signal on day 5 (Fig. A.3 B). These mice were 
healthy and had no visible neurological symptoms. The TMZ-only mice were observed 
up to 27 days after the drug treatment, at which point, the mice showed significant loss of 
motility, appetite and weight. Luciferase expression was increased on day 27, compared 
to day measurements (Fig. A.3 B), demonstrating that the tumor can recover after TMZ-
only treatment in an intracranial xenograft model. The future direction for this 
experiment is to analyze the combination of TMZ + LY411,575 treatment on intracranial 
xenografts. Due to the symptoms of intracranial tumors (including decreased motility and  
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Figure A.3 TMZ-only treated intracranial xenografts are capable of tumor 
progression. U87NS-luciferase cells were injected intracranially into immuno-
compromised mice. Day 0 began one week after the tumor injection. DMSO treated mice 
(n = 3) had very quick tumor progression, and were sacrificed on day 5. In contrast, 
TMZ-only mice (n = 2) showed an initial decrease of tumor volume, followed by tumor 
regrowth. The TMZ-only treated mice were sacrificed on day 27.  
A. 
B. 
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loss of appetite) the synthetically infused LY chow is not an ideal form of GSI 
administration. Therefore, oral administration of LY411,575 solution by gavage will need 
to be tested for dosage and schedule treatment. 
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